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ABSTRACT

Background: Streamlining onboarding processes for new hires to maximize
efficiency and reduce costs while meeting regulatory requirements is a constant challenge
for healthcare systems’ Employee Health staff. Health screening is a required step and
includes obtaining a detailed health history, tuberculosis screening, drug screens,
immunizations, fit for duty examinations, obtaining medical records, clarification of
disability accommodations, pre-work screens, and other tests which are time consuming
and result in delays in hire dates. Faced with a high volume of potential new employee
hires a major southeast healthcare system was concerned about delays in new hire start
dates. The two-step tuberculin skin test administration and follow-up process was
identified as a potential area for concern to improve onboarding efficiency.
Method: A quality improvement study was designed and implemented to
compare baseline testing for new employees with an Interferon-Gamma Release Assay
(IGRA) known as QuantiFERON®-TB Gold In-Tube Test (QFT®-GIT) to the two step
PPD Tuberculin Skin Test (TST) for tuberculosis screening time, overall onboarding
time, compliance with screening within 10 days of hire date, and associated costs. A
retrospective electronic record review included a sample of 484 new hire employees.
Results: Results showed that the QFT®-GIT for tuberculosis screening in
comparison to the TST testing significantly reduced tuberculosis screening time for new
hire employees (TST = 8.03 days, QFT®-GIT = 4.11 days; p<.0001) and overall
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onboarding time (TST = 7.92 days, QFT®-GIT = 5.07 days; p<.0001) while improving
compliance with tuberculosis screening within 10 days of hire date (TST = 92.92%,
QFT®-GIT =100%; p<.0001).
Conclusions: The utilization of QFT®-GIT for tuberculosis screening of new
employees significantly reduced screening and onboarding time while improving
compliance with screening within 10 days of the hire date. Anecdotal feedback from
hiring managers and senior management indicated improved satisfaction with the
Employee Health hiring process.
Implications: Healthcare systems should consider implementation of an IGRA
to streamline processes for onboarding new employees. New processes require
negotiations between healthcare systems and lab vendors, changes in policies and
procedures, and employee health and laboratory staff development. Future research
should focus on cost analyses, as well as, IGRA use for annual screenings.
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CHAPTER 1
INTRODUCTION
Description of Clinical Problem
Occupational health nurses in healthcare settings are challenged with promoting
the health and safety of employees. This includes practicing current evidence-based
interventions to prevent the spread of communicable disease including tuberculosis (TB)
(Massante & Stinson, 2014). Healthcare workers are at increased risk for contracting
mycobacterium tuberculosis (TB) from “sharing air space” with infected patients through
airborne droplet transmission (Jensen, Lambert, Iademarco, & Ridzon, 2006). The
Department of Health and Human Services Centers for Disease Control and Prevention
(CDC) recommends that all healthcare workers receive initial screening for TB upon hire
by a 2-step tuberculin skin test (TST) (Jensen et al., 2006).

The TST is performed by

injecting tuberculin purified protein derivative (PPD) intradermally. If someone has been
exposed to TB, they will develop induration at the injection site which is measured in
millimeters in 48-72 hours. According to CDC guidelines for interpretation of healthcare
worker TST results, a reading of >10 mm of induration is positive. However, if the
healthcare worker has HIV or other immune compromised conditions, a positive reading
is > 5 mm of induration. A positive result can indicate active TB, latent TB (LTBI), or
may be due to history of vaccination with Bacillus Calmette-Guerin (BCG) vaccine or
exposure to other non-tuberculin mycobacteria. Healthcare workers are at risk for
spreading TB if they are not tested and unaware that they have latent TB and are
1

asymptomatic. Latent TB can be reactivated and the healthcare worker can then spread
infection endangering the safety of patients and the community (Jensen et al., 2006).
There are three main categories of problems with utilization of the two step
tuberculin skin test: extended screening time, noncompliance, and potential inaccuracy in
placement and results. Problems with extended screening time and noncompliance occur
due to the multiple steps that are required to complete the two step tuberculin test. The
two step baseline tuberculin skin test requires 4 steps including: step 1- Intradermal
placement of PPD, step 2- read the result in 48-72 hours, step 3- placement of second step
in 1-3 weeks after the first step, and step 4- read the second step in 48 to 72 hours (Jensen
et al., 2006). If the patient is noncompliant with returning for PPD reading, then the PPD
must be replaced. Accuracy of the two step tuberculin skin test occurs due to variation in
skin test placement, subjective reader interpretation, false-positive results, and falsenegative results. Proper placement of the TST should include injection of 0.1ml of PPD
solution injected intradermally on the inner forearm creating a pale skin elevation (wheal)
of 6-10 mm. If a wheal does not appear, then the test is incorrectly placed and should be
repeated. Inaccurate placement can lead to false-negative results when an untrained
healthcare worker inadvertently places the skin test too deep or too shallow. Furthermore,
errors in reader interpretation can lead to false-negative or false-positive results.
Tuberculin skin tests results should measure millimeters of induration which is a raised,
palpable area (Jensen et al., 2006). Often, inexperienced readers may inaccurately
measure erythema rather than induration resulting in false-positive results. These falsepositives may result in unnecessary anxiety for the patient and may lead to the patient
taking LTBI treatment medications which have potential strong adverse side effects. In
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contrast, some readers who are inexperienced or who do not understand the importance of
accurate interpretation, may interpret results as negative which are really positive. In this
case, the patient who needs treatment for LTBI will be left at risk for TB activation.
Further compounding problems with false-positive results, tuberculin skin tests also react
to Bacille Calmette-Guerin (BCG) vaccination and other non-tuberculous mycobacteria
leading to false-positives (Swindells, Aliyu, Enoch, & Abubakar, 2009). Additionally,
TST can give false negative results in immune suppressed individuals. In summary, the
two step TST is subject to issues with extended screening time, noncompliance, and
inaccuracies due to required multiple visits, variation in placement and readings, results,
and false-positive or false-negatives (Swindells et al., 2009).
The purpose of this DNP project was to compare baseline testing for new
healthcare employees with QuantiFERON®-TB Gold In-Tube Test (QFT®-GIT) to the
two step PPD TB skin test in regards to tuberculosis screening time, overall onboarding
time, compliance with tuberculosis screening within 10 days of orientation, and costs.
This quality improvement project assessed whether implementation of the QFT®-GIT in
place of the two step TST, met the organizational goal to reduce the number of days to
complete tuberculosis screening, reduce overall Employee Health onboarding clearance
time, and improve compliance with completion of tuberculosis screening within 10 days
of hire date, while maintaining cost-effectiveness.

Scope of the Problem
Tuberculosis remains a major threat in the world with 9 million new cases each
year. TB is the leading cause of death by an infectious disease, killing 1.5 million people
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annually and 4,100 daily. This represents a 50% decrease in TB deaths globally
(“National Action Plan to Combat Multidrug-Resistant Tuberculosis,” 2015). Death rates
in the United States have fallen below 10,000 annually largely due to implementation of
CDC recommended infection control measures (Jensen et al., 2006; “National Action
Plan to Combat Multidrug-Resistant Tuberculosis,” 2015). In 2015, South Carolina had
104 cases of active TB, and 14 in the Upstate with less than 5 of those being in
Spartanburg, South Carolina with a rate of 1.36 cases per 100,000 (South Carolina
Department of Health and Environmental Services, 2016). Even though death rates are
falling, it is estimated one third of the world’s population are infected with latent TB and
are at risk for converting to active TB. Multidrug-resistant tuberculosis has also emerged
threatening this progress. Action must be taken to prevent the spread of this drug resistant
strain of TB. If efforts to prevent and diagnose latent and active TB are not actively
continued, TB can spread rapidly around the world and to the United States and reverse
decades of infection control measures (“National Action Plan to Combat MultidrugResistant Tuberculosis,” 2015).
Healthcare workers have up to 3 times higher risk of TB than the general
population (Verkuijl & Middelkoop, 2016). The healthcare system accepts patients with
TB and confines noncompliant TB patients for direct observed therapy. The healthcare
system treated two patients with TB in 2015. Employees of the healthcare system may
care for patients whose TB status is initially unknown for several days without
respiratory protection and can unknowingly develop latent TB infection (Kathy Bryant,
personal communication, November 2015). If an employee with undetected latent TB
develops active TB, this employee can transmit TB to 10-15 other patients, coworkers,
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family or community. This can be costly to the organization and the employee. If the TB
strain is drug-susceptible then treatment consists of a four drug regimen for 6 months and
can cost up to $17,000. However, if it is drug resistant, treatment is more complex and
expensive costing $150,000 to $482,000. Compounding drug resistance, adherence to
drug regimens is difficult due to side effects and length of required treatment. If an
employee acquires active TB, then the employee is subject to lost work time up to 4
months accounting for 30 percent of their income (“National Action Plan to Combat
Multidrug-Resistant Tuberculosis,” 2015). Moreover, the organization can incur
additional costs such as increased worker’s compensation benefits and interrupted
staffing schedules or locum tenens coverage. Legally, the organization can also expect
citations or sanctions by DHEC or other regulatory agencies if it is determined that
proper infection control measures were not in place. From a public relations perspective,
the organization may expect a tarnished reputation or at least some employee and public
backlash that may instill a lack of trust or confidence as a healthcare institution or
employer.
Healthcare systems must continue to monitor CDC recommendations and DHEC
regulations to prevent spread of TB. Detection of latent or active TB in new employees
plays a large role in this effort. Healthcare systems are required to maintain stringent
respiratory protection plan that includes appropriate ventilation of TB patient rooms, N95 mask fit testing, exposure follow up plans, and periodic testing of employees(Verkuijl
& Middelkoop, 2016). Employee Health staff must refer all employees with positive
tuberculosis screening to the health department for appropriate evaluation and treatment.
Through appropriate surveillance, early detection of TB, and infection control measures
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the organization can reduce the TB burden to the community, patients and employees
(Jensen et al., 2006).

Analysis of Current Practices
The healthcare system currently employees approximately 6,800 employees and
had experienced a 15% employee turnover rate in 2015 and 2016 which led to staffing
issues and utilization of expensive locum tenens temporary contract employees (Kathy
Sinclair, personal communication, March 2016). The hospital has 78 locum tenens
Registered Nurses which costs the healthcare system $119,600 per RN or total 9.33
million annually. Hiring a permanent RN would save $46,782 per position (Rachel
Datillo, personal communication, July 2016). This does not include costs for non RN
locum tenens employees. New hire RN orientation only occurs one time per month. If the
new hire RN orientation is delayed due to incomplete tuberculosis screening or other
requirements in Employee Health, then a locum tenens nurse will need to fill that spot for
another month. The average full time RN salary is approximately $30 per hour, but locum
tenens RNs cost approximately $60 per hour for 160 hours, totaling $10,800 for one
month of locum tenens. Therefore, a one-month delay would cost $5,400 per month
additional to the healthcare system. If only 2 RNs per month have delayed orientation,
this would cost the healthcare system $129,600 per year.
Further contributing to short staffing concerns, the process for hiring positions
requires multiple time consuming steps. Managers must go through a position committee
for approval of any job postings. This process can take 1-3 weeks or more. Recruitment
then must post the job, actively recruit, screen applications, and submit top applications

6

to the manager for review which can take 1-2 weeks or more. The Manager must then
conduct interviews and select the candidate. Recruitment must then obtain the pay rate
from the compensation department and negotiate the offer with the candidate which can
take a few days. The average amount of days it takes to fill positions from job posting to
job offer in 2015 was 51 days (47 for RNs), and the January to February 2016 average
was 58 days (Rachel Dattilo, personal communication March, 2016). The 2016 days to
fill job offers ended wrapped up at 47 days compared to the national standard of median
of 48 days (Rachel Dattilo, personal communication, March 2017). Following this, it can
take 1-2 weeks to get an appointment in Employee Health for pre-placement assessments.
Once the new employee has an appointment in Employee Health, it could take 3 days to
30 days to clear the employee for orientation. Clearance for orientation includes, health
assessment, labs, immunization titers, drug screens, tuberculosis screening, review of
medical records, and in some cases pre-work screen lift tests and fit for duties with a
provider. This process could take 2 to 30 days with the Fall 2015 average being 15 days
from time of first appointment to health clearance for orientation. Orientation only
occurred twice per month except for RNs which was monthly, and new hires were
required to attend. It was requested that new hires come to Employee Health at least 10
days prior to orientation, so that orientation will not be delayed due to waiting for drug
screen results, for completion of 2 step PPD tuberculin skin test, and fit for duty
appointments. If drug screen results were not back in time, fit for duties are not
completed or the employee does not complete the PPD tuberculin skin test process prior
to orientation, then the employee would not be able to start work until the next orientation
in 2-3 weeks. Delays in orientation only compounded the short staffing concerns. Senior
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management asked the Employee Health department as well as Recruitment to assess
procedures for expediting new employee total onboarding time.
The healthcare system Employee Health examined its processes to determine
measures to contribute to this reduction in new employee onboarding time. In 2015,
Employee Health screened approximately 100 to 125 new hire employees monthly.
Employee Health completed tuberculosis screening with the two step PPD skin test. This
process took 2-4 visits and sometimes took 10 days to 4 weeks or more to complete. The
first visit took approximately 2 hours and cost $48.70 in staff time (5 min for PPD
placement is $2.58 of time) plus $4 for the PPD test and 0.36 for the syringe and needle.
This does not include the cost for other supplies, and lab processing. The second visit for
PPD reading number one cost $10.15 in staff time. The third visit which would include
PPD placement number 2 and lab result review cost total $10.15 in staff time (5 min of
time for the PPD placement) plus $4.36 for PPD. The fourth visit which would include
PPD reading cost approximately $10.15 in staff time (see Table 1.1). New employees
were required to have at least 1 PPD skin test placed and read prior to orientation. New
employees sometimes failed to return for first PPD reading which resulted in the need for
replacement and delay in orientation. Therefore, if the new employee failed to complete
this first skin test prior to orientation, then the employee could not start work for 2 or
more weeks, or 1 month for RNs. The second step of the tuberculin PPD skin test is also
problematic. New employees were required to have the second PPD skin test placed and
read within 10 days of orientation. However, 6-10% of new employees do not return for
this second PPD which caused Employee Health staff to spend additional time contacting
the new hire to request a return visit and replacement of the PPD. If the Employee Health
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RN spent 15-30 min per noncompliant new hire employee contacting the employee and
scheduling another visit, it cost approximately $7.75-$15.50 in salary time per person that
is non-compliant. If the average non return rate of 10% which would result in $1,550 $3,100 cost for contacting approximately 200 new hires to reschedule visits. An extra
PPD placement visit cost $14.51 per person or $2,902 for 200 new hires in staff time and
supplies. This figure grows if you consider the costs of replacing 10% of 6,800
employees for annual PPD skin tests. Noncompliance with completion of two step PPD
within 10 days of orientation can also result in citation by the Department of Health and
Environmental Services (DHEC), or other regulatory agencies (Jensen et al., 2006).
Recent DHEC surveys have resulted in survey staff questioning Employee Health’s past
practice of not reading step one. one A DHEC survey discovered one second step PPD
not being read which could result in citation or penalty. A citation will reflect negatively
on the organization and Employee Health. In fall of 2015 and early 2016, the Employee
Health department reevaluated current practices and implemented processes to expedite
new hire onboarding time, reduce tuberculosis screening time, improve new hire and
manager satisfaction, and streamline processes. Some of these changes included adding
appointment times, additional staffing, and renovation of a storage room to create another
exam room. However, the largest change was implementation of an IGRA for
tuberculosis screening.
Employee Health began verifying all positive tuberculin skin tests with a QFT®GIT approximately 2 years before implementation of this study at the advice of the local
department of health. If the test and symptom review were negative, then the employee
did not have to be referred to DHEC for evaluation and treatment of LTBI. The test was
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also utilized for tuberculosis screening for new employees who reported a history of a
positive tuberculin skin test, but who did not have proper documentation. Staff were
already familiar with the test and a contract was already in place with a local lab called
external Lab. The initial cost for QFT®-GIT was $85 per test.

Table 1.1
Costs per Visit for New Hire Screening in Employee Health

Employee Health average staff salary
RN
$31
OHT
$14
Clerical
$14.79
LPN
$20
Visit 1 Costs
Clerical
15 min
OHT
1 hr.
RN
1 hr.
Plus PPD cost
Total visit 1

$3.70
$14.00
$31.00 (PPD placement, 5 min, $2.58)
$4.36
$53.06

Visit 2 Costs
Clerical
5 min
OHT
5 min
RN
15 min
Total visit 2

$1.23
$1.17
$7.75
$10.15

Visit 3 Costs
Clerical
5 min
OHT
5 min
RN
15 min
Plus PPD cost
Total visit 3

$1.23
$1.17
$7.75 (PPD placement, 5 min, $2.58)
$4.36
$14.51

Visit 4 Costs
Clerical
5 min
OHT
5 min
RN
15 min
Total visit 4

$1.23
$1.17
$2.58
$10.15
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Total costs all 4 visits (cost of labs excluded)

$87.87

Annual cost new hire visits 2,000 new hires per year $175,740
Missed visits 10% average (10% of average 2,000 new hires annually)
Contacting noncompliant patient staff time 30min15.50 = $3,100 per year
Cost of one Replacement visit $14.51 per patient = $2,902 Additional Cost of visits for
noncompliant 200 employees = $6,002
Total costs new hire screening including noncompliant
$181,742

Practice Innovation
Tuberculin skin test was the only available test for TB screening until 2001 when
Interferon gamma release assays (IGRA) were developed. Interferon gamma release
assay are blood tests for TB which specifically measure interferon-gamma which is
released by T cells in response to tuberculosis antigens (Swindells et al., 2009). The first
approved IGRA was the QuantiFERON®-TB test (QFT®) in 2001, followed by the
QuantiFERON®-TB gold test (QFT®-G) in 2005, QuantiFERON®-TB Gold In-Tube
(QFT®-GIT) test in 2007 and the T-SPOT® in 2008. In 2010, the CDC published
updated guidelines for use of IGRA’s and approved both the QFT®-GIT and the TSPOT®. TB for healthcare worker TB screening (Mazurek et al., 2010). IGRA’s can
potentially overcome issues with TST tuberculosis clearance screening time and
compliance, as well as problems with inaccurate results. In contrast to TST, IGRA’s do
not react to nontuberculous mycobacteria or BCG vaccination. IGRA’s can also be
completed in one visit and eliminate the need for multiple visits. Furthermore, IGRAs
have been found to have a higher correlation to TB exposure than TSTs improving
accuracy. IGRA’s are more expensive than TST’s, but utilization is expect to reduce
costs associated with staffing requirements, inadequate testing results, poor employee
11

compliance follow up, and potential DHEC citations for organization noncompliance
(Mazurek et al., 2010).
When a person is exposed to TB, they develop a white blood cell response
(WBC). When white blood cells are re-exposed to TB, they secrete a small amount of
interferon-gamma (TFN-ƴ) protein in response. The QFT®-GIT measures the TFN-ƴ
protein response which is a marker for cell mediated immune response to mycobacterium
tuberculosis. The procedure for testing includes drawing one milliliter of blood is
collected in 3 tubes including the nil (negative control), TB antigen, and mitogen
(positive control). The antigen peptides include ESAT-6, CFP-10, and TB7.7. All tubes
are gently shaken 10 times and must be transferred to a 37ºC+ 1 incubator within 16
hours. Results are measured by TB antigen minus nil and positive is > 0.35 IU/ml. The
advantages of this test include completion in one visit, result is unaffected by BCG
vaccination, test has positive and negative controls, and interpretation of results is
objective (Nienhaus, 2013).
A potential barrier to implementation of IGRAs is the high cost of the lab test.
The healthcare system microbiology department lab manager was contacted in 2015 to
investigate the costs and acceptability associated with implementation of the QFT®-GIT
or the T-SPOT®.TB for all new hires. The manager advised that the QFT®-GIT would
be preferred for the healthcare system due to availability of a local external lab that is
already conducting the test for the organization. This external lab has staff that are
experienced with the testing and are better able to have consistent test performance than
the in house lab. Experienced lab personnel conducting the test will ensure accurate,
quality results and reporting. Furthermore, the manager reported that the T-SPOT®.TB

12

would require extra staff time for packaging to ship. It was discussed that the lab would
have adequate facilities for incubating the tubes of blood (Frankie Rice, personal
communication, September 2015). With the assistance of the lab manager, the price for
the QFT®-GIT was negotiated from $85 to $53. While the QFT®-GIT is more expensive
than the PPD, cost savings is found when you factor in staff time, and cost savings from
not having delays in orientation, decreasing the amount of time locum tenens staff are
utilized, and avoiding regulatory penalties. Onboarding just 2 full time RNs 1-month
sooner every month would save the organization $129,600 in salaries. Another advantage
of utilizing the QFT®-GIT is that new hire visits can be completed in 1 visit and
therefore reducing Employee Health workload and reduced salary costs to track down
each non-compliant new hire. Reducing each new hire visit from 4 to 1 visit opened up
additional available appointment times for new hire and other visits increasing visit
volume capacity in Employee Health. Potentially, this decrease in number of required
visits would also improve new hire satisfaction with the process. Cost of implementation
of QFT®-GIT can be a barrier or a benefit, while process improvement is a potential
benefit for new hires and Employee Health staff.

Table 1.2
Estimated Cost for New Hire screening with QFT®-GIT
Visit 1 Costs
Clerical
15 min
OHT
1 hr., 5 min.
RN
55 min
QFT®-GIT
Total visit 1
Result follow up LPN 5 min

$3.70
$15.16 (blood draw additional 5 min $1.16)
$28.41
$53.00
$100.27
$1.66

Total new hire screening cost (titers, routine labs excluded) $101.93
13

Total cost 2,000 new hires annual with QFT®

$203,860

Minus Cost of one locum tenens RN per month delayed by 2 step
$64,800
Total annual cost of new hire screening
$139,800
Minus cost of two locum tenens RN monthly due to delayed orientation -$129,600
Total annual cost of new hire screening
$74,260
Comparison
Annual cost new hire screening
with 2 step PPD
$175,740

with QFT® $74,240

Purpose
The purpose of this DNP project was to compare baseline testing for new
healthcare employees with QuantiFERON®-TB Gold In-Tube Test (QFT®-GIT) to the
two step PPD TB skin test in regards to tuberculosis screening time, overall onboarding
time, compliance with tuberculosis screening within 10 days of orientation, and costs.
This quality improvement project assessed whether implementation of the QFT®-GIT in
place of the two step TST, met the organizational goal to reduce the number of days to
complete tuberculosis screening, reduce overall Employee Health onboarding clearance
time, and improve compliance with completion of tuberculosis screening within 10 days
of hire date, while maintaining cost-effectiveness.
Project Question/PICOT
As a foreground question, among all adult newly hired healthcare employees at a
healthcare system, how does baseline testing with QuantiFERON®-TB Gold In-Tube test
(QFT®-GIT) compare with two step PPD TB skin test in regards to time for completion
of tuberculosis screening, overall onboarding screening time, and compliance with
screening within 10 days of orientation over a 2-month time frame (see Tables 3 and 4)?
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Table 1.3
PICOT
_________________________________________________________________
PICOT
PICOT components
_________________________________________________________________
Population
New hire employees at Spartanburg Regional Healthcare System
Intervention

QuantiFERON®-TB Gold In-Tube test (QFT®-GIT) for TB
screening

Comparison

2 step tuberculin PPD skin test for TB screening

Outcome

Reduction in completion time for TB screening reduction on overall
onboarding time, and increased compliance with completion within 10
days of orientation

Time

2 months: chart review of 2 months with 2 step PPD standard of care,
compared to 2 months with QFT®-GIT
__________________________________________________________________
PICOT definitions (Melnyk & Fineout-Overholt, 2015)

Table 1.4
PICOT Definitions

Key Terms

Definitions

New Hire Employee

Any person newly hired to work scheduled for
health assessment in employee health after offer, prior to
orientation.

QFT®-GIT

QuantiFERON®-TB Gold In-Tube blood test screening for
latent tuberculosis infection

PPD

Purified protein derivative intradermal skin test for TB
screening

Tuberculosis screening

Time for employee to complete TB screening. For
Tb skin test- time from first skin test to reading of
second test. QFT®- time from lab draw to result.

Onboarding Time

Number of days from first visit to completion of all
requirements to begin work including at least one TST
15

placement and reading or QFT®-GIT result, drug screen
result, lab results, pre-work screen, fit for duty,
documentation, fit for duties
Compliance

Completion of PPD skin test or QFT®-GIT TB screening
within 10 days of orientation. Also, completion of
Chest X-Ray and/or retesting prior to orientation if + PPD
or QFT®-GIT.
________________________________________________________________________

Assumptions
It was assumed that the new employee, employee health employees as well as
hospital administration prefer for the amount of time it takes to clear employee health
prior to orientation to be as short as possible. It was inferred that other healthcare
organizations will prefer this shortened time as well. Another assumption is that the
procedures in the hospital lab and external lab will be standardized and followed. It was
assumed that laboratory staff were proficient and have achieved competency in all
procedures for QFT®-GIT and lab equipment is in working order. It was assumed that
lab interpretation of positive or negative results was accurate. Likewise, it was assumed
the Chest X-ray procedures and interpretation was accurate.
The Centers for Disease (CDC) is recognized as national experts in tuberculosis
control. It was assumed that this is true and that recommendations from CDC are best
practice. Likewise, it was assumed that DHEC regulations are best practice and
employees of DHEC have expert knowledge.
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Summary
The healthcare system is required to complete tuberculosis screening on all new
hire employees through tuberculin skin tests or blood assays for mycobacterium
tuberculosis (Jensen et al., 2006). Employee Health has traditionally completed the 2 step
PPD as a method of screening all new hires. Processes for completion of this 2 step
process can be problematic due to compliance with visits, and false-positives due to BCG
vaccination or reader interpretation. The 2 step PPD can take 10 days to weeks or longer
to complete delaying orientation dates for new hires. Employee health was tasked with
review of regulations and processes to expedite new hire clearance. Tuberculosis
screening was targeted in this process review. QuantiFERON ®-TB Gold In-Tube test is
a blood test for latent TB and was identified as a possible method to overcome barriers to
TSTs and would help expedite new hire clearance (Mazurek et al., 2010). Tuberculosis
remains a threat to employees and to the community (South Carolina Department of
Health and Environmental Services, 2015). Early detection of TB is essential to stop the
spread of TB (“National Action Plan to Combat Multidrug-Resistant Tuberculosis,”
2015). This project examined whether baseline testing with QuantiFERON®-TB Gold
In-Tube test would reduce tuberculosis screening time, overall onboarding time, and
improve compliance while remaining cost effective in comparison to the 2 step PPD skin
test.
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CHAPTER 2
LITERATURE REVIEW
Introduction
A literature search was conducted in order to determine if a blood assay for
mycobacterium tuberculosis would be acceptable for implementation of tuberculosis
screening of new hires in a healthcare system Employee Health in place of the two-step
PPD skin test. The primary purpose of the literature review was to answer the PICOT
question: As a foreground question, among all adult newly hired healthcare employees at
a healthcare system, how does baseline testing with QuantiFERON®-TB Gold In-Tube
test (QFT®-GIT) compare with two step PPD TB skin test in regards to time for
completion of tuberculosis screening, overall onboarding screening time, and compliance
with screening within 10 days of orientation over a 2-month time frame? The literature
review focused on articles that pertained to healthcare workers and screening in low
incidence countries since the United States is considered to be low incidence overall. The
healthcare system was considered to be low risk by CDC standards, however has been
medium risk in the past. Therefore, studies that included medium or middle tuberculosis
incidence were included in the review. The literature review examined whether blood
assays for tuberculosis met with CDC and DHEC regulations, would be more efficient
than the two-step tuberculin skin test process, have equal or better accuracy than TSTs,
and be cost-efficient.
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Literature Search Strategy
In order to make evidence-based practice change, clinicians should conduct a
thorough search of peer-reviewed research (Melnyk & Fineout-Overholt, 2015). Thomas
Cooper Library database links were used to browse different databases including
CINAHL, PubMed and Science Direct. Keyword searches included a combination of
IGRA, Interferon gamma, tuberculosis screening, quantiferon, employee, healthcare
worker, and tuberculosis (see table 4). An initial search on Science Direct of “IGRA”
revealed too many results which needed to be filtered to obtain applicable evidence. A
search on Science Direct for keywords “Tuberculosis screening” and “employees”
revealed 2,095 results. When this result was filtered for 2010-2016 there were 32 articles
found, but these did not meet the inclusion criteria. Science Direct was searched for
Quantiferon which revealed 2,181 results. Many of these results were not specifically
about quantiferon and some were in other languages. The search was for 2016 and found
65 results. The strategy was adjusted and this author searched keywords “quantiferon”
and “employee”, 2008 to present and found 87 results with a few relevant articles. Then
PubMed was searched for keywords “IGRA” and “Tuberculosis” and found 596 results.
Filters of 5 years and newer was then added which narrowed it to 450 results. When a
third keyword of “employee” was added in addition to “IGRA” and “Tuberculosis”,
PubMed revealed 4 results with 1 applicable study. PubMed was searched for keywords
“Quantiferon” and “healthcare workers” for the most recent 5 years and found 77 results.
CINAHL proved to be the most user friendly for this author and all of the above the
search strategies were utilized with multiple results found. A search for keywords
“tuberculosis” and “IGRA” revealed 120 results with a few articles selected. The most
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specific search that was helpful was “tuberculosis” and “employee” and “interferon
gamma” which revealed 10 good results (see Table 2.1). Reference lists from the
reviewed articles were also utilized to identify a few selected articles. Any articles that
this author could not find full text articles for were obtained through the Thomas Cooper
Library interlibrary loan request. During the course of the peer review, this author
contacted South Carolina Department of Health and Environmental Control (DHEC) for
guidance regarding a cluster of positive QFT®s with borderline results. The Columbia
DHEC office referred this author to Dr. F Richard Ervin, regional TB clinician district 4
who emailed relevant articles regarding QFT® cutoff and conversions which was
incorporated into the table (Dr. F Richard Ervin, personal communication, March 2016).
Initially selected articles included approximately 40 articles that were reviewed and
ultimately included 23 articles that were included in this evidence table (see appendices
A).
Table 2.1
Keywords
Keyword
IGRA
Tuberculosis screening
Quantiferon
Employee
Healthcare worker
Tuberculosis
Interferon gamma

Combination of keywords
IGRA and Tuberculosis
Tuberculosis screening and employees
Quantiferon and employee
Quantiferon and healthcare worker
Tuberculosis and IGRA
IGRA and tuberculosis and employee
Tuberculosis and employee and interferon gamma
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Table 2.2
Criteria for inclusion/exclusion
Inclusion criteria

Exclusion criteria

English
Low or Medium TB risk setting
Published in 2005 and newer
Included any version QFT®
Included T-SPOT®.TB
IGRAs related to healthcare workers

Non-English
Single study primarily in High TB risk
Published prior to 2005
Only examined TST
Studies including only children
Studies including only immunosuppressed

Inclusion criteria included studies published in English conducted in low or
medium TB incidence settings from 2005 to present with relevant information to IGRA
testing in healthcare workers including QFT®, QFT®-TB Gold, QFT®-GIT, or TSPOT®.TB. Studies were excluded that were conducted primarily in high TB incidence
settings, did not include healthcare workers, were published in other languages, and those
that were primarily about children or immune compromised patients (see table 5). The
Centers for Disease Control updated guidelines were examined first to determine if
utilization of Interferon Gamma Release Assays (IGRA) would meet required regulations
before proceeding with the PICOT and literature search (Mazurek et al., 2010). Initially
this author tried to limit articles to 5 years but did not find the required number of
relevant articles. Since the QuantiFERON®-TB Gold was developed in 2005 and the
CDC guidelines were written in 2005, articles were limited to those published in 2005 to
present with focus on newer articles. The main inclusion articles of interest were studies
that examined baseline IGRA testing of healthcare workers. Articles were included that
examined IGRA alone with single or multiple retests, or IGRA with Tuberculosis skin
test (TST) conducted separately or simultaneous. Studies that only examined non21

healthcare workers were excluded unless this was a small portion of a larger study.
Studies were included that examined IGRAs in low or moderate incidence countries since
the setting for this project is in a low to medium TB risk setting. Studies that looked at
IGRAs in high-incidence settings or countries were excluded unless they were part of a
larger study that also included low-incidence setting. Articles on cost-effectiveness of
IGRAs were also included in order to examine financial feasibility for the project. There
were not many articles directly related to new hire tuberculosis screening time and
compliance, but two specific ones were found. Due to the concern regarding falsepositives and at the direction of DHEC, studies regarding QFT®-GIT cutoff values and
retesting were included (see Table 2.2). Overall, there was good evidence to continue on
with the PICOT question and study (see Appendices A for full evidence table).
Literature Analysis
Twenty-three studies were included in the review of the literature. The articles
were classified into levels I through IV according to John Hopkins Research and NonResearch evidence appraisal tools (Dearholt & Dang, 2012). Level I includes
experimental studies, II quasi-experimental, III Non-experimental, IV clinical practice
guidelines, consensus or position statements, and level V literature review, expert
opinion, community standard, clinician experience, and consumer preference (see
Appendices B for level and quality guide). Of the 23 articles analyzed there were four
level II articles, seven level III, two level IV, and 10 level V (see Table 2.3). Quality of
the articles were also analyzed as shown in table 5 according to John Hopkins appraisal
tools with ratings of A- high quality, B- Good quality, and C- Low Quality (Dearholt &
Dang, 2014). All of the studies were conducted in the United States with the exception of
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two in Germany that report that the study was conducted in low incidence settings (Diel,
Loddenkemper, Meywald-Walter, Gottschalk, & Nienhaus, 2009; Schablon, Nienhaus,
Ringshausen, Preisser, & Peters, 2014). Most of the studies focused on healthcare
workers with the exception of 4 studies that included healthcare workers as well as other
groups such as close contacts but all were published in English (Banaei, Gaur, & Pai,
2016; Diel et al., 2009; Pai, Zwerling, & Menzies, 2008; Rangaka et al., 2012). The 23
articles were published by 18 different journals or sources (see table 2.4). The articles
reviewed were classified according to type of study which includes quality improvement,
clinical practice guidelines, quasi-experimental, systematic review, financial, program
evaluation, expert opinion/literature review, and case report (see table 2.5).
Table 2.3
Quality Ratings per evidence level

# of Articles in Quality Rating
Level

A-High

B-Good

C-Low

II

1

3

0

III

3

4

0

IV

2

0

0

V

2

8

0
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Table 2.4
Journals/Sources
American Journal of Respiratory Critical Care Medicine
Annals of Internal Medicine
Archives of Internal Medicine
BMC Health Services Research
Chest
Infection Control & Hospital Epidemiology
Journal of American College Health
Journal of Clinical Microbiology
Journal of Hospital Infection
Journal of Occupational & Environmental Medicine
Journal of Occupational Medicine & Toxicology
Lab Medicine
Lancet Infectious Disease
MMWR
PLoS One
Qiagen
Thorax
Workplace Health & Safety
Total

Table 2.5
Categories of Articles

Total

Case Report
Clinical Practice Guidelines
Correlational
Expert Opinion/Lit. review
Financial
Program Evaluation
Quality Improvement
Quasi-Experimental
Systemic Review

1
2
1
3
1
2
3
4
6
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2
1
1
1
2
1
1
1
1
1
1
1
1
2
1
2
1
2
23

Evidence level II, high quality (A) articles.
A longitudinal study of healthcare workers at four organizations undergoing
tuberculosis screening from February 2008 through march 2011 was conducted (Dorman
et al., 2014). The purpose of this study was to assess the performance of IGRAs for serial
testing of healthcare workers compared to tuberculin skin test (TST). The sample
included 2,563 healthcare workers in Denver, Colorado; Houston, Texas; Baltimore,
Maryland; and New York City. Healthcare workers with a history of TB, TST within the
past 6 months, and those with history of anaphylactic reactions to TST reagents were
excluded from the study. Initially participants were interviewed regarding demographics,
occupations, TB exposure, history of LTBI and BCG status. Then blood was drawn for
T-SPOT®.TB and QFT® followed immediately by TST. Participants had a second TST
in 1-3 weeks if they did not have another TST in the past 12 months. Participants had
repeat interview, QFT®, T-SPOT®.TB and TST at 6, 12, and 18 months. Those with a
positive TST were asked to have a repeat TST. There was a sub-study wherein
participants had blood drawn two weeks apart without a TST in-between and by drawing
two sets during a single blood draw. It is important to note that mid-study, participants
had repeat ELISA testing for all positive tests because there was a higher than expected
rate of conversion. Another sub-study was conducted in which participants with baseline
negative IGRAs had repeat IGRA in 7-21 days. Statistical analysis included K coefficient
for agreement, two-proportion Z-test for independent proportions and McNemar’s test for
dependent proportions. Multiple comparisons were assessed by Holm-Bonferroni method
and mean changes were compared by t test. Linear mixed-effects models were used and
confirmed by residual plots. SAS 9.2 was used for calculations. Results show a 6.1%
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(138 of 2,263) conversion rate for QFT®-GIT, 8.3% (177 out of 2,137) conversion for TSPOT®.TB, and 0.9% (21 out of 2,293) for TST. There was a statistically significant
difference in conversion rate of QFT®-GIT compared to TST (p<0.001). Baseline testing
results showed 125 positive TSTs (5.2%), 118 positive QFT®-GIT (4.9%) and 144
positive T-SPOT®.TB (6.0%). The rate of positives in the IGRA groups was not
significantly higher than the TST groups. Agreement of test results for those with triple
positives was high with agreement between TST and QFT®-GIT 93.2%, 91.2% for TST
and T-SPOT®.TB, and 93.8% between QFT®-GIT and T-SPOT®.TB (95% CI for all
comparisons). There was a higher rate of baseline positive TST and negative IGRAs in
BCG vaccinated participants (odds ratio 33.4). There was a 53.7% reversion of baseline
positive TSTs in 29 out of 54 participants. Likewise, there was baseline reversion from
positive to negative for QFT®-GIT of 56.8% (67 of 118) and 63.9% for T-SPOT®.TB
(92 of 144) without statistically significant differences in comparison between the groups.
Those with higher baseline values for QFT®s had lower rates of reversions but there was
no difference in the T-SPOT®.TB group. Test conversions during this study were 0.9%
for TST, 6.1% QFT®-GIT, and 8.3% for T-SPOT®.TB which was significant for TST vs
QFT®-GIT and for T-SPOT®.TB (p<0.001) but no significant difference between
QFT®-GIT and T-SPOT®.TB. When converters were retested in 6 months, 76.4% (81 of
106) QFT®-GIT positive tests reverted and 77.1% (91 of 118) of T-SPOT®.TB. It is
important to note that not one participant converted in all three tests at once and there was
no association with TB exposure for any of the conversions. In the sub study that was
retested in 2 weeks, 7.5% of QFT®-GITs changed from negative to positive and 8.1% for
T-SPOT®.TB. In the positive testes, 33.3% and 52.6% reverted for QFT®-GIT and T-
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SPOT®.TB respectively. In the sub study that had two sets of blood drawn in one visit,
there were discordant results in 5.8% for QFT®-GIT and 6.5% for T-SPOT®.TB (p=.39).
When a subset of samples was retested by ELISA in 8 days, all negatives remained
negative, but 27 out of 114 positives turned negative. An intervening TST boosted
QFT®-GIT in 9.1% and 11.3% for T-SPOT®.TB and those with baseline positive TST a
boosting affect. The authors conclude that conversions of IGRAs over 18 months
occurred 6-9 times more often than TST which demonstrates false-positives and a need
for retesting of converters. The authors did not feel that changing the cut point would be
helpful since this only attributed to 15-18% of conversions in this study (Dorman et al.,
2014).
The prospective study by Dorman et al. (2014) is a level II comparative study,
quality A high study. This is an example of a prospective comparison study of which
there are few for IGRAs. The authors analyzed several conversion factors by statistical
methods. The sample size was sufficiently large and spanned different areas of the US
but each were in larger metropolitan areas. The authors report the limitations of limited
generalizability to groups with immunosuppression and limited generalizability for other
higher incidence countries. There was also some attrition in the TST repeat groups
(Dorman et al., 2014). This study was very thorough and has good applicability to this
project. However, this study does point to the necessity for retesting of any positive
QFT®s.
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Evidence level II, Good quality (B) articles.
The Switch study was conducted to determine what cost an IGRA would need to
be in order to cost less overall than the tuberculin skin test for health care employees
(Wrighton-Smith, Sneed, Humphreys, Tao, & Bernacki, 2012). All of the actual costs for
materials and employee health staff labor costs involved with tuberculosis screening were
gathered from a large healthcare facility’s finance records. The setting was John Hopkins
in Baltimore, Maryland that screens about 18,000 employees annually with the TST.
Secondarily, 393 random employee encounters were selected for time motion study to
measure the time it takes to complete each step with the TST including data entry as well
as time for the IGRA lab draw as well as how much time away from work the employee
had to take for testing. This study also randomly invited new hire and annual employees
to participate in parallel testing of T-SPOT®.TB and TST with a total sample of 750 (473
annual, 270 new hires). Of the 113 employees (69 foreign born) with a previous history
of positive TST, two thirds had negative IGRA. The nonreturn rate for TST was 10%,
while only 0.4% of IGRA results were unavailable. The IGRA test also showed a lower
rate of positive results than the TST in new hires. Questionnaires completed by
participants revealed that 62.3% preferred the IGRA to the TST. The cost model revealed
that when considering non return rates, the average cost for TST for annuals was $73.20
and $90.80 per new hires. The IGRA costs overall $78.05 per annual screening when
adding in labor and supplies, and $64.47 for new hires. The IGRA would save money if
the test costs $54.83 or less per test for each new or current employee. A sensitivity
analysis was also conducted to determine which of 38 variables had the most effect on
the cost model. None of the variables had much effect beyond 0.75 cent except for labor
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cost. Labor costs would impact the overall cost due to higher costs for time off work. If
employees made 20% higher salaries, then IGRA would save money if it was $61.16 per
test (p value not provided). The sensitivity analysis of variables was shown in a bar graph
and statistical significance was not revealed. In conclusion, the authors report that the
IGRA saves money and improves compliance rates for health care employee tuberculosis
screening (Wrighton-Smith et al., 2012).
This Switch study was rated level II and quality B. The strengths of this study
include that the study did have some elements of random selection and it did a parallel
comparison of the TST and T-SPOT®.TB. The study also supports the conclusion that
non-return rates for the TST affect cost. There may be potential bias in this study since
the manufacturer of T-SPOT®.TB, Oxford Immune provided the test free of charge and
provided John Hopkins a grant of $49,300 for the study (Wrighton-Smith et al., 2012).
The salaries had to be weighted and estimated to give an estimate of the average hourly
wage. This could have skewed the results. A more accurate direct measure would have
been to use the exact salary of each participant. The authors report the limitation that the
study considered the TST and IGRA to be equally accurate. Descriptive statistics were
described, rather than statistically significant testing. This is probably not necessary for
the cost result, but would be important to ascertain for parallel testing of results. Overall,
this is a good study to support this project.
Cummings et al. (2009) conducted a study of newly hired healthcare workers at
West Virginia University prospectively comparing the tuberculin skin test and QFT®GIT. A convenience sample of 182 out of 266 invited new hires from June 2007 to
February 2008 was obtained by offering 2 QFT®-GITs to all new hires who were having
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a TST. The QFT®-GIT was drawn first, followed by the first TST up to 3 weeks later,
followed by a second QFT®-GIT and second TST if needed 1 week later. A unique
feature of this study was that any indeterminate or positive QFT®-GIT was retested in
the lab by ELISA. If the positive results agreed, then the result was confirmed. If the
results did not agree, a third test was conducted and the mean of the values was used. In
order to determine specificity, the study assumed that participants who had no risk factors
for TB did not have latent TB. The study used mixed-model repeated measure analysis of
variance (ANOVA) to compare results of first and second QFT®-GIT results and timing
of TST was considered as a variant. The sample included 96% born in the US, 93%
without BCG vaccination, and 62% having no risk factors reported for TB. For initial
testing, the TST and QFT®-GIT had 96% agreement of negative results (both results
were negative) but no agreement on positive results (none had both positive TST and
QFT®). It was determined that specificity for the TST was 99% and QFT®-GIT 98% for
healthcare workers that reported no risk factors. Eighty-five participants completed the
second blood test and out of these two of the participants with initial negative QFT®-GIT
results had subsequent positive results. The authors considered both blood test results and
found that 4 had positive blood tests but negative TST, while 3 had positive TSTs but
negative QFT®-GIT results. Only one participant had both a positive QFT®-GIT and
TST. Sixteen indeterminate results were repeated in the lab by ELISA and 11 remained
indeterminate while 5 were negative. The study found that employees with diabetes or
who were on immunosuppressive therapy had greater odds of having an indeterminate
result (rate 6.8, 95% confidence interval). Out of the 5 positive results, 2 were confirmed
positive. This study did not find any statistically significant difference between the first
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and second QFT®-GIT results. The INFƴ result for participants that had only 1 TST
showed a mean increase of 0.02 which was statistically different (p=.04). The authors
conclude that overall agreement and specificity for the TST and QFT®-GIT was good
due to the fact that there was a high rate of negative results, but positive results did not
agree. Retesting of samples in the lab may improve diagnostics due to the reversion of
follow up testing. There was a small boost in IFN-ƴ results from the TST which may
limit testing. Immune status of participants should also be considered due to increase in
indeterminate results. The authors state that the QFT®-GIT may be beneficial due to
fewer visits required for QFT®-GIT as compared to multiple visits for the TST
(Cummings et al., 2009).
This study by Cummings et al. (2009) is level II with rating of good quality. The
study is good in that it compared both QFT®-GIT and TST tests and included statistical
analysis. The authors have clear discussion of the results, but do not assert which testing
is recommended. However, the study had important findings to consider when
determining whether to retest employees when QFT®-GIT are positive or indeterminate.
This setting is low- incidence which is relevant to this project, but would limit
generalizability to other settings. A limitation is that the study lacks randomization and
only 47% returned for the second blood rest resulting in attrition bias (Cummings et al.,
2009). The authors assumed that employees without risk factors for tuberculosis did not
have LTBI which could have skewed results. The sample included 96% United States
born and 93% did not have BCG vaccination which could limit generalizability to other
countries (Cummings et al., 2009).
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Diel, Loddenkemper, Maywald-Walter, Gottschalk, and Nienhaus (2009)
conducted a study to assess agreement between the QFT® and T-SPOT®.TB in
comparison to people with positive TSTs who had recently been exposed to tuberculosis.
The sample included 2,004 people who were close contacts of patients with culture
confirmed tuberculosis, which were reported to the Hamburg Public health department
from December 2006 through February 2008. Six people were excluded from the study
because they had already had contact investigations, and seven did not follow up for
testing. Eight hundred and forty-two contacts tested positive by TST and had subsequent
QFT® and T-SPOT®.TB testing. Twenty- two were eliminated because the TSPOT®.TB could not isolate sufficient lymphocytes. Results were indeterminate for 7 TSPOT®.TB and 1 QFT®. The final sample was 812 TST positive contacts who were
exposed to 123 tuberculosis patients. The results revealed 245 (30.2%) positive QFT®s
and 233 (28.7%) positive T-SPOT®.TB. The rate of negative IGRA results significantly
increased in the BCG vaccinated groups with 140 negative T-SPOT®.TB (versus 93
positive) and 146 negative QFT®s (versus 99 positive) (p<0.0001). Statistical analysis
revealed high agreement between the QFT® and T-SPOT®.TB with k value of 0.852,
95% confidence interval. Furthermore, QFT® and T-SPOT®.TB were more statistically
likely to be positive if the patient coughed in the presence of the contact (p<0.0001 for
each). There was also a statistically higher rate of IGRA positive results for those with
higher exposure time (p<0.0001) and those with contact with AFB positive patients
(p<0.0001). Those with exposure >40 hrs. to AFB positive patients had a 6 times higher
positive rate than those with < 8 hours of exposure and twice as likely in the AFB smear
negative sources. It appeared that higher cutoffs for TST positive results showed greater
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association with positive IGRAs. Those with TST result of >15 mm had 68.3% positive
QFT® and 87% for T-SPOT®.TB. However, this agreement decreased to 56.7% and
54.4% for patients with TST positive results of 11-15 mm and decreased further to 14.2%
and 12.9% for those with TST of 6-10 mm. Multiple regression analysis showed a
statistically significant relationship between increase age (p=.003), and foreign birth
(p<0.001), source AFB-positive contacts (p<0.001) and positive QFT® and TSPOT®.TB results. Overall, the QFT® and T-SPOT®.TB had good agreement of 93.9%
and were associated with increasing exposure risk factors. Metanalysis revealed the
QFT® to be more specific for active TB than the T-SPOT®.TB but less sensitive,
however in actuality there were more positive QFT®s found than T-SPOT®.TB.
Specificity of the TST was poor (64.5%) for those with TST cutoff of >5 mm if you
consider that patients with positive results to both QFT® and T-SPOT®.TB had true
infection. The authors conclude that the QFT® or T-SPOT®.TB is more accurate
indicators of LTBI than TST and utilization would decrease the number of patients with
suspected LTBI by 70% (Diel et al., 2009).
The article by Diel et al. (2009) is rated level II, good quality. There is excellent
prospective comparison of the TST and QFT® and T-SPOT®.TB. Not many studies have
conducted these analyses with statistically significant results. This was a convenience
sample which can lead to some selection bias. There was just a small attrition in this
study. Multiple statistical tests were applied which result in statistically significant results
by chance (Melnyk & Fineout-Overholt, 2015). This article is relevant to this project in
that it shows that QFT® is associated with greater likelihood of exposure to tuberculosis.
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Evidence level III, high quality (A) articles.
Schablon, Nienhaus, Ringshausen, Preisser, and Peters (2014) performed a large
scale study of serial QuantiFERON® Gold in Tube (QFT®) tests on 3,823 healthcare
workers in Germany. Participants included a convenience sample selected by
occupational health physicians from 32 different hospitals, nursing homes and out-patient
centers from 2006 through 2013. Each participant signed a written informed consent and
physicians collected information regarding age, gender, reason for the test, exposure to
TB, work history, history of TB, birth country, and tuberculosis screening results.
Statistical analyses were performed by SPSS version 21 and included Chi-square,
adjusted odds ratios, 95% confidence intervals, and logistic regression models. At
baseline, there were 318 positive QFT®s (> 0.25 IU/ml) which is 8.3% of the sample.
There were four variables found to be associated with positive QFT®s including age > 55
with odds ratio 6.89 (95% CI), foreign birth odds ratio 2.39 (95% CI), personal or family
history of TB with odds ratio 6.23, and place of work. Interestingly, there was no
association with job title (RN versus MD, etc.) or with the reason for the testing
(screening versus contact investigation). Out of the sample, 817 had repeat QFT® testing
from 7 days to 48.6 months apart. The amount of time between testing had no difference
in conversion, reversion, or results that did not change. 97.2% of those with negative
baseline tests had consistently negative QFT® results (721 out of 742) and 62.5% were
consistently positive (47 of 75). The odds of remaining positive increased from 2% to
18% for those over 55 years of age. Age did not appear to affect conversion or reversion
rates. Those who were foreign born outside of Germany had higher reversions rates of
7.8% versus 2.7% German born. Conversions on serial testing after baseline occurred in
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2.8% (21 out of 742) and reversion rate of 37.3% (28 out of 75). If the definition of
QFT® result was changed to a borderline zone of 0.2 to <0.7 IU/ml, then conversions
would decrease to 1.1% and reversions to 18.8%. If the definition of conversion was
changed to 1.0 or 3.0, then conversion rates decreased even further to 1.0% or 0.4%
respectively and the reversion rate changed to 18.6% or 11.1%. The authors conclude that
a borderline interpretation zone of 0.35 to 0.7 or 1.0 IU/ml would be safe and reduce the
number of chest x-rays for healthcare workers without symptoms of TB in countries with
low TB incidence (Schablon et al., 2014).
This study by Schablon et al. (2014) is a level III correlational, quality B Good
study. The authors discuss the limitations of using a convenience sample with selection
bias. The occupational health physicians did not have a strict study protocol for schedules
of retesting or selection of groups to test (Schablon et al., 2014). There appears to be a
preconceived bias by the authors that there should be a borderline testing zone, however
it does not appear that the authors directed the physicians to retest participants in this
zone. There was no specific inclusion or exclusion criteria for participant selection to
control for any variables. The sample size was sufficiently large at 3,823.
Generalizability to US healthcare workers could be limited since this study was
conducted in Germany and authors report that from literature there is a historical positive
rate of TSTs to be 24-50% in healthcare workers. This would not be the general result
that is found in the US. Furthermore, 45.5% of participants had BCG which did not affect
the odds ratio for positive QFT®s (Schablon et al., 2014). This high rate of BCG
vaccination might not be found in the US. It would be helpful to know the number of
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foreign born US participants in this study. A comparison with TST would strengthen this
study.
Lamberti et al. (2015) conducted a system review of the literature with metaanalysis with the purpose of reviewing healthcare worker screening with TST and QFT®
test agreement and association with BCG vaccination and TB incidence. The authors
searched PubMed for articles from January 2004 through October 17, 2013 with
combination of search words “workers”, “tuberculosis”, “TB infection”, “TB disease”,
“TB”, “tuberculin skin test”, “Tuberculin skin testing”, and “quantiferon”. The Preferred
Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) was utilized for
the review and meta-analysis. Studies included were cross-sectional or longitudinal
articles about screening of healthcare workers with TST and QFT®, and comparison of
the tests as well as those with vaccination information. Studies were excluded that were
case reports and those that were about patients with immune system diseases or HIV.
Twenty-nine studies were chosen out of 1,430 abstracts. The authors considered the
QFT®-TB Gold and the QFT®-GIT to be QFT® for purposes of analysis. Cohen’s k was
used with a confidence interval of 95% calculated. Meta-regression was used to examine
the covariates. The selected articles included 10 studies in low TB incidence settings, 7
intermediate and 7 high incidence settings. Studies were excluded that did not define a
positive PPD at cutoff of 10 mm. The sample size was 10,314 with patients with
indeterminate results being excluded. Results regarding agreement between the tests
showed that 6,893 tests agreed for TST and QFT®, while 3,421 did not. TST positive and
QFT® negative occurred four times more often than TST negative and QFT® positive.
The Cohen’s K for agreement between the TST and QFT® overall was 0.28 with 95%
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Confidence Interval which the authors report is low and shows that 33% of the time the
tests do not agree. However, this improved to 0.38 for high incidence settings while
intermediate was 0.19 and low incidence 0.25 Cohen’s k. The intermediate group had the
worst agreement and was significantly different than the high incidence (p=0.041).
However, the intermediate group had the highest BCG vaccination rate. When the sample
was divided by low and high BCG vaccination rates, the group of studies with the lower
rate (15 studies) had a Cohen’s k of 0.34 and the higher group (9 studies) was 0.17. The
authors conclude that TST should be used in areas with low vaccination rates or high
incidence of TB, while QFT® is helpful in settings with high incidence of TB. Providers
should consider that the QFT® higher specificity for mycobacterium tuberculosis may be
causing the differences in test results because the TST reacts to nonspecific antigens
(Lamberti et al., 2015).
The systematic literature review by Lamberti et al. (2015) is a level II study with a
quality rating of A High. This study applied statistical analyses to multiple articles to
generate new statistics. A table is provided with the variables of interest for each study.
The sample size was very large. The review included articles dated to 2004, but all
studies were relevant to QFT® testing in healthcare workers. One limitation is assuming
that the TST which measures nonspecific antigens is a valid indicator of LTBI when
comparing agreement with QFT® which tests specific mycobacterium antigens.
Therefore, the QFT® should reduce false-positives which would result in discordant
agreement between the tests. Another limitation of the review was the combined testing
of the QFT®-G and QFT®-GIT. It would be beneficial to examine whether there was a
difference between the QFT®-G and QFT®-GIT improved testing.
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Zwerling et al. (2012) completed as systematic review of the literature regarding
IGRAs for healthcare worker screening. The authors searched PubMed, Embase, Biosis
and Web of Science for all articles up through 2010 and included sources from
conferences, article references, and references from experts and test manufacturers. A
total of 50 articles were reviewed with 44 that examined LTBI prevalence and incidents,
agreement of IGRA results or agreement between IGRA and TST. Three of the studies
were included regarding cost-effectiveness and three on feasibility. Of the 44 main
studies, 35 studied QFT® only, 3 T-SPOT®.TB only and 6 studied both. Five of the
studies were conducted in high incidence settings. The total sample across the studies was
11,963 healthcare workers. Fisher exact 95% confidence interval was calculated for
prevalence estimates. Three cross sectional studies from in India, Russia and Vietnam
were included, but the Russian study did not perform TST. The India and Vietnam
studies showed a high positive rates for IGRA in healthcare workers of 40-60%. The rate
of IGRA positives was only slightly lower than TST positive in the two studies. The
prevalence between the TST and IGRA was only statistically significant (statistic not
provided) in the Vietnam study which had a lower BCG vaccination rate of 37.3%
compared to 71% in the India study. Thirty-one of the studies were from low or
intermediate risk settings. Out of 25 studies, 24 showed lower prevalence of positive
QFT® or T-SPOT®.TB compared to TST with 17 statistically significant (p value not
provided). There did not appear to be an association between BCG vaccination and
higher prevalence of positive TST or difference between the tests. Agreement between
the TST and IGRA was weak with more common TST positive and IGRA negative
results with k values from 0.05 to 0.56 with agreement improving if TST cutoff was
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increased to 15 mm. in 14 studies in low incidence countries, there was an association
between positive IGRA results and occupational risk factors for TB such as working in
high risk TB units, working in TB clinics or geriatric areas and longer employment
duration with two studies not finding this association. Four studies showed relationship
between foreign birth or history of living in high TB incidence country and positive
QFT® results with 3 showing correlation with TST positive. One study did not find this
association with foreign birth but it was the only study that used T-SPOT®.TB. Two
studies in high incidence settings showed IGRA conversion rates of 11.6% and 21%.
Only four studies examined conversion rates in low incidence settings and ranged from
1.8 to 14%. Three studies showed reversion rates for IGRAs to be 40-52.9%. Two more
recent studies showed that conversion and reversion rates were more stable when the
IGRA results were higher than those close to the cutoff. The authors concluded that use
of IGRAs for baseline would result in lower positive rates and few treated for LTBI,
however conversions for serial testing may result in healthcare workers taking
preventative medications on subsequent testing. The authors conclude that guidelines for
serial testing of IGRAs should be reviewed due to issues with conversions and reversions.
The study by Zwerling et al. (2012) is a level II systematic review that is rated A
high quality. The search strategy was comprehensive and the sample size large.
Characteristics of each study are displayed in tables with an online supplement for
review. The authors report limitations of the study including lack of reporting of HIV
prevalence in the studies, inherent publication bias, and a lack of evidence at the highest
hierarchy. A limitation was noted in the review of all studies that combined QFT®s
together as one test methodology. The review included studies from different countries
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which could limit generalizability to US populations. The study would have been
strengthened by meta analysis. Overall, this article is high quality and relevant to this
project.
Rangaka et al. (2012) conducted a systematic literature review with meta-analysis
to assess whether IGRAs can predict the development of active TB compared to TST.
This review included 15 studies found through search of PubMed, Embase, Biosis, Web
of Science, bibliographies from other reviews, and expert recommendations. Studies
included longitudinal studies of adults or children who did not have active TB at the
study onset with the primary objective of predictability of IGRAs for TB by ELISA,
ILISPOT, commercial or noncommercial assays. Statistical analysis included NewcastleOttawa quality assessment scale, incidence rate ratios, calculated risk ratios,
DerSimonian and Laird random-effects with 95% CI. Seven of the reviewed studies
showed a higher rate of positive IGRAs at baseline for those that developed TB (n=9,530,
IRR 2·10, 95% CI). In five studies there was no statistically significant difference
between the progression to active TB for people with TST positive versus IGRA positive
results (IRR 2·11, 95% CI). Studies that used ELISPOT showed a sensitivity of 72%
(95% CI) for developing active TB and specificity of 50% with TST sensitivity of 72%
and specificity of 41%. The risk for developing active TB in positive IGRA people was
low. The authors concluded that the association between IGRAs and active TB
development is weak to moderate and no test is available that has high prognostic value,
and therefore, decisions regarding testing should be based on logistics, population type,
cost and patient preference (Rangaka et al., 2012).
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The study by Rangaka et al. (2012) is a level III systematic review with metaanalysis high quality. The study had a very large sample size. The application of
statistical analyses provides value and strength to the study although the article is very
technical and difficult to understand. The authors noted that most of the reviewed studies
had bias by not accounting for risk factors for TB, and did not fully answer whether
IGRAs are predictive of TB. The authors also note that most studies were not in high
income countries and most had industry involvement (Rangaka et al., 2012).
Evidence level III, good quality (B) articles.
Swindells, Aliyu, Enoch, and Abubakar (2009), conducted a literature review of
82 articles related to healthcare workers and interferon-gamma release assays. PubMed
was used to find articles published from 1990 through 2008 with the combination of
search words health care, health care worker, doctors, nurse, medical staff, tuberculosis,
TB, quantiferon, elispot, IFN, interferon, IFNƴ assays, t cell assays, ESAT-6, CFP10, or
rd1 antigens. The results were published in narrative and no meta-analysis was
conducted. A total of 22 articles met the inclusion criteria with 2 about T-SPOT®.TB and
20 QFT® articles. Out of 11 articles, 9 found that the TST and QFT® results did not have
good agreement while two found good agreement in high incidence countries (CI 95%).
The studies that were examined regarding healthcare worker and BCG vaccination status
had varied results. Two of the studies found agreement between TST and QFT® in those
without BCG vaccination (kappa 0.676, kappa 0.649) but poor agreement in BCG
vaccinated (Kappa 0.090 and 0.029). But two studies did not find any difference in
results according to BCG status (84.2% concordance without BCG and 80.2% with
BCG). Three of the studies did find that positive QFT®s was more closely related to
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increasing TB exposure for healthcare workers (p value not provided). Another reviewed
study also found that the QFT® was more likely to be positive for healthcare workers
that were older and had worked longer in health care. Likewise, a Swiss study reviewed
showed that healthcare workers in higher risk departments were more likely to have a
positive QFT® (p= 0.03). One Italian study did not agree with this assessment and did
not find any correlation between professional category and QFT® result (p value not
provided). Studies that examined contact investigations found that positive QFT®s were
more likely associated with exposure than positive TSTs (p < 0.05). When examining
articles regarding conversions/reversions, there was one that showed a 24% QFT®
reversion rate, one showed good QFT® reproducibility, and one that reported a
significant increase in QFT® results in repeat testing over time (CI 95%). The authors
reported that overall there was poor agreement between the TST and QFT® in healthcare
workers in high incidence countries, however this discordance most likely is due to false
positive TSTs in BCG vaccinated individuals. The authors report that the QFT® was a
good marker of TB exposure in contact investigations. It was concluded that IGRAs are
important to screening and prevention of tuberculosis for healthcare workers (Swindells
et al., 2009).
The study by Swindells et al. (2009), is a level III systematic review of the
literature rated good. The literature review used a reputable database (PubMed) and had
clear criteria for inclusions and exclusion. However, the reviewed articles were published
within the past 18 years which is longer than recommended. This long period of time may
have been necessary due to limited research regarding QuantiFERONs® since the test
itself was fairly new at the time of publication. The authors published results in Euros and
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did not report p values or confidence intervals. Several assumptions were made regarding
specificity and sensitivity of the TST and QFT®. The authors did not specify which
QFT® was used in the reviewed studies and QFT®s only became approved in 2001.
Different types of QFT® could have altered the results since newer versions of the test
are considered to be more accurate. The authors did not discuss the limitations of the
articles reviewed. The authors mentioned that there were only 2 studies that assessed the
T-SPOT®.TB and therefore there was not adequate evidence for its use in healthcare
workers at the time. Another limitation was that the review included articles published in
different countries which may have different TB incidence rates. Overall this was a good
study, but would have been strengthened by conducting some form of meta analysis.
Nienhaus, Schablong, Costa, and Diel (2011) conducted a systematic review of
the literature to evaluated cost effectiveness of utilizing IGRAs to replace TST in
tuberculosis screening. The authors searched Medline and Embase for search terms cost,
interferon, and tuberculosis for articles in English and German. 76 studies were identified
and narrowed down to 13 articles that met inclusion criteria of studies regarding cost,
included high risk groups such as healthcare workers, immigrants, contacts, included TST
and/or IGRA. In five cost analysis studies, two found the QFT®-GIT to be less costly
than TST only, and in three studies the QFT® after positive TST was less costly than
IGRA only. In all five cost analysis studies, the TST only method costs more than IGRA
alone. Eight cost effectiveness studies were reviewed with one study examining TST only
versus IGRA and seven studies comparing TST only, IGRA after TST, and IGRA only
methods. One of these examined T-SPOT®.TB and one examined both T-SPOT®.TB
and QFT® (4 QFT®-G, 1 QFT®-G and QFT®-IT, 3 QFT®-GIT). In all cost43

effectiveness studies, the TST only strategy was found to be the most expensive method
of tuberculosis screening. In four of the studies, IGRA after TST was the least expensive
and in two the IGRA only testing was least expensive. The authors conclude that there is
strong evidence that IGRAs are cost-effective for tuberculosis screening in high risk
healthcare workers, immigrants, close contacts, or those from high incidence countries.
Cost savings is found in less frequency of chest x-rays and less preventive therapy for
LTBI. The IGRA only strategy would be the least expensive if it is proven to predict
progression to active TB more accurately, however more studies are needed to prove this
assumption (Nienhaus et al., 2011).
The study by Nienhaus et al. (2013) is a level III systematic review rated B good
quality. This study used a comprehensive search strategy with clear inclusion and
exclusion criteria and followed the prisma guidelines. The article lists the different
articles in tables for a clear view of differences. The authors discuss the limitation of the
studies lacking consistency in assumptions regarding test parameters and specificity,
progression rates, and different models for cost analysis. While the studies all targeted
high risk groups such as healthcare workers and immigrants, the studies were in different
countries and therefore, cost ratios had to be calculated (Nienhaus et al., 2011). This
could limit generalizability of the conclusions. This study would be strengthened by
applying meta analysis but overall it is a good study to support cost savings for use of
IGRAs.
Pai, Zwerling and Menzies (2008) conducted a meta-analysis of 38 studies
examining sensitivity and specificity of QuantiFERON®-TB God, QuantiFERON®-TB
Gold IN-Tube, and T-SPOT®.TB. This is an update to a previous study adding 20 newer
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studies with stricter inclusions criteria compared to the previous study. Eight of the
previous studies were excluded due to noncommercial assays, fewer than 10 participants,
articles that only studied immune compromised patients, or that used an older antigen for
testing. The authors used PubMed to search for articles published through March 2008.
Studies were included that assessed sensitivity by microbiologically confirmed cases of
tuberculosis (by culture). Studies were also included that assessed specificity by
including samples of healthy low- risk people without tuberculosis exposure. Studies with
fewer than 10 participants were excluded from the review. The statistical method
included a calculation of sensitivity or specificity with 95% confidence intervals and
displayed results in forest plots. MetaDiSc software was used for fixed-effects metaanalysis which corrected for variability between studies. Chi-square and I2 tests were
used to test heterogeneity. This analysis included 22 studies of QFT® with 1369
participants and 13 T-SPOT®.TB studies with 726 sample size. Three of the QFT®
studies were from high incidence countries, while none of the T-SPOT®.TB studies
were. The results showed pooled sensitivity for all QFT® studies to be 76% (95% CI).
For each study investigating QFT®, sensitivity of the QFT®-TB Gold was 78% (CI 7382%), QFT®-TB GIT 70% (CI 63-78%), and T-SPOT®.TB was 90% (CI 86-93%). Six
out of seven studies found that T-SPOT®.TB had higher sensitivity than QFT® (3-25%
difference) while one showed equal sensitivity between the tests (CI 95%, p value not
specified). There were 16 studies from low or incidence countries that examined
specificity of QFT® with 8 of them including BCG vaccinated and 8 non vaccinated with
a sample of 1624 participants. There were 2 studies that examined specificity for TSPOT®.TB and 4 that used ELISpot with a sample of 290. Specificity for all QFT® was
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98% (CI 96-99%), QFT® non-BCG was 99% (CI 98-100%), and 96% (CI94-98%) for
BCG vaccinated. T-SPOT®.TB and TB/ELISpot specificity was 93% (CI86-100%)
overall with T-SPOT®.TB alone being 87% (CI 80-92%). T-SPOT®.TB sensitivity in
relation to BCG was not reported, but one study included BCG vaccinated participants.
TST sensitivity from 20 studies was 77% (CI 71-82%) and specificity in non-BCG
vaccinated in 6 studies of 97% (CI 95-99%). Specificity for TST in BCG vaccinated
participants was low. The authors concluded that IGRAs have excellent specificity that is
not influenced by BCG vaccination status particularly for QFT®s but there are few
studies on T-SPOT®.TB. TSTs were found to have high specificity for those not
vaccinated with BCG but specificity was variable for BCG vaccinated participants (Pai et
al., 2008).
This article by Pai et al. (2008) is a B good quality level III systematic review
with meta-analysis. The authors list the limitation that most of the studies examined were
small and the studies had different cutoffs for testing results. The authors also report that
studies were not included that examined TST alone which could alter the TST analysis.
The authors also report that interpretation of the usefulness of sensitivity and specificity
is limited since there is no gold standard for latent tuberculosis diagnosis. Not all of the
studies reported sensitivity and specificity. The authors caution that results regarding TSPOT®.TB should be carefully interpreted since there were few studies. The authors
clearly discussed limitations of their studies which is important for readers to ascertain
strength. The analyses included scatter plots in the appendix with information about each
article’s sensitivity/specificity results as well as tables comparing BCG vaccinated versus
non-vaccinated (Pai et al., 2008). This improves this studies validity. The meta analysis
46

rather than just systematic review is a strength of this study. The results of this study are
comparable to many other articles found in this review of the literature and contribute to
considerations for policies and procedures for the project.
Evidence level IV, high quality (A) articles.
Jensen, Lambert, Iademarco, and Ridzon (2006), published recommendations for
preventing tuberculosis in healthcare settings. These are the recommendations that are
approved by the CDC and that DHEC require to be followed. This article is 141 pages
long and the aspects that pertain to this project will be summarized for brevity. This
article discusses healthcare workers that should be screened, epidemiology and
transmission of tuberculosis. The authors report that tuberculosis may be transmitted in
healthcare settings and healthcare workers are at risk. Therefore, healthcare facilities
should implement infection control measures. The article describes in detail the infection
control measures including administrative controls, environmental controls, and
respiratory protection controls in detail (Jensen et al., 2006).
The article outlines methods for determining risk level in health care settings and
describes the required screening for low, medium and healthcare workers with potential
ongoing transmission settings (Jensen et al., 2006). According to recommendations,
healthcare workers in low risk settings should receive two step tuberculosis skin testing
on hire or a single blood assay. Those with positive tests should have a chest x-ray to rule
out TB. Healthcare workers in medium risk settings should have the same baseline
screening but should have annual TB screening. Baseline testing with a single blood
assay is acceptable. Facilities should complete only one test without overlapping the
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blood test and TST except for a trial period of evaluation for 1-2 years. The article
reviews care of patients with TB and managing exposures. Proper TST procedures
include first step followed by a trained designated reader in 48-72 hours. The second step
should be placed in 1-3 weeks and read in 48-72 hours. If a patient does not return for
reading within 72 hours and the result is negative, the test must be repeated. Positive
results can be read up to 7 days after placement. The second step is necessary because an
initial TST may be falsely negative while the second step boosts a person with LTBI’s
ability to react to the TST with subsequent positive test. Healthcare workers must have a
trained health care professional to read the TST result. Reading is determined by
measuring mm of induration perpendicular to the forearm. The QFT®-G blood assay for
mycobacterium tuberculosis (BAMT) is reported as an alternative to the TST and this
article reports that the test reacts to two specific proteins found in mycobacterium
tuberculosis “(M. tuberculosis, M. Bovis, M. africanum, M. microti, M. canetti, M.
caprae, and M. pinnipedii)” but not to m. bovis found in BCG vaccine. The blood test
interpretation is less subjective than the TST, may be more cost effective, efficient, and
eliminate two step testing. The TST is subject to variability in placement and reading but
healthcare professional TST administration training can help overcome these barriers.
The authors report that the likelihood that a positive TST represents TB infection in low
risk settings is low but the specificity improves in higher prevalence settings. The authors
report that one single negative BAMT is all that is needed to determine if a healthcare
worker is not infected with tuberculosis. Conditions that reduce immune function could
reduce the predictive value of a negative BAMT or TST (Jensen et al., 2006). BAMTs
may result in indeterminate results if the IFN-ƴ antigen response is low or if the antigen
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response is not at least 50% of the Nil (Jensen et al., 2006). Some reasons for
indeterminate BAMT results include low immune response, improper storage or transport
of blood, lab error, or other illness in the healthcare workers. BAMTs or TSTs should be
completed within 10 days of hire for baseline screening (Jensen et al., 2006). Healthcare
workers with positive blood assays or positive TSTs should be referred for healthcare
evaluation and testing (Jensen et al., 2006). Treatment options for healthcare workers
with positive test results should be guided by considering test results, epidemiologic
factors, risk factors and by diagnostics including chest x-ray or bacteriology, and
histology (Jensen et al., 2006).
Prior to making any changes in tuberculosis screening in healthcare settings, the
Centers for Disease Control and Prevention recommendations must be reviewed and
followed. Therefore, this was the first resource reviewed prior to considering this project.
While the date of publication is 2006, this article had to be included as it is still the most
current guidelines with the addendum on IGRAs published in 2010. There is clearly
expert input in the article including CDC, experts in TB and infection control as well as
experts in respiratory protection and occupational health (Jensen et al., 2006). A list of
departments for which the experts come from are given, however a specific list of who
these experts are is revealed. There is a comprehensive list of 487 references is given.
The authors did not specify their method of obtaining the references for review. Overall,
Jensen et al. (2006) is rated a high quality A level IV study of clinical practice guidelines.
The literature search revealed that the CDC gathered a group of experts and
published an article in 2010 regarding guidelines for IGRAs (Mazurek et al., 2010). This
group of experts reviewed 96 out of 152 articles published through 2008 which examined
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agreement between QFT®-GIT and T-SPOT®.TB or with TST, sensitivity or specificity
of QFT®-GIT or T-SPOT®.TB, QFT®-GIT and T-SPOT®.TB in relation to TB risk,
and use of QFT®-GIT or T-SPOT®.TB in contact investigations. The authors searched
PubMed as well articles from the test manufacturers. The purpose was to provide
guidance for use of IGRAs for tuberculosis diagnosis for healthcare providers, public
officials, and laboratory workers. The result is a lengthy article with discussion of the
strengths and limitations of QFT®-GIT and T-SPOT®.TB. The review of articles by the
authors showed varying results regarding sensitivity of the QFT®-GIT and TSPOT®.TB, however, in general sensitivity is similar to the TST. Pooled QFT®-GIT
sensitivity was reported as 81-83%. Out of 11 studies that examined confirmed active
tuberculosis patients, six studies showed no statistically significant difference between
QFT®-GIT and TST, three showed greater sensitivity for TST, and two showed greater
sensitivity for QFT®-GIT (p<0.01). Pooled T-SPOT®.TB sensitivity was about 90-91%.
Pooled QFT®-GIT specificity for those not likely to have TB was 99% and for TST 85%,
and 86% for T-SPOT®.TB. The authors caution that the reviewed articles for specificity
have varied risk for infection and test methods and interpretation may vary. Tables are
available in this article listing the p values for each study by country. The articles which
the experts reviewed showed varied results with regards to agreement among tests due to
differences in test interpretation criteria, estimates of exposure, BCG status, TST status,
and coexisting conditions. The review did reveal that in contact investigations, positive
IGRAs were more strongly associated with recent exposure and longer duration of
exposure or infectiousness as compared to the TST. Therefore, IGRAs may be better at
detecting more recent infection with TB than the TST. There have been few studies to
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examine whether IGRAs will predict development from LTBI to active TB. However, a
few have reported that the QFT®-GIT performed better than TST at predicting
conversion to active TB. There is limited data regarding using QFT®-GIT for
immunocompromised persons, but two found that QFT®-GIT sensitivity was 81-88%.
Further study is recommended for all aspects of IGRA use. The authors suggest that
ultimately the organization should consider logistical factors such as single visits for
IGRAs, quicker results and less error with reading of results, and cost factors (Mazurek et
al., 2010).
Mazurek et al. (2010) gives guidelines for general use of IGRAs and approve use
for surveillance. It is recommended that quantitative and qualitative results be utilized. It
is recommended that organizations evaluate cost, availability, and benefits of each test in
order to choose which test to implement as studies vary as to which test is better
regarding sensitivity and specificity. IGRAs are preferred for individuals who have a low
rate of return for TST reading and for those who have received a BCG vaccine. An IGRA
or TST may be used without preference for contact investigations and period screening
for occupational exposure. It is mentioned that repeat of an IGRA may be useful if the
result is indeterminate or borderline. After testing, a person with a positive IGRA should
be assessed for likelihood of active TB versus LTBI based on risks, exam, history, chest
x-ray and symptom assessment. A single positive IGRA should not be used as reliable
evidence that someone has tuberculosis as false-positives do occur (Mazurek et al.,
2010). Overall, use of IGRAs are acceptable and approved by the CDC for tuberculosis
screening in healthcare workers.
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Evidence level V, high quality (A) articles.
A study comparing the cost-effectiveness of the QFT®-G, QFT®-GIT, and the
TST for new health care workers was conducted based on data from the Veterans
Healthcare Administration in 2007 (dePerio, Tsevat, Roselle, Kralovic, & Eckman,
2009). The study conducted a Markov stat-transition decision analytic model and
measured quality adjusted life years (QALYs) in relation to direct costs, missed work
time and probabilities. A hypothetical sample of 35-year old RNs was used for this study.
The analysis ran decisions for those with and without BCG vaccination, those with and
without LTBI. The study also accounted for those that fail to return for TST readings.
Also, analyzed was whether isoniazid treatment might be indicated for 9 months and
whether medication induced hepatitis might develop as a result of INH treatment. Direct
and indirect costs were considered, including costs for conducting the tests missed time
from work. Sensitivity analysis was conducted to examine all probabilities and changes
in age. Final results indicated that for all models IGRAs were less expensive than TSTS.
According to the sensitivity analyses, the IGRAs were less costly as long as tests were
conducted in batches of at least 12 for non BCG vaccinated and at least 4 for BCG
vaccinated. For batch QFT® testing, in order to cost less than the TST, the cost for the
QFT®-G should be $32 or less and for the QFT®-GIT $36 or less. The authors
demonstrated that the IGRAs were less costly than TST 100% of the time, but the rate of
LTBI did not change this result. It is concluded that the QFT®-GIT is less costly than the
QFT®-G if it is more sensitive. The authors conclude that the QFT®-G or the QFT®GIT can lower costs in comparison to the TST for tuberculosis screening of new
healthcare workers and have “superior clinical outcomes” (dePerio et al., 2009).
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The study by de Perio (2009) is level V Financial evaluation with a quality rating
of high. This study analyzed multiple hypothetical variables to assess cost of QFT®s in
comparison to TST and the results were very clear that the IGRAs were less costly.
Limiting the age to 35 could have skewed the results, however the authors did vary the
age in some of the models and there were no changes in the result. The figures for salary
could vary by institutions which could change the outcome of this study. The study also
only considered RN salary which is the largest employed group in the hospital, however
this could have skewed the results by not considering lower and higher paid staff. It is
important to note that this study was published in 2009 and the salary and costs for
testing would be considerably higher today. The authors mention the limitation that
decision analyses are dependent on quality and accuracy of the model parameters. The
authors attempted to use pooed data from multiple studies to help overcome this.
However, readers need to understand QALYs definitions. The study could be
strengthened by including decisions regarding cost of subsequent annual TST testing as
well as analyzing actual versus hypothetical data.
An article by Banaei, Gaur, and Pai (2016) discuss the literature regarding
variability for IGRA results and recommendations. According to the authors, studies
have shown some issues with reproducibility and conversion rates with respect to
variability. Factors that contribute to this variability including pre-analytical, postanalytical, manufacturing, and immunological problems. A pre-analytical source of
variability is timing of the blood draw since QFT®-GIT results tend to be higher when
blood is drawn in the evening rather than morning. Also, if the blood collection tube and
the skin is not properly disinfected, there can be contamination causing
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immunomodulatory response from bacteria. If the blood is not drawn in the correct order
of nil, antigen, and then mitogen tubes, then there could be contamination of the antigen
tube from the mitogen giving a false-positive or from the nil tube with mitogen causing
false-negative. The volume of blood and vigorous shaking can affect results as well. The
higher volume of blood can result in false-negatives. Excess shaking can cause increased
IFN-ƴ response and false- positive or negatives depending on whether it was the nil or
antigen tube shaken too much. The authors report that literature shows that delay in
incubation can cause false negative or indeterminate results due to reduction in mitogen
response for QFT®-GIT. For T-SPOT®.TB, indeterminate results are more common in
fall and winter perhaps due to lower temperature during transport of the blood. Longer
incubation does not appear to affect results. Analytical sources of variability can be due
to pipetting that is not precise, errors with centrifugation, washing steps and operator
incorrect measurements. The authors report that studies have shown variability in results
of +0.6 overall and a variability of + 0.24 IU/ml for those with initial results close to
cutoff levels. Post-analytical errors can be the result of error in clerical data entry.
Manufacturing errors can be due to faulty antigen tubes or bacterial contamination
causing false-positive or faulty mitogen tubes causing indeterminates. Immunological
variability may be due to boosting from TST causing conversions. Contamination from
microorganisms on skin or in the environment can cause microbe-associated molecular
patterns that increase the TB response. Staphylococcus aureus contamination in the
antigen tube can cause increase in false-positive results. Recommendations to reduce
variability include: proper disinfection, correct collection tube order, standardize order of
blood draws standardize filling of tubes to 1 ml, gentle shaking of QFT®-GIT tubes,
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prompt incubation, use of automated instruments, quality assurance equipment
calibrations, and draw blood within 72 hours of TST placement (Banaei et al., 2016).
The article by Banaei et al. (2016) is a level V, high quality expert opinion with
some literature review. Recommendations are very clear and helpful for policy and
procedures for QFT®-GIT implementation. References are comprehensive and recent.
This article was not primarily a literature review, but did discuss the literature. The article
did not discuss the limitations of the articles presented in the expert review. Overall, this
is an excellent article which provides clear guidance to avoid variability in IGRA results.

Evidence level V, good quality (B) articles.
Weddle, Hamilton, Potthoff, Rivera, and Jackson (2014), conducted a study with
the purpose of determining performance of the QFT®-GIT in healthcare employees in a
children’s hospital setting determined to be in a low TB incidence. Secondly, the study
examined whether repeat testing of positive QFT®s was useful to determine TB
infection. The study utilized occupational health records to retrospectively review 758
employees screened for TB in 2010-2011. Out of 47 who had positive QFT®s, 34 had
repeat testing with 64.7% (22) positive on repeat and 35.5% (12) negative on repeat. The
mean QFT® result of those who had positive repeat testing was 1.19 and 0.92 on initial
testing. The initial mean and median of negative repeat testers was 0.61 and 0.5. This
revealed that the negative repeat individuals had a statistically significant (p=.01) lower
IFNƴ results than those with positive results. The authors did not reveal which statistical
test was used to compute the findings. There was no statistically significant difference in
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reported risk factors between the repeat negative and repeat positive groups (p=.86). Out
of the 707 negative QFT® employees, 37.9% had risk factors for TB and 36.2% of the
positive QFT® individuals had risk factors for TB. The authors conclude that the QFT®GIT is useful for tuberculosis screening in healthcare workers, however false positive
may occur when results are less than 1IU/ml and repeat testing should be considered
(Weddle et al., 2014).
Overall, this study is level V quality improvement with a quality rating of good.
While statistical analyses were conducted, the authors did not reveal which tests were
employed. The authors give a clear discussion of implications for repeat testing.
However, the authors do not discuss the results of the risk stratification. This study would
have been strengthened by a larger sample of positive repeaters. Comparing 707 negative
employees to 47 positive employees may have skewed results unless this was adjusted for
in the statistical analysis. This study is important to consider when designing policies and
procedures for repeat testing.
Foster-Chang, Manning, and Chandler (2014), conducted a study at the Veteran’s
Administration health care facility to determine if an IGRA was acceptable in lieu of the
TB skin test to improve processes for pre-placement assessments. This medical center
employees 3,500 with 64% in the 41-60 age group. It was reported that many employees
were foreign born and had BCG vaccination but the total number or percent was not
given. This study included a convenience sample of 100 new employees hired from
March 19 through May 30,2013 who were asked to have a T-SPOT®.TB instead of the
TST during pre-placement assessment. Data from this group was compared to
retrospective electronic chart review of 100 new employees who had the TST in the
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previous time periods of 2011 and 100 new employees in 2012. The study examined
compliance with completing the entire pre-placement process within 14 days.
Compliance in the T-SPOT®.TB group was 97% while compliance in the PPD group
was 77%. Chi-square goodness of fit tests showed statistically significant difference
between the TST group and the T-SPOT®.TB group compliance rates with p <.001 for
2012 compared to 2013 and p < .0001 for 2011 compared to 2013. The study also
reviewed the clearance for work time defined as the time from pre-placement assessment
to provider signed clearance to start work. The average clearance for work time for the TSPOT®.TB group was 5.91 days while the average for the TST groups was 12.67 in 2011
and 13.18 in 2012. There was statistically significant difference in clearance time by
Kruskal-Wallis equality of populations rank test between the T-SPOT®.TB and the TST
groups regardless of whether the employee in the TST group brought prior TB
documentation (p <.001, 95% confidence interval, Chi-square 30.981) or did not (p<.001,
95% confidence interval, chi-square 28.479). Cost comparison for the IGRA with cost of
TST process was $78.53 per person versus $47.02 per person in the T-SPOT®.TB group
(Foster-Chang et al., 2014). No statistical analyses were conducted for the cost estimates.
The authors conclude that IGRAs are acceptable in place of the TST for new employees
and will improve tuberculosis screening processes (Foster-Chang et al., 2014).
The strengths of this article by Foster-Chang et al. (2014) included good precision
with results that were statistically significant for compliance and screening time with
adequate sample size of 300. Another strength of the study is that the purpose and design
are closely related to the PICOT questions for this project, however the authors used the
T-SPOT®.TB rather than QuantiFERON®-TB Gold In-Tube-Test. External validity is
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good in that conclusions can be applied to similar healthcare settings, however the fact
that the sample may have a higher percentage of foreign born employees who may have
received BCG vaccination could affect the generalizability. For construct validity, other
facilities might interpret clearance time different than this organization. One weakness is
that the authors admit that reliability could have been affected due to the physician signed
clearance with impending vacation plans, a chart for a T-SPOT®.TB employee was
misplaced and discovered 21 days later, and two employees chose not to have blood
drawn on date of pre-placement assessment, returning 2 weeks later (Foster-Chang et al.,
2014). These factors could have affected the results causing increase in clearance time
and reduction in compliance. Furthermore, data from misplaced charts were probably not
readily available for data analysis of the TST groups. This study was not a controlled
experiment which affects internal validity. Investigators may have also had bias due to
the expected reduction in clearance times at the start of the study. A strength in the
internal validity is that the T-SPOT®.TB group had no attrition. Overall the evidence
level for this study is V quality improvement with quality rating of B Good. This article
supports that implementation of an IGRA is acceptable for new healthcare employees.
Gonzalez and Conlon (2013) described how their organization developed a needs
assessment to determine which tuberculosis surveillance program would meet the needs
of the facility. The hospital is described as moderate sized and has 4,300 employees with
a low risk assessment per CDC guidelines. Approximately 25% of the employees had
previous BCG vaccination. TB screening is conducted by TST annually for those without
previous BCG vaccination or previous positive. This organization was originally
exempting pregnant employees from screening and conducted annual symptom
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assessments. The organization also conducted an annual symptom review and a chest xray every 5 years for those with a history of positive TST. The authors admit that these
practices were outdated and did not meet current CDC guidelines as pregnant women do
not need to be excluded and an x-ray every 5 years is not necessary. New employees
were screened with two-step TST. The organization developed a 12 item table comparing
the attributes of the TST, QFT®-GIT, and the T-SPOT®.TB. The organization
eliminated the T-SPOT®.TB as an option due to the lack of on-site lab testing and the
time limitations for the specimens. The authors’ literature review revealed that QFT® and
TST had comparable sensitivity and specificity when BCG vaccinated people are not
included in the TST data. The authors were concerned about the report reversion rates
with the QFT® and the laboratory preparation and incubation time. The organizations lab
did not conduct testing on the weekend which would limit QFT® testing due to the 16hour time limit for processing. The QFT® can be conducted in one visit which saves
money in lost productivity. Ultimately the organization chose to continue two step TSTs
for new hires without BCG vaccination and for annual testing. The organization chose
QFT® for BCG vaccinated new hires but only a symptom assessment for annuals. The
organization will utilize QFT® additionally for exposures, pregnant employees and
immunocompromised employees. This article provides an example of how organizations
should consider all of the variables when deciding on which tuberculosis screening test to
implement (Gonzalez & Conlon, 2013).
The article by Gonzalez and Conlon (2013) is a level V Organizational
Experience/Quality Improvement quality B good article. This is a non-research article
that provides useful information to consider when choosing a tuberculosis screening tool.
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The article had a small amount of literature included but certainly is not comprehensive.
The decisions in this tool cannot be generalized but the techniques for decision making
can be applied. A concern, is that they continue to exclude pregnant workers from their
standard TST, rather choosing to use the QFT® demonstrates an improvement in
standards. Decision making for tuberculosis screening is certainly complex and unique
for each organization due to multiple variables such as demographics and geographics.
Veeser, Smith, Handay, and Martin (Veeser, Smith, Handy, & Martin, 2007)
evaluated the results, acceptability and costs for QFT®-G implementation at the
University of Tennessee Health Science Center at Memphis. There are approximately
2,200 students and 6,000 direct patient care employees that are screened for tuberculosis.
The authors conducted a retrospective chart review for those that were screened for
tuberculosis with QFT®-G from June 2005 through August 2006 through University
Health Services (UHS). The organization began using the QFT®-G in 2005 for special
groups included those that reported a history of positive TST but did not have
documentation from the health department, those with questionable history of positive
TST, people who had been BCG vaccinated and those that tested positive by TST at
UHS. The sample size was 109 including 55 employees and 54 students. Out of the
sample, 84 had negative QFT®-G, 10 positive and 5 indeterminate. Out of the 10 positive
results, 7 were students who had BCG vaccination and 1 that reported a history of
undocumented positive TST. One was an employee that had documented past positive
TST and one employee had history of undocumented positive TST. The 5 people that had
indeterminate results were tested a second time and had indeterminate results again. One
case study is discussed in which one employee had a positive TST after years of negative
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testing and was referred for treatment. The authors state she was tested with bot methods
but do not report if the QFT®-G was positive. There were 3 people who had a past +TST
but negative QFT®-G result. The authors state that this may have been due to improper
readings, or thimerosal reactions. The authors conclude that the QFT®-G is acceptable
and provides operational improvements. The authors report that phlebotomy was
acceptable to the patients. At this facility the QFT®-G costs $62.60 and the TST is $9.79
but report that patient time requirements could make the QFT®-G cost effective. The
authors report that the cost of one false-positive TST would be $445 to $1,195 for chest
X-ray, office visits, lab monitoring, and medications. In this organization implementation
of the QFT®-G was successfully implemented for specific groups (Veeser et al., 2007).
The study by Veeser et al. (2007) is a level V program evaluation rate B good
quality. This study had clear recommendations and clearly described the program.
However, there was no attempt to complete statistical analyses of the results. The sample
lacked randomization, and there was not control for extraneous variables. The
conclusions regarding the past positive TST but negative QFT®-G is presumptive and
not objective. The conclusions regarding acceptability of phlebotomy is not verified by
any objective information that is provided in the article. Logistical improvements were
discussed but this conclusion would have been improved by tracking objective data. This
study could be strengthened by including statistical analysis and further measures of
logistical improvement and acceptability surveys for the patients.
Slater, Welland, Pai, Parsonnet and Banaei (2013) conducted a retrospective study
to examine the reproducibility of QFT® in healthcare workers at Stanford University
Medical Center (SUMC). SUMC has 10,000 employees and averages 14 cases of TB per
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year between 2006 and 2011. The TST conversion rate in 2006 was 0.4%. SUMC screens
employees for TB annually and in 2006 began using the QFT®-G for screening and
changed to QFT®-GIT in 2008. SUMC clinic screened all employees with QFT®
regardless of previous history of LTBI or positive results. Anyone who had a conversion
was retested in 6 weeks. The study period was from June 1, 2008 through July 31, 2010
and the sample size was 9,153 healthcare workers who had at least 2 QFT®s. Data was
obtained from lab databases and no information was obtained regarding previous test
results or risk factors. Statistical analysis included independent group t test for
comparison of variables, ȥ for proportions, linear regression, and kappa statistic
performed using Stata. The results showed that when those with initial positive QFT®s
(1,223) were retested 67.5% (n=828) remained positive. When employees who had
negative initial QFT®s (8,277) were retested, 4.4% (361) converted to positive. There
was a statistically significant (p< .001) increase in conversions and reversions in groups
that had results between 0.35 and 1.0 IU/ml compared to those who were persistently
positive. Three hundred and sixty-one healthcare workers that converted to positive and
retested 262 (72.3%) retested within 60 days and reverted to negative, and 38 people
tested negative after 60 days, while 11.1% (40) failed to retest. Twelve out of 16
Healthcare workers who received a second repeat test reverted to negative. If the cutoff
for positive results was changed to 1.0 IU/ml, 67% of discordant results would be
eliminated, however 33.7% of the persistent positive results would have been missed. In
order to obtain the same 0.4% conversion result as with the TST, the cutoff for QFT®
would have to be 5.3. The authors conclude that QFT® cutoff values result in increased
conversion rates and conversions suggest false-positive results (Slater et al., 2013).
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The article by Slater et al. (2013) is a level V organizational experience, quality
good study. The authors discuss the limitations of a lack of gold standard, the lack of
information regarding TB risk factors for this study, and intervals between retests were
not standardized. The authors also mention the limitation of possible changes in lab
practices over the years (Slater et al., 2013). This study did include a large sample size
which improves validity. There was some attrition bias as 11.1% of positive testers did
not follow up for repeat testing. There was no randomization for this study. The authors
did not do any comparison for the QFT®-G versus the QFT®-GIT which might have
provided some helpful information. Information regarding previous BCG vaccination
status and risk factors would have improved interpretation of results.
Loddenkemper, Diel, and Nienhaus (2012) wrote an expert opinion article that
discuss a few studies. The authors report that the specificity of IGRAs is well established
and sensitivity for diagnosis of active TB is higher than with the TST. IGRAs are useful
for identifying who will benefit from preventive treatment, however research on the
positive predictive value is still small. The few studies that have examined serial IGRA
testing have found high reversion rates for positive IGRAs and simple negative or
positive result interpretation can overestimate reversion and conversions. Some studies
have suggested using a gray interpretation zone of 0.35 to 1.0 IU/ml, but that figure has
not been validated. The authors conclude that positive IGRAs should be repeated for
routine screening of healthcare workers. Chest x-rays are not needed if healthcare
workers with positive IGRAs are asymptomatic and the IGRA reverts (Loddenkemper et
al., 2012).
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This article by Loddenkemper et al. (2012) is a level V Expert opinion, quality B
article. The article is short but contains 13 references. It is too short to discuss all the
limitations of the studies mentioned. The authors appear to be experts from German
Central Committee Against TB, Department of Pulmonary Medicine Medical School and
a physician from University Medical Center Hamburg-Eppendorf as well as being
authors of other articles reviewed in this literature review (Loddenkemper et al., 2012).
The conclusions would be more credible if the authors were able to specify frequency for
when IGRA results should be repeated, but as they state, there is no validated
recommendations at this time (Loddenkemper et al., 2012).
Nienhaus (2013) provides expert opinion and a short literature review regarding
use of QuantiFERON®-TB Gold (QFT®) in healthcare workers. This article discusses
the risk for tuberculosis in healthcare workers which is still a concern globally. Ongoing
screening for TB is essential for TB control. The advantages of IGRAs include one visit,
clearer interpretation, results are not affected by BCG vaccination, and objective results.
The authors report that studies show that IGRAS have superior specificity in comparison
to TST in low incidence countries with QFT® offering the highest specificity of 99.2%.
Utilization of QFT®s would reduce the number of chest x-rays by 25 to 98% as shown in
a head to head comparison (Nienhaus, 2013). The author reports that QFT® can predict
the development of active TB better than TST and reduce the number of patients needing
chemotherapy. QFT® results should not be compared to TST or Elispot due to different
cutoff levels and methods as well as the TST has non-return rates and Elispot invalid
results are usually not published. The author reports that studies have shown IGRAs to
improve cost-effectiveness. The article reviews the criteria for interpreting negative and
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positive with a flowchart. If TB Antigen Minus Nil is > 0.35 IU/ml and that result is >
25% of the Nil value and the Nil is < 8.0 IU/ml, then the result is positive. Healthcare
workers are usually more accepting of taking medications for positive IGRA results
versus TST results. The author discusses that studies show that healthcare workers do
have a higher rate of reversion from positive to negative IGRA results, and therefore,
should have retesting if positive and TB is not suspected. Some studies have suggested a
borderline retesting zone of 0.35 to 1.0 IU/ml but the FDA has not approved a change in
cut off (Nienhaus, 2013).
The article be Nienhaus (2013) is level V expert opinion/literature review quality
B good. Recommendations and review are clear and concise. This article is published by
QIAGEN® which is a limitation that could introduce bias. The number of references is
large at 63. The number of articles discussed in depth is smaller at 10. The article does
not review limitations of articles but the main purpose of the article is expert opinion.
Expert opinion is evidence since the author is a Professor and occupational physician in
Germany and has written several other studies on QFT® testing. Overall, this article is
useful for providing guidance for QFT® testing in employees.
Graban and Filby (2015) discussed a case study of a ‘lean’ process applied to a
healthcare facility’s evaluation for utilizing the QuantiFERON®-TB Gold test for
tuberculosis screening of new hires. ‘Lean’ processes aim to improve work flows, reduce
delays and other barriers to completion of work. The health system has 5,000 employees
and hires about 1,000 new employees annually with an employee turnover rate of 1520%. The system currently uses a 2 step TST process for new hire screening requiring
four different visits for each new hire. According to data, new hires do not follow up for
65

TST readings which delays onboarding. This further contributes to the need for
temporary staffing or locum tenens and additional recruitment efforts to fill employee
vacancies. The organization has a goal of completing onboarding within 30 days and the
2 step process can delay this. The one step QFT® can reduce ‘waste of transportation’ in
‘lean’ terminology which means it reduces the number of visits improving efficiency. If
the QFT® has a false positive rate that is less than TST then there may be a reduction in
‘waste of defects’. QFT® results are reported within 1-3 days which can reduce
tuberculosis clearance by 7-9 days. Reduction in Chest X-rays and medications for falsepositive can also reduce waste. More objective results reduce waste. Reduction in ‘overprocessing’ and ‘talent’ occurs when staff do not have to spend time following up on new
hires who don’t return for TST readings. QFT®s may reduce costs by reducing, and
therefore, reduce temporary staffing or locum tenens needs. The authors conclude that
QFT® testing of new hires for screening can reduce waste (Graban & Filby, 2015).
The article by Graban and Filby (2015) is a Good B quality level V case report.
This article reviews how ‘lean’ business principles can be applied to QFT® for new hires,
but does not report any actual statistical results. This would add value and validity to this
article. This article was published by QUIAGEN which could result in bias. There were
only 6 references for this article which is small limiting validity. This article has good
generalizability with principles that can be applied to many different healthcare facilities.
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Synthesis of Literature
Tuberculosis screening process.
Studies suggest that organizations should conduct a needs assessment prior to
selection and implementation of IGRAs (Gonzalez & Conlon, 2013; Graban & Filby,
2015). The first step in the needs assessment is to make sure that the tuberculosis
screening method meets regulatory requirements. The Federal Drug Administration
(FDA) and the CDC has approved IGRA’s for screening of workers who may have
occupational exposure to tuberculosis (Jensen et al., 2006; Mazurek et al., 2010). Studies
show that organizations should choose the appropriate test based on availability, costs,
logistics, population TB risk, BCG Vaccine status, staffing, and organization resources
(Gonzalez & Conlon, 2013; Graban & Filby, 2015; Lamberti et al., 2015; Mazurek et al.,
2010; Rangaka et al., 2012). Healthcare employee health offices should examine current
processes and any impact the change would make to the organization. After impact to the
organization has been identified, the organization can then individualize the test selection
and process plan (Gonzalez & Conlon, 2013).
Logistics and adherence of utilizing IGRAs in place of TB skin tests should be
considered (Foster-Chang et al., 2014; Gonzalez & Conlon, 2013; Graban & Filby, 2015;
Mazurek et al., 2010; Rangaka et al., 2012). IGRAs do have the advantage of one single
visit rather than 4 visits for two step TB skin tests. Studies report that IGRAs improve
compliance and expedite completion of tuberculosis screening (Cummings et al., 2009;
Foster-Chang et al., 2014; Graban & Filby, 2015; Mazurek et al., 2010). Lean processes
applied to analyzing logistical processes for tuberculosis screening and can help with
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improving flow, work time, and efficiency. The required four visits for tuberculosis
screening is inconvenient to new hires and can result in noncompliance and hiring delays.
Hiring delays can result in further understaffing which can lead to stress and increased
turnover and costs due to temporary agency staffing. One study showed that onboarding
of associates in an organization with 5,000 employees with a 15-20% turnover rate rarely
resulted in meeting the onboarding goal of completion in less than 30 days. The QFT®
presents a possible contributing solution for reduction in onboarding time since results
can be received within 1-3 days and the candidate can be cleared 7-9 days sooner than
with the 2 step TST (Graban & Filby, 2015). Studies have shown that use of IGRA’s can
indeed increase compliance, reduce tuberculosis screening time and improve compliance
(Foster-Chang et al., 2014; Veeser et al., 2007; Wrighton-Smith et al., 2012). Veeser,
Smith, and Martin (2007), successfully implemented QFT®-TB Gold tests for students
and employees of a health science college and saw improved completion rates. Likewise,
Wrighton-Smith et al. (2012) conducted parallel testing of healthcare workers at a large
healthcare system and reports that only 0.4% of IGRA test results were unavailable in
comparison to the typical rates of noncompliance with TST follow up to be 20%. This
shows an improvement in tuberculosis screening compliance from 80% to 99.6% with
utilization of IGRAs (Wrighton-Smith et al., 2012). Foster-Chang et al. (2014), revealed
successful implementation of the T-SPOT®.TB for all new hire hospital workers. This
study showed that use of the T-SPOT®.TB for new employees improved overall
employee health clearance to work time from 13.18 to 5.91 days showing a reduction of
7.27 days. Compliance with completion of the pre-placement process within 14 days also
increased from 77% to 97% (Foster-Chang et al., 2014). This demonstrates that
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implementation of an IGRA for new hires can significantly reducing overall onboarding
time and improve compliance. It would be expected that the QFT®-GIT should yield
similar results with increased compliance and reduced onboarding time. However, if
QFT®-GIT is selected, the facility must have resources and staff to draw the blood, and
incubate or send the specimens to a lab for incubation within 16 hours (Banaei et al.,
2016; Gonzalez & Conlon, 2013). The T-SPOT®.TB has similar process issues such as
need to process fresh blood within 5 hours (Gonzalez & Conlon, 2013; Mazurek et al.,
2010). If procedural difficulties are overcome, IGRA results are quicker and not subject
to reader bias which can improve efficiency in the employee health department (Graban
& Filby, 2015; Mazurek et al., 2010)
Of high importance is that studies found use of IGRAs was found to be acceptable
by patients (Foster-Chang et al., 2014; Veeser et al., 2007; Wrighton-Smith et al., 2012).
One study administered a questionnaire to healthcare workers who were enrolled in a
study with parallel TST and IGRA testing. This study revealed that 62.3% of participants
preferred the IGRA and had better confidence in IGRA results (Wrighton-Smith et al.,
2012). One visit is more convenient than 2 or 4 visits for employees. Improved employee
satisfaction with use of IGRAs can lead to reduced turnover, improved compliance, faster
onboarding, and provide logistical benefits to employee health offices (Graban & Filby,
2015).
Cost.
Cost-effectiveness of using an IGRA versus TST was evaluated in several studies
and found to be cost-effective (dePerio et al., 2009; Graban & Filby, 2015; Mazurek et
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al., 2010; Nienhaus, 2013; Nienhaus et al., 2011; Wrighton-Smith et al., 2012) The IGRA
costs more than the TST on the surface, but savings can be found in staff time, less
missed work time, less treatment of false positive results, and reduced turnover (FosterChang et al., 2014; Graban & Filby, 2015). In a high quality financial evaluation utilizing
a Markov state-transition decision analytic model, QFT®-TB Gold and QFT®-GIT were
both found to be less costly and more effective than TSTs for healthcare workers
regardless of BCG vaccination status. This study measured direct and indirect costs
including quality-adjusted life-years (QALYs) which considers missed work time into
costs and analysis revealed reduced costs (dePerio et al., 2009). Foster-Chang et al.
(2014) conducted a quality improvement study in which new hires had IGRAs. When
salaries, supplies, staff time, failure to return for TST, and monitoring of positive results
were considered in cost analysis, there was a reduction in costs of 38% to 40% in
comparison to the TST. Costs were reduced from $7,852.70 for 100 new employee TSTs
in 2011 to $4,699.50 for 100 new employees with IGRA (Foster-Chang et al., 2014).
Veeser et al. (2007) found similar results when QFT®-G was implemented for health
science students and employees which revealed reduction in costs related to less false
positive results and follow up. They estimated that the cost of one single false-positive
TST to be $445 to $1,195 for chest x-rays, medications, and follow up (Veeser et al.,
2007).
The SWITCH study was conducted at John Hopkins Healthcare system employee
health which screens 18,000 employees annually with the purpose of determining the
price at which IGRA becomes less costly than TST. This study analyzed material and
labor costs, conducted a time-motion study of 393 patients and assessed labor costs, and
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thirdly 743 health care workers had TST and IGRA parallel testing. Material costs,
employee health labor costs, employee labor costs, employee health staff time, and
employee time off work were considered. When considering all these factors, switching
to IGRA for annual as well as new hires there would be savings if the IGRA costs $54.83
or less per test. When considering only new hires, switching to IGRA would result in
savings if the IGRA costs $81.16 or less per test (Wrighton-Smith et al., 2012).
Nienhaus, et al. (2011) conducted a systematic review of 13 studies and found
that TST’s were the most expensive method for tuberculosis screening while utilization
of IGRAs decreased costs in all scenarios. Only two of the studies reviewed examined TSPOT®.TB while the other studies examined QFT®-TB gold or QFT®-GIT. Four of
seven of these studies this review examined revealed that IGRA after positive TST was
the least expensive. The authors concluded that there was strong evidence that IGRAs
including QFT® or T-SPOT®.TB are cost effective in high risk groups including
healthcare workers, high incidence country immigrants and close contact with
tuberculosis (Nienhaus et al., 2011). Literature review by Nienhaus (2013) also revealed
that studies that considered that TST sensitivity is well below 100% for countries with
low incidence of TB, found that IGRA alone will improve cost-effectiveness. The
evidence shows that screening with IGRA can be cost-effective if cost of the test is
controlled and staff time, labor costs and adherence are considered (dePerio et al., 2009;
Nienhaus, 2013; Nienhaus et al., 2011; Wrighton-Smith et al., 2012).
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Accuracy.
Several studies examined the sensitivity and specificity of IGRAs as well as
agreement between TSTs and IGRAs with varied results. Sensitivity assessments attempt
to determine whether positive tests results are truly positive. Assessment of sensitivity of
IGRAs is complicated by the fact that there is no “gold standard” test to confirm culture
negative latent tuberculosis infection (LTBI). IGRAs are indirect tests that measure
immunologic response rather than testing for the organism. Published reports vary in test
methods and interpretation criteria further confounding interpretation analysis of the
literature (Mazurek et al., 2010). Some of systematic reviews and single studies that
were reviewed found that agreement between TST and IGRA to be low in regards to
sensitivity with predominance of positive TST compared to negative IGRA (Cummings
et al., 2009; Dorman et al., 2014; Lamberti et al., 2015; Swindells et al., 2009). However,
positive TST can likely be the result of false-positives from BCG vaccination status,
immune factors, boosting or poor reader interpretation (Dorman et al., 2014; Lamberti et
al., 2015; Rangaka et al., 2012; Swindells et al., 2009). Pai et al. (2008) conducted a
meta- analysis of 20 studies and reports inconsistent results of sensitivity for IGRAs, but
does report 70% sensitivity for QFT®-GIT. The authors do admit that the studies
analyzed were small and had varying TST methods and cutoffs (Pai et al., 2008).
However, Mazurek et al. (2010) report that when studies consider sensitivity of the
QFT®-GIT in patients with active tuberculosis, the combined data show QFT®-GIT
combined sensitivity of 81% in comparison to 70% for studies that use meta-analysis.
Furthermore, analysis shows that when QFT®-GIT is compared to TST in culture
positive patients, QFT®-GIT sensitivity is 83% while TST is 89% (Mazurek et al., 2010).
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Assessment of specificity (likelihood that a true negative test result is negative) of
IGRAs shows more consistency in results. Specificity of IGRAs appears to be high
(Cummings et al., 2009; Mazurek et al., 2010; Nienhaus, 2013). This high specificity is to
be expected since IGRAs and QFT®-GITs in particular do not react with BCG
vaccination or other nontuberculous mycobacteria (Mazurek et al., 2010). Cummings et
al. (2009) conducted a study comparing QFT®-GIT in low risk healthcare workers with
tuberculin skin tests and found high agreement and specificity. Two QFT®-GITs were
offered to newly hire healthcare workers who were having TSTs. Specificity of the
QFT®-GIT was 98% for healthcare workers without risk factors (Cummings et al.,
2009). One systematic review found that QFT® have 99% specificity in patients not
BCG vaccinated and 96% in BCG vaccinated (Pai et al., 2008). Nienhaus (2013) reports
that a review of the literature supports that QFT®s have superior specificity in
comparison to TSTs especially in countries with low TB incidence. In particular, results
of pooled studies show QFT®-GIT show specificity of 99% while TST was 85%
(Mazurek et al., 2010). This shows a higher rate of specificity for QFT®-GIT than TST
supporting its use in low risk areas.
Risk factors, BCG vaccination status and exposure risk should be considered
when choosing testing methods. Several studies agree that IGRAs are the test of choice
for individuals vaccinated with BCG (Foster-Chang et al., 2014; Jensen et al., 2006;
Lamberti et al., 2015; Mazurek et al., 2010; Rangaka et al., 2012; Wrighton-Smith et al.,
2012). The CDC reports that IGRA is the preferred method for tuberculosis screening for
individuals who have received the BCG vaccine and for those who are unlikely to return
for follow up (Jensen et al., 2006; Mazurek et al., 2010). IGRAs have been correlated
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with exposure risk including length of employment in healthcare, age, foreign born, and
exposure level (Diel et al., 2009; Nienhaus, 2013; Swindells et al., 2009; Zwerling et al.,
2012). In one quasi-experimental study, close contacts of tuberculosis culture confirmed
sources were tested with IGRAs and found that IGRAs were a better indicator of latent
tuberculosis in relation to exposure risk in comparison to TST (Diel et al., 2009).
Mazurek et al. (2010) had similar findings when reviewing the literature and found that
positive IGRA results were more closely associated with greater recent exposure
measured by exposure duration. Therefore, IGRAs should be chosen over TST in
situations when the individual is BCG vaccinated or has high risk of exposure.
Conversions, reversions and result cutoffs.
Several studies examined conversion (change from negative to positive) and
reversion (change from positive to negative) rates and discussed possible need for change
in IGRA cutoffs (Banaei et al., 2016; Cummings et al., 2009; Dorman et al., 2014;
Loddenkemper et al., 2012; Schablon et al., 2014; Slater et al., 2013; Weddle et al., 2014;
Zwerling et al., 2012). This evidence will be important to consider when designing
processes for interpretation and implementation of QFT®-GITs. Weddle et al. (2014)
conducted repeat QFT®-GITs in healthcare employees who had positive QFT®-GITs. Of
the 34 QFT®-GIT positive employees who had repeat testing 64.7% had positive repeat
tests and 35.3% had negative on repeat tests. The mean result of the repeat positive
testers was 1.19 while the mean repeat negative test results was 0.61. This article
suggests that healthcare workers with QFT®-GIT results of 0.35 to 1 IU/ml should have
repeat testing to avoid false-positives (Weddle et al., 2014). Zwerling et al. (2012) also
examined four studies that addressed conversion and reversion rates in healthcare
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workers in low incidence settings. Rates of conversions and reversion in IGRA results
upon repeat varied in results due to different cutoff definitions. The studies had higher
rates of conversions and reversions if a simply positive or negative cutoff was used
(Zwerling et al., 2012). Slater et al. (2013) conducted a retrospective evaluation of
QFT®-GIT results for 9,153 healthcare workers in relation to conversions and reversions.
Three hundred sixty-one (4.4%) of healthcare workers with baseline negative QFT®-GIT
converted to positive over 2 years. Of 261 healthcare workers with positive QFT®-GITs,
169 (64.8%) reverted back to negative when retested within 60 days. This article states
that a result cutoff of 5.3 IU/ml would result in a conversion rate of 0.4% similar to the
institutions tradition rate of conversion (Slater et al., 2013). Dorman et al. (2014) found
similar results when healthcare workers with QFT®-GIT test conversions were retested 6
months later, 76.4% reverted to negative. Schlabon et al. (2014) showed a small
conversion rate of 2.8% and reversion of 37.3% when healthcare workers were screened
with QFT®-GIT. This study found that an interferon cutoff result of <0.2 to >0.7 IU/ml
would decrease the conversion to 1.2% (Schablon et al., 2014). Similarly, Cummings et
al. (2009) found that of 5 positive QFT®-GITs, only 2 were confirmed on repeat testing.
Loddenkemper et al. (2012) also reports that a cutoff for QFT®-GIT results may be
warranted. The author suggests a gray zone of 0.35 to 1.0 IU/ml and states that treatment
medications should not be given for IGRA results of <0.1 IU/ml (Loddenkemper et al.,
2012). CDC recommendations agree that repeat IGRA testing with another blood sample
may be useful if the result is borderline or invalid. However, ultimately treatment should
be based on likelihood of infections, risk factors and symptoms (Mazurek et al., 2010).
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Indeterminate results should also be considered when choosing IGRAs.
Cummings et al. (2009) repeated ELISAs on the same blood sample for indeterminate
testers. Of 16 indeterminate results due to low mitogen response, 11 (69%) remained
indeterminate and 5 (31%) converted to negative. Healthcare workers with diabetes or
immunosuppression had a greater odds ratio (6.8) of having a confirmed indeterminate
result. It is also important to note that there was found to be statistically significant higher
IFN-y concentrations in QFT®-GIT results when healthcare workers had 1 intervening
TST regardless of the time between tests (Cummings et al., 2009).
There are some sources of variability in lab procedures that can contribute to
false-positive QFT®-GITs that should be considered when making recommendations.
Sources of variability include time of day the blood is drawn, inadequate
disinfection/contamination of tubes, vigorous shaking, blood volume, processing delays,
and incubation issues. It is possible that contamination with bacteria can lead to higher
IFN-y concentration. Vigorous shaking of the tubes may also lead to false positive or
negative results. The blood should be collected in the proper order, nil, antigen, and then
mitogen as tube contamination may be a factor in results. Incubation delays could
potentially decrease antigen response. Processes for disinfection, tube order, and 1 ml
blood fills should be standardized to eliminate variability. All 3 tubes should be gently
shaken together. Processing delays should be minimized. As mentioned above TSTs can
boost IGRAs and therefore IGRAs should be drawn within 72 hours of placement.
Standardization can assist with variability concerns (Banaei et al., 2016).
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Discussion
Analysis of the literature revealed pros and cons to choosing the QFT®-GIT for
TB skin testing for new healthcare workers. There are a number of positive logistical
factors that would provide value for employee health offices while improving costeffectiveness. Since QFT®-GITs are completed in one test, new hire onboarding and
tuberculosis clearance time should be reduced. This will also reduce the burden on
employee health staff time spent on tuberculosis clearance activities, and enhance
convenience to the new hire (Foster-Chang et al., 2014; Graban & Filby, 2015; Veeser et
al., 2007). Cost analysis revealed that IGRAs are cost effective (dePerio et al., 2009;
Foster-Chang et al., 2014; Graban & Filby, 2015; Nienhaus, 2013; Nienhaus et al., 2011).
The QFT®-GIT has high specificity but there are some concerns about sensitivity
(Banaei et al., 2016; Cummings et al., 2009; Dorman et al., 2014; Loddenkemper et al.,
2012; Schablon et al., 2014; Slater et al., 2013; Weddle et al., 2014; Zwerling et al.,
2012). However, sensitivity of the QFT®-GIT improves with consideration of patients
with active tuberculosis (Mazurek et al., 2010). Some studies have shown that there can
be issues with conversions and reversion and a borderline cutoff with retesting may be
appropriate (Dorman et al., 2014; Loddenkemper et al., 2012; Mazurek et al., 2010;
Schablon et al., 2014; Slater et al., 2013; Weddle et al., 2014; Zwerling et al., 2012).
When interpreting results, the immunologic status of the patient should also be
considered with indeterminate results (Cummings et al., 2009). Standardization of lab
procedures can help overcome some of the variability in results (Banaei et al., 2016).
Overall, there is good evidence to implement QFT®-GITs in new hire healthcare workers
while considering all the interpretation factors.
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CHAPTER 3
PROJECT DESIGN AND PLAN
Introduction
Employee Health was faced with the dilemma of increasing volume of new hires
coming for pre-placement assessment appointments and increasing frustration by
management regarding delays in orientation. Employee Health management formed a
new hire committee in Fall of 2015 to investigate the factors involved with delays in
orientation. One factor identified that contributed to orientation delays was the amount of
time it takes for new employees to complete the two-step TST. The literature was
reviewed and multiple steps were taken to investigate the ability for Employee Health to
offer an IGRA for all new hires in order to reduce the amount of time it takes to be
cleared for orientation. In February of 2016, Employee Health implemented the QFT®GIT in place of the two-step TST for tuberculosis screening of all new hire employees.
This project evaluated the success of this implementation by retrospective review of the
data to compare the two methods of tuberculosis screening in regards to tuberculosis
clearance time, overall onboarding time, compliance, and costs. The study utilized a
descriptive comparative non-research design Data collection for this project was designed
to protect the privacy of the subjects and was guided by a comprehensive framework.
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Conceptual Framework
Triggers
The Iowa Model of Evidence-Based Practice to Promote Quality Care (Iowa
Model) was utilized to guide implementation of the project. This model begins with
identification of “triggers” that are problem or knowledge focused. These triggers occur
when the clinician questions current practices. Problem focused triggers in the Iowa
Model include process improvement data (Melnyk & Fineout-Overholt, 2015). The initial
process improvement problem that triggered this project was the initial question of
whether processes for onboarding new hires could be more efficient. The demand for new
hire appointments exceeded the available appointments in Employee Health, which led to
delays in orientation dates. Knowledge focused triggers in the Iowa Model includes new
research and standards. IGRAs are relatively new and represent a potentially new
standard of care. Along with new standard of care, new research has been generated to
assess utilization of the tests.
Priority.
The Iowa Model has been utilized for clinical and operational programs (Melnyk
& Fineout-Overholt, 2015). After the triggers for change are identified, the question is
formulated. The next step is to ask whether this is a priority for the organization (Melnyk
& Fineout-Overholt, 2015). The need to reevaluate onboarding practices was instigated
by upper management which resulted in this project. The Vice-President of Human
Resources asked this author to make this a priority for the department. According to the
Iowa Model, if the change is a priority for the organization, then a team should be formed
to develop and implement the change including stakeholders (Melnyk & Fineout79

Overholt, 2015). A new hire committee was formed including managers who had
expressed concern about onboarding delay, recruitment staff and management, education
management, operations director and information services. Problems were discussed and
ideas were shared for improvement in the overall onboarding process. This author
listened to the ideas and implemented some of them and discussed why we could not
implement others. This author knew about the QuantiFERON® lab test but also knew
that implementation had been rejected in the past due to the high cost.
Research and Implementation.
The next steps in the Iowa Model include research and analysis of the literature.
After the team agreed that utilization of the QuantiFERON® may be a good idea, this
author began to review the literature. The next step in the Iowa Model includes asking
whether the literature show a sufficient base for the change (Melnyk & Fineout-Overholt,
2015). If the answer is yes, then the change should be piloted. Outcomes will be chosen,
baseline data collected, change pilot implemented and outcomes evaluated. If the pilot
reveals that the change is appropriate for practice, then the change should be instituted in
practice. The structure, process and outcome data should be monitored. Last, results
should be disseminated (Melnyk & Fineout-Overholt, 2015). The literature review did
reveal that there was sufficient base for change in tuberculosis screening processes.
Preliminary baseline data of implementation of the IGRA indicated that the new
processes was increasing available appointments and appeared to be reducing onboarding
time. This study represents a full analysis of outcomes for the IGRA implementation.
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Project Design
The design of this project will be evidence-based a descriptive comparative level
III non-experimental design. Four outcomes will be measured (1) tuberculosis screening
time for new hires, (2) overall onboarding time, (3) compliance with tuberculosis
screening within 10 days of hire date, and (4) cost-effectiveness comparing the traditional
two-step PPD tuberculosis screening versus screening with QFT®-GIT.
Justification for Need
At the organization level, Employee Health was asked by senior management to
improve time efficiency for TB clearance in order to onboard a larger volume new hires
more efficiently. At the department level, Employee Health was unable to accommodate
the volume of appointments needed to process the increased volume of new hires.
Furthermore, Employee Health was having difficulty getting some new hires to return for
appointments to complete the 2-step PPD skin test. This resulted in delays in orientation
and could have led to DHEC and other regulatory agency citations or penalties. The 2step tuberculin skin test requires 4 visits which was inconvenient to the new hire
employee and filled available appointments in Employee Health. Department Managers
seeking to hire potential applicants expressed frustration with delays in orientation for
their new hires which left the departments short staffed. Thus, management requested
measures to improve efficiency, new hire satisfaction, and reduce costs. Investigation of
changes included use of interferon gamma release assays and was a priority for the
organization. At a larger level, there is minimal research and data regarding
implementation of interferon gamma release assays for new employees.
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Feasibility
Stakeholder support.
Feasibility for implementation includes examination of stakeholder support
(Melnyk & Fineout-Overholt, 2015). Leadership and stakeholder support is essential to
success of the study. This project for implementation of QFT®-GIT and for the
subsequent retrospective data analyses was supported by the Vice President of Human
Resources, Recruitment Director, Director of Operations, and managers part of the new
hire committee. Approval was obtained in January of 2016 for implementation of QFT®GIT beginning February 2016 for all new hires. Continued support was critical to
ongoing success of the project and for continued implementation beyond the study. The
Vice President of Human Resources is currently in favor in continuing with the QFT®GITs due to preliminary findings of a reduction in Employee Health clearance time.
Initially, nursing staff were concerned about procedural and process difficulties with
having only one pre-placement visit. A meeting was convened with the nursing staff to
talk through and agree upon processes. One area that was resolved was how to provide
follow up on all lab results since the new employee would not follow up with a second
visit in Employee Health. It was determined that staff would mail the lab results to the
employee’s home and call the employee for any significantly abnormal results per a
revised protocol. Approval from risk management was obtained prior to mailing the lab
results. Employee Health staff were educated regarding the benefits of testing and how
to draw the blood. Initially staff were hesitant to accept the change, but after several
months, staff members realized the benefits of the process for the new employees and for
themselves. They discovered that they had to spend less time trying to complete
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tuberculosis testing and less time trying to obtain compliance with testing. Employee
health staff now support QFT®-GITs for new employees. Meetings were initially
convened monthly with the new hire committee and Employee Health staff in order to
review progress and to maintain support. The Employee Health manager continued
ongoing conversations with the microbiology lab manager to continue to problem solve
and maintain support. Preliminary non-statistical data regarding increased volume in new
hire visits and reduction in onboarding clearance time in Employee Health was shared
with the VP of Human Resources and this author was asked to present the data at the
quarterly leadership meeting.
Sample size and accessibility.
Access to an adequate sample size enhances feasibility (Melnyk & FineoutOverholt, 2015). Adequate sample size was easily obtained since the data was collected
retrospectively and all new hires were required to complete tuberculosis screening for
employment. There were approximately 100-125 new hires per month in 2015 and 150180 in 2016.
Financial resources.
Financial resources for implementation of the QFT®-GIT and for this DNP
project was examined. While a TST only costs $4, factoring in staff time and supplies for
four visits would cost approximately $87. The QFT®-GIT is an expensive test, however
this author was able to negotiate a reduced price from its original price of $85 to $53
which enhanced feasibility. This was not in the budget to implement but senior
management believed that the extra expense would be offset by the benefits of reducing
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onboarding time. Although difficult to directly measure, implementation ultimately
contributed to cost savings in the form of reduced employee health staff time, reduced
onboarding time and subsequent reduction in locum tenens staffing. If the current high
turnover rate slows or upper management cuts budget for the lab tests, then a more
thorough cost benefit analysis will need to be conducted to continue with QFT®-GIT
testing. There were no direct costs for the retrospect data collection and analyses other
than time for this author and the secondary researcher to collect the data.
Time and expertise.
Data collection for this DNP project was time consuming. One Employee Health
staff member was enlisted to assist with collection of the data ensuring no breaches in
HIPPA or IRB protocols. This secondary researcher completed all training requirements
from the IRB and was added to the project committee. Utilization of QuantiFERON® is a
new process for the author and for the organization, but knowledge barriers were
overcome through the literature review, and utilization of resources such as consultation
with DHEC experts and microbiology staff.
Legal and Ethical Implications.
CDC and DHEC regulations in regards to tuberculosis screening were monitored
and it was determined that QFT®-GITs were acceptable for tuberculosis screening of
healthcare workers. There was little risk to the subjects since the data was collected
retrospectively for the project. Measures were taken to ensure confidentiality by
removing all identifiers from the data.
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Summary
Stakeholder support, sample access and size, financial, legal and ethical resources
were substantial. An adequate sample size was easily obtained through the retrospective
chart review. Benefits of QFT®-GIT and dissemination of results of the project will be
provided to stakeholders including senior management, the healthcare system’s research
council members, and Employee Health. Presentations to senior management was
provided. Limitations such as time, knowledge barriers, and budget concerns were
overcome. Since findings will be important to the organization, Literature, DHEC staff,
and laboratory management was consulted for any knowledge gaps.
Intervention Plan
Design.
The design of this project was evidence-based quality improvement project that is
descriptive comparative level III non-experimental. Data was collected retrospectively.
Tuberculosis screening time for new hires, overall onboarding time, compliance with
screening within 10 days of hire date, onboarding time, and costs was compared between
the traditional two-step PPD tuberculosis screening versus screening with QFT®-GIT.
Sample.
The sample included a convenience sample of all new hire employees that are
completed pre-placement assessment at the healthcare system Employee Health in April
and May 2015 and 2016.
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Setting.
The healthcare system consisted of 3 acute care hospitals, a post-acute facility,
hospice house, home health, multiple outpatient offices, and other healthcare services.
The healthcare system Employee Health serves over 6,800 employees in addition to
volunteers, staff providers, and contract workers. The healthcare system is state supported
and is designated as a health professional service area and critical shortage facility.
Employee Health staff performed pre-placement assessments including tuberculosis
screening for all newly hired employees in the Employee Health department post offer
but prior to orientation up until February 2016, when implementation of QFT®-GIT.

Timeline


September 2015:
o Formed new hire committee to review new hire processes and garner
support from key stakeholders including: recruitment staff, education staff,
key managers, employee relations manager and staff, outpatient office
directors, employee health staff, and Information Services staff.



October through December 2015
o Reviewed current processes and data regarding onboarding time and rate
of new hire appointments.
o Reviewed regulations for interferon gamma release assays
o Compared literature regarding available types of assays
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o Reviewed lab procedures and recommendations with healthcare system
lab managers
o Began literature review



January 2016
o Negotiated price and procedures with external lab
o Obtained permission from VP to proceed with testing
o Reviewed process and procedures with Employee Health staff
o Updated policies in Employee Health
o Ordered lab supplies-QFT kits
o Reviewed staffing needs and incubation procedures with lab
o Completed competencies for Employee Health staff completed
o Ongoing literature review



February 2016
o Began QFT®-GIT for all new hires
o Conducted ongoing literature review
o Developed tracking methods for new hire log



March 2016
o Contacted DHEC for recommendations and update policies to retest in
borderline result range



March-May 2016
o Testing continued for new employees
o Completed CITI training
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Summer 2016
o Planned project



September 2016
o Presented poster of literature review at conference



Fall 2016
o Reviewed healthcare system’s requirements for nursing research council
o Reviewed IRB requirements for healthcare system and University of
South Carolina
o Reviewed new hire volumes and onboarding times
o Completed Healthcare system CITI requirements



January 2017
o Completed DNP project proposal defense
o Presented DNP project to Nursing Research Council and obtained
scientific reviews and approval
o Submit IRB application to University of South Carolina and obtained
approval
o Received approval from healthcare system IRB.



February 2017
o Completed Retrospective data collection
o Completed data analyses



March 2017
o Defend dissertation University of South Carolina



April 2017
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o Final edits and submission to graduate school
o Submission of manuscript to Association of Occupational Health
Professionals Journal


September 2017
o Potential Conference presentation

Resources.
Retrospective data was compiled in excel spreadsheets in a password protected sdrive folder that is only accessible by the primary and secondary investigators.
Information was obtained from the paper new hire logs and Agility electronic medical
record. No further technology assistance was required. The QFT®-GIT cost was accepted
mid-budget year with VP understanding that lab cost budget would exceed budget in
fiscal year 2016.
Evaluation Plan
Questions/Outcomes/Evidence-based measures
Q1. Did implementation of QFT®-GIT reduce the number of days to complete
tuberculosis screening for new hires?


Retrospective data was collected from electronic and paper Employee
Health records. This data was stored on a password protected spreadsheet
and all identifiers were removed prior to submission for analyses.



Tuberculosis screening time included the number of days to complete TST
screening from the time of placement of step 1 to reading of the 2nd step. If
the new hire brought documentation of step 1, then only time for
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completion of step 2 was recorded. If the new hire failed to complete a
step and had to be replaced, then that additional time was also included in
the number of days for clearance.


Tuberculosis screening clearance time for subjects who completed the
QFT®-GIT included the date of blood draw to date the result was
reviewed. If the QFT®-GIT needed to be repeated for borderline positive
result, this time was included in overall screening time.



If any test was positive, the amount of time for result of a chest x-ray was
also including in tuberculosis screening time.



Those with a previous positive TST will be included with days to
clearance being 0 days since the symptom review was completed on the
day of pre-placement. However, if the subject did not bring the
documentation on day one, then the number of days it took to bring in the
documentation was recorded.



Data was analyzed by simple t test. Nonparametric testing and frequency
was completed to analyze and describe demographic variables.



The time for completion of DHEC evaluation for positive testers was not
included in screening time.

Q2. Did implementation of QFT®-GIT for new hires reduce the overall number
of days to complete onboarding?


Time for onboarding include days from first appointment to completion of
all requirements including tuberculosis screening, assessments, fit for
duties, lab results, and review of any requested records. Completion of
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immunizations and Hepatitis B waivers were not included because those
are not completed until after orientation.


Data was analyzed by t test, and spearman correlation.

Q3. Did implementation of QFT®-GIT improve compliance with completion of
tuberculosis screening within 10 days of orientation?


Compliance included completion of both steps of the 2 step PPD
tuberculin skin test within 10 days of orientation or completion of QFT®GIT results along with any required repeat results, symptom reviews, or
chest x-rays.



The data was analyzed by chi-square testing.

Q4. Was implementation of QFT®-GIT be cost-effective?


A simple review of associated costs with QFT versus PPD including staff
time was reviewed. Actual average salary of employees in Employee
Health in relation to the time it takes to complete testing and assessment
requirements, phone calls to contact non-compliant employees, and call
employees with results of lab testing will was considered. Cost of supplies
will include the cost for the PPD derivative, the syringe/needle, and cost of
lab charges for QFT®-GIT. Labor costs from missed work for the new
hire will not be considered since the new hire is not yet working for the
organization and current salary cannot be determined.



Data was collected regarding average staff salary and the amount of time
for each step of the assessment process and was described without
statistical analyses.
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Data Collection Procedure
Data was collected retrospectively from electronic medical record chart review,
review of paper new hire logs, and by the human resources data system. Data was
compiled in a password protected excel spreadsheet initially separated into months of the
year. Data was collected for subjects that came to Employee Health for pre-placement
assessments during the months of April and May of 2015 and 2016. In 2015, TST was the
standard of care and in 2016, QFT®-GIT. Data collected in the spreadsheet included: preplacement date, hire date, gender, race, age at hire, job titles, dates for placement or
reading of TSTs, dates for QFT®-GIT results, dates for Chest X-ray results, dates for
completion of screening and overall onboarding, and whether the employee brought
documentation of previous positive or negative TST or IGRA results. The number of
days to complete each step were calculated manually and by excel spreadsheet. Anything
completed on the date of first pre-placement visit was counted as zero days. Tuberculosis
screening time with TST was defined as the number of days from first placement of PPD
in Employee Health to reading of second PPD. If the employee brought in documentation
of first step PPD within previous 12 months, only the time for the one step was recorded
for tuberculosis screening time. If the new hire employee failed to return for a reading or
placement, the time it takes for the employee to complete the entire screening process
was included in total screening time. The definition for tuberculosis clearance time with
QFT®-GIT was defined as the number of days between blood draw and result including
any repeat QFT®-GIT for borderline results of 0.25 to 1.0 IU/ml. If the new hire required
a chest x-ray for a positive PPD or QFT®-GIT, the time to complete x-ray and receive
result as well as completion for symptom questionnaire was included. The time for the
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patient to complete any DHEC appointments or treatment was not included because this
is often lengthy, unpredictable and cannot be controlled by employee health. Compliance
with completion of tuberculosis screening within 10 days of hire date was also recorded
as yes or no, and if the new hire failed to complete at least one TST placement/reading or
QFT prior to orientation was recorded.
In addition to tuberculosis screening time and compliance within screening within
10 days of hire date, dates and time for completion of other onboarding requirements was
recorded. Data for overall onboarding time was recorded including dates and number of
days to complete: overall tuberculosis screening, drug screens, fit for duty examinations,
pre-work screens, required medical records/provider notes, and any other requirements
for orientation clearance. A simple review and comparison of costs associated with TST
and QFT®-GIT was conducted including Employee Health staff labor costs, lab fees,
PPD fees. Data for volunteers, and for employees who did not begin work due to
declination of the position, positive drug screens, failed pre-work screens or fit for duties
or those who did not start for unknown reasons were removed from the final spreadsheet
submitted for analyses. However, the primary investigator kept notes regarding the
number of subjects excluded and the reasons.
Data Management and Analyses Procedures
Once the survey data was entered into the excel spreadsheet and the identifiers
removed the investigator in collaboration with the committee statistician, reviewed the
data and, organized the data in the form that would be useable in SAS for analyses. Data
analysis included both descriptive and inferential statistics using SAS 9.4. Frequency
distribution was included for categorical variables. The continuous variable statistics
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included measures of central tendency (mean and median) and measures of spread
(standard deviation and range). Inferential statistics included T-test, spearman correlation,
and nonparametric testing. P-values less than or equal to .05 were considered significant.
A power analysis at 80% power was conducted and revealed that a sample size of 300
would be sufficient for statistical significance (see Table 3.1).
Table 3.1
Required sample size for Ttest analysis with 80% power,
Different effect size, and alpha.
Effect Size
0.2 (Small)
0.3
0.4
0.5 (Medium)
0.60
0.7
0.8 (Large)

Alpha = 0.05
788
352
200
128
90
68
52

Alpha = 0.01
4676
524
296
192
134
100
78

Human Subjects

The primary and secondary investigators completed CITI training for the
University of South Carolina and for the healthcare system. After the committee
approved the DNP proposal, the primary investigator presented the project to the
healthcare system’s Nursing Research Council for approval. Two members of the
committee provided scientific review of the proposal and the committee approved the
study (see Appendices D). An application for exempt status was submitted to the
University of South Carolina and exempt from human subjects research was obtained
(see Appendices D). The Healthcare System IRB agreed to accept the IRB decision from
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the University of South Carolina and approved the secondary investigator. After
approval, the investigator began data collection. The primary and secondary investigators
are employees of the Employee Health department and are in charge of routinely
collecting data regarding onboarding times and have access to the electronic medical
records. The investigators only retrieved data essential for project. The excel spreadsheet
was saved in the primary investigator’s access limited S-drive folder, with a password
protected spreadsheet. All computers were password protected and all data on the
healthcare system’s computers are encrypted. The health reasons for any required fit for
duties or pre-work screens, as well as substance found in the results of drug screens was
not noted on the spreadsheet. Notations were made regarding any positive TST or QFT®GIT results, required chest x-ray dates and results, symptom review dates, and DHEC
referrals. However, there was no record included on the spreadsheet to identify subjects.

Summary
The Iowa Model was utilized as a framework to evaluate the effectiveness of the
quality project implementation and comparison of new hire tuberculosis screening with
TST and QFT®-GIT (Melnyk & Fineout-Overholt, 2015). The quality improvement
project arose out of a need to improve efficiency within the Employee Health department.
Senior level management supported the decision to implement QFT®-GIT for new hires.
IRB and the Healthcare System approved this study to assess differences in TST and
QFT®-GIT methods for tuberculosis screening for new employees in regards to
tuberculosis screening clearance time, overall onboarding time, compliance with
screening within 10 days of hire date, and, costs. Data was collected without identifiers to
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protect the health information of the subjects.
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CHAPTER 4
FINDINGS AND CONCLUSIONS
Introduction
The purpose of this chapter is to present the findings and conclusions,
implications for nursing practice and future evidence-based projects and dissemination
activities for this quality improvement project. The purpose of this DNP project was to
compare baseline testing for new healthcare employees with QuantiFERON®-TB Gold
In-Tube Test (QFT®-GIT) to the two step PPD TB skin test in regards to tuberculosis
screening time, overall onboarding time, compliance with tuberculosis screening within
10 days of orientation, and costs. This quality improvement project assessed whether
implementation of the QFT®-GIT in lieu of the two step TST, met the organizational
goal to reduce the number of days to complete tuberculosis screening, reduce overall
Employee Health onboarding clearance time, and improve compliance with completion
of tuberculosis screening within 10 days of hire date, while maintaining costeffectiveness. The findings will be presented in relation to the primary questions
discussed in chapter three.
The data was collected by Agility medical record chart review and from new hire
spreadsheets in Employee Health. When hire data or job title was not available in agility,
data was obtained from the Human Resources Capital Management system. For statistical
analyses, race was identified as white, black or other. For comparison purposes, data was
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divided into two groups including the “TST group” and the “QFT group”. The 2015
sample included subjects who had tuberculosis screening with the two step tuberculin
skin test as a standard of care was identified as the TST group. The 2016 sample was
screening with the QFT®-GIT as the standard and was identified as the QFT group. The
data was analyzed by descriptive and inferential statistics utilizing SAS 9.4. Descriptive
statistical analysis included frequency procedures, measures of central tendency and
spread. Inferential statistics included T-test, Pearson correlation, fisher exact test, general
linear model (GLM) and chi-square. P-values of less than or equal to .05 were considered
to be significant. Power analysis was conducted to determine an appropriate sample size.

Findings
Sample.
The initial sample included 537 subjects who had pre-placement assessments at
the healthcare system’s Employee Health department in April and May of 2015 and 2016.
Subjects were excluded from the study if they were volunteers (n=40), new hire subjects
with positive drug screens (n=6), subjects who failed to report for employment (n=4) or
failed fit for duty examination (n=1), and subjects who failed pre-work screen (n=1) or
did not show for pre-work screen (n=1). The final sample included 484 new hire
employees comprising 81.4% female subjects (see Table 1). The three most frequently
hired age groups included ages 21, 25, and 27 years. The mean age for the sample was
35.08 (n=484) (see Table 1). There were 323 Caucasian subjects (66.73%), 112 African
American (Black) (23.14%), 13 Hispanic (2.69%), 12 Asian (2.48%), and 24 other
(4.96%). The most frequent job title for the sample was registered nurses (n=111),
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followed by nursing support (n =62). Of the sample, 227 had TST testing and 257 had
QFT Testing (Table 4.1).

Table 4.1
Frequency distribution for demographic variables
Sample demographic variables

N

%

Gender
Male
Female

90
394

18.60
81.40

Age: Most frequently hired
25 yrs.
27 yrs.
21 yrs.
Other

24
24
23
413

4.96
4.96
4.75
85.33

Race
White
Black
Hispanic
Asian
Other

323
112
13
12
24

66.73
23.14
2.69
2.48
4.96

Job
RN
Nursing Support
EMS/Transport
Resident physicians
Epic/IS
Other

111
62
32
15
14
245

23.03
12.86
6.4
3.11
6.64
47.96

The mean number of days for completing all onboarding requirements to begin
orientation was 6.40 days. The mean number of days to complete tuberculosis screening
by TST was 8.06, ranging from 0-36 days. One hundred twenty-four subjects supplied
documentation of at least one previous TST, thereby reducing the number of days
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required for subsequent testing. Seven subjects required repeated TST’s due to failure to
follow up for TST reading. TB clear days included the amount of time required for
tuberculosis screening and was 5.92 mean days for the TST and the QFT groups.
However, Quantiferon® testing yielded an average 4.11 days to complete testing with a
range of 1 to 10 days. There were four positive QFT® results with 3 of those being
borderline less than 1.0. The mean number of days for drug screen results was 2.71 days
with a maximum of 19 days resulting from subjects who had 2 dilute drug screens,
necessitating a hair drug screen. Thirty-six employees were required to have pre-work
screen tests, averaging 5.68 days to complete. Six subjects were required to bring
documentation from their personal health care provider regarding work status.
Nonparametric testing did not demonstrate was a statistically significant relationship
between race and number of clear days (p=0.0942), fit for duty days (p=0.1823), drug
screen days (p=0.0712), QuantiFERON® result days (p=0.9555), TB clear days
(p=0.0718), TST clear days (p=0.0879), and pre-work screen days (p=0.9920) (Table
4.2).
Table 4.2
N, means, standard deviation, minimum, maximum for select variables
Variable
age
cldy
tstcldy
tbclrd
qftdy
dsdy
ffddy
pwsdy
pcpndy

Label
Age
Clear days
TST clear days
TB clear days
# days result QFT
d/s days
FFD days
PWS days
PCP note days

N
484
481
223
481
255
481
36
31
6

Mean Std Dev Minimum
35.08
6.40
8.06
5.92
4.11
2.71
7.94
5.68
7.17

100

11.54
5.08
7.16
5.35
1.26
2.27
4.26
4.77
8.57

18.00
1.00
0.00
0.00
1.00
1.00
2.00
0.00
1.00

Maximum
67.00
30.00
36.00
36.00
10.00
19.00
18.00
21.00
24.00

Question 1. Did implementation of QFT®-GIT reduce the number of days to
complete tuberculosis screening for new hires?
There was a statistically significant difference in number of days to complete
tuberculosis screening for the QFT® group in comparison to the TST group (p<.0001)
(see Table 3). The average mean number of days to clear tuberculosis screening was 8.03
for TST and 4.11 for the QFT®. When comparing age between the two groups for
testing completion days, there was no statistically significant difference (p=0.0849) (see
Table 4.3)

Table 4.3
N, mean, standard deviation for select variables by group
Variable

TST group

QFT group

Agea

N Mean Std.
227 34.11 11.78

N Mean Std.
257 35.93 11.27

TB screen clear days b

224

QFT complete days

0

TST complete days

223

8.03

7.16

257

4.08

1.29

.

.

255

4.11

1.26

8.06

7.16

0

a. t-test p=0.0849
b. t-test p<.0001

Question 2. Did implementation of QFT®-GIT for new hires reduce the
overall number of days to complete onboarding?
Findings indicated a statistically significant difference in the overall number of
days to complete Employee Health screening for the QFT®-GIT in comparison to the
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TST group (p<.0001), even when factoring in other new hire screening requirements. A
reduction in number of onboarding days was demonstrated when using the QFT method
as compared to the TST group (7.92 TST group; QFT® group 5.07, p<.0001). There was
no statistically significant difference between the TST and the QFT® groups in the
number of days to complete drug screens (p=0.8009), fit for duties (p=0.8009), or prework screens (p=0.1265) (see Table 4.4).

Table 4.4
N, mean, standard deviation for select onboarding variables by group
Variable

TST group

Clear daysa

N Mean
223 7.92

Drug screen daysb

225

2.74

2.84

256

2.68

1.61

Fit for duty daysc

11

10.18

5.10

25

6.96

3.52

Pre-work screen daysd

20

6.6

5.0

11

4.00

4.00

6

7.17

8.57

0

.

PCP note days
a. t-test p<.0001
b. t-test p=0.8009
c. t-test p=0.0768
d. t-test p=0.1265

Std.
6.54

QFT group
N Mean
256 5.07

Std.
2.68

.

Data was further analyzed to determine if there was a correlation between
onboarding clearance time and age, TST clear days, QFT®-GIT clear days, drug screen
days, fit for duty days, pre-work screen days, or PCP note days. A weak but positive
correlation was demonstrated between overall onboarding time and age (r=0.10094,
p=0.0268) (see Table 14). However, findings showed a statistically significant stronger
positive relationship between overall onboarding time and number of days to complete
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TST screening (r=0.71838, p<.0001) and number of days for clearance by QFT®
(r=0.62275, p<.0001). A positive relationship was also found between onboarding
clearance time with number of days to complete drug screens (r=0.30298, p<.0001).
There was also a positive relationship between the number of days and fit for duties
(r=0.76433, p<.0001), however, only 36 subjects were required to complete the
examination. For onboarding time with the number of days to complete pre-work screens,
a positive correlation was found among six subjects (r=0.68600, p<.0001) but none was
found between onboarding clearance time and the number of days to supply
documentation clearance from the PCP (r=0.40584, p=0.4247) (see Table 4.5).

Table 4.5
Spearman Correlation of selected variables for onboarding clearance days
Variable

Onboarding Clear Days
N

Correlation

Agea

481

0.10094

TST clear daysb

223

0.71838

QFT days b

255

0.62275

Drug screen days b

479

0.30298

Fit for duty days b

36

0.76433

Pre-work screen days b

31

0.68600

PCP note days c

6

0.40584

a. p=0.0268
b. p<.0001
c. p=0.4247
Question 3. Did implementation of QFT®-GIT for new employees improve
compliance with completion of tuberculosis screening within 10 days of
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orientation?
Analyses showed a statistically significant improvement in compliance with the
QFT® group in comparison to the TST group (p<.0001). Overall, the compliance rate for
completing the tuberculosis screening was 99.29% in the TST group and 100% the QFT
group. There was no statistical difference for tuberculosis screening compliance between
races. However, there was a statistically significant difference in compliance between
genders with an increase in compliance among female employees (97.96%; p=.0010) (see
Table 6). Three employees failed to complete two step TSTs. Ten employees failed to
have at least one TST read prior to orientation. Sixteen employees in the TST group
failed to complete tuberculosis screening within 10 days of orientation. No QFT group
subjects failed to complete screening within 10 days of hire date Table 4.6).

Table 4.6
Frequency distribution for clear within 10 days
Variables

Yes

No

N

%

N

%

Gendera
Female
Male

385
82

97.96
91.11

8
8

2.04
8.89

Raceb
White
Black
Other

309
109
49

95.96
97.32
100

13
3
0

4.04
2.68
0

92.92
100

16
0

7.08
0

Groupc
TST
210
QFT
257
a. Fisher exact test p value= .0010
b. Fisher exact test p value= .3092
c. Fisher exact test p value<.0001
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Q4. Was implementation of QFT®-GIT cost-effective?
The average cost for a two-step TST in Employee Health was estimated at $87.87
per person and for QFT® $101.66 (cost of lab test, supplies, staff time for review of
results). At initial glance, the QFT®-GITs appears to cost more per person ($13.79).
However, further consideration is warranted when factoring other variables. Ten subjects
failed to have at least one TST read and had to be replaced which required a second TST
at an additional cost of $30.01- $37.76 per person (total costs of $377.60). Sixteen
subjects failed to complete screening within 10 days of orientation which resulted in an
increase in Corporate cost to allocate Employee Health staff time recalling these new
hired employees ($25 per hour x 8 hours per week used for recalls = $200.00 per week).
If the 16 noncompliant new hire employees were RNs and were delayed start dates,
Corporate would have had to contract with a staffing agency for 16 locum tenens nurses
while waiting for the new hire employees to begin work. This locum tenens contract
would have resulted in an additional potential cost of $76,800 per month ($30/hr. for each
locum tenens for full time x 160 hours in month = $4,800 x 16 employees = $76,800).
Four subjects in the TST group did not complete both steps of the two-step tuberculin
skin test within the specified time frame, which potentially placed the system at risk for
DHEC penalties ranging from $100 for the first violation and up to $5,000 for a third
violation (S.C. Department of Health and Environmental Control, 2015). Occupational
Health Safety Administration penalties could be 12,675 to 126,749 each (OSHA, 2017).
Fortunately, Employee Health staff were vigilant in their efforts to have new hires
complete the testing but again allocating staff time was costly to Corporate.
Accounting for the QFT® cost is easily done as a single test in comparison to
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TST testing which includes other cost variables such as staff time incurred for
noncompliant new hires in regards to follow up and TST re-testing and overall costs for
locum tenens use to fill temporary vacancies. Overall, the costs are for utilizing the
QFT® for new hire screenings demonstrated a cost savings to the healthcare system (see
Table 4.7).

Table 4.7
Average estimated costs based on data collection
Estimated Annual TST screening cost
For 2,000 compliant

$175,740

+ cost of noncompliant replace
Total

For 2,000 compliant

$203,320

8,823

+ Repeat QFT®-GIT 1 monthly

$184,563

656

Minus brought hx step 1
Minus hx +PPD
Total

Estimated Annual QFT®-GIT cost

18,347

Minus hx +PPD $53x 60/yr.=

1,479

3,180

$164,737

Total

$200,796
Minus savings on locum tenens -

Plus locum tenens cost

$576,000

$576,000

Plus DHEC fines x 20= $2,000 $100,000
Plus OSHA fines 20 x $12,675= $253,500

Conclusions
Data analyses revealed that utilization of the QFT®-GIT for tuberculosis
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screening of new hire healthcare employees in place of the TST significantly reduced
tuberculosis screening and onboarding time while improving compliance with
tuberculosis screening within 10 days of hire date (p<.0001). The mean tuberculosis
screening time for both screening methods combined was 5.92, while TST screening time
was 8.03 days and 4.11 days for the QFT® group. TST screening can be completed
within 2 days for those that bring in documentation of previous TST, however the range
in TST screening time was from 0 to 36 days. In contrast, screening time with the QFT®GIT was 1-10 days with the average of 3-4 days. The only QFT® group subjects that
required 10 days or more for repeat testing were due to borderline positive test results.
Overall, the healthcare system was able to increase the number of pre-placement visits in
Employee Health from 104 pre-placement visits in September of 2015 to 187 in July of
2016. This 56% increase in volume contributed to improved satisfaction for the senior
management and hiring managers by increasing the volume and decreasing delays in
orientation.
More efficient onboarding time has been shown to improve employee satisfaction
and retention, although not measured in this DNP project. Anecdotal feedback back from
hiring managers and senior management indicated an improvement in satisfaction with
the Employee Health new hire process. They fully appreciated the decrease in
onboarding time, quicker start dates for new hires, less delays in orientation, and an
increase in volume of new hire visits. Employee Health manager admits to receiving less
complaints regarding appointment availability for screening processes and orientation
start dates for new hires. Streamlining processes also facilitated regulatory site visits
with DHEC because the QFT®-GIT data is more easily retrievable and accurate. Clearly,
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the cost of QFT®-GIT is more than a TST, but as a single test but agencies should
account for other variables in the cost analyses including staffing costs, lab testing, and
locum tenens use. Streamlining processes and improved efficiency are critical to
Corporate overhead costs and compliance.

Implications for Practice
Employee and Occupational health staff confront barriers with processes and
compliance with tuberculosis testing with TSTs for new hire employees. The QFT®-GIT
significantly reduced screening time and onboarding time and improve compliance.
Organizations should consider implementation of an IGRA in order to streamline
processes for onboarding new hires. Of course, new processes require negotiations
between hospital departments and lab vendors, changes in policy and procedures, and
Employee Health staff development for IGRA testing procedures in order to facilitate
new hires and onboarding.

Future Research
Future research should include detailed cost analyses comparing screening with
TST versus QFT®-GITs for both new hires and annual testing. A pilot study could
provide foundation for future research to compare annual screening with QFT®-GIT and
TST. Analyses could include measurements of process improvement, screening time, and
employee satisfaction surveys for onboarding. Another area of future study would be
implementation of an IGRA for patients being transferred to nursing homes or other long
term care facilities to determine costs associated with extended hospital stays. Similarly,
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IGRA’s might prove useful in reducing hospitalization days for other patients awaiting
transfer to other facilities. Additionally, more studies are needed to analyze whether
IGRAs predict active tuberculosis. Further study should be conducted to determine the
predictive serum levels for borderline GRA and factors yielding false-positive or falsenegative results. Other studies in a variety of higher risk settings should be duplicated and
further examined.

Dissemination
The review of the literature for this study was presented at the Fourteenth Annual
Research Symposium: Research Impacting Clinical Practice sponsored by Upstate AHEC
on September 30, 2016. Introduction to the problem, purpose of the review and methods
for literature search were presented. Results of the literature review included process
improvement, cost effectiveness, accuracy and conversions/reversions was shared.
Discussions involved comparison of the TST and QFT® were reviewed (see Appendix
D). A manuscript for the for Association of Occupational Health Professionals Journal
(AOHP Journal) will be submitted for publication. An abstract of this quality
improvement project has also been submitted for presentation at the AOHP conference in
Denver, Colorado in September of 2017 (see Appendix E). Results will be shared with
the new hire committee, the Vice-President of Human Resources, Employee Health, and
in house lab staff.
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APPENDIX A
EVIDENCE TABLE

Table A.1
Evidence Table Abbreviation Guide
_________________________________________________________________
IGRA

Interferon Gamma Release Assay

TST

Tuberculosis Skin Test

QFT®-GIT

QuantiFERON®-TB Gold In-Tube Test

LTBI

Latent Tuberculosis Infection

BAMT

Blood Assay for Mycobacterium Tuberculosis

CDC

Centers for Disease Control

BCG

Bacillus Calmette-Guerin vaccine

HCW

Healthcare Worker

INH

Isoniazid

____________________________________________________________________
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Table A.2
Evidence Table
Reference, Type, Quality

Methods

Article 1

116

Foster-Chang, S. A.,
Manning, M. L., &
Chandler, L. (2014).
Tuberculosis screening of
new
hospital
employees: Compliance,
clearance to work Time,
and cost using tuberculin
skin test and InterferonGamma Release
Assays. Workplace Health
& Safety, 62(11), 460-467.
doi:10.3928/2165079920140902-02
(Foster-Chang et al., 2014)
Level V- Organization
Experience/Quality
Improvement
Quality B Good- purpose is
clearly stated, findings are
relevant, recommendations
clear, consistent results in a
single
setting,
good
literature review
(Dearholt & Dang,
2014)

Sample: Convenience
Sample
IGRA sample size =100
Sample size using
retrospective chart
review using TST in
2011=100
Sample from 2012 with
TST= 100
Procedure:
A) New employees
offered IGRA or TST
for screening: all chose
IGRA between March
19 and May 30,2013
B) Retrospective chart
review of new
employees using TST
for screening in 2011
and 2012

Statistical analysis:
Chi-square goodness of
fit
Lab tests:

Threats

Findings

Conclusions

Conclusion Validity-reasonable,
lists limitations. Sample size is good
-100 with IGRA compared with 100
sample in 2012 and 100 in 2011=
300 sample size

There was a reduction in time to
clearance with average reduction from
13.18 days 2011 w TST to 5.91 days.
Time to clearance based on screening
method with and without prior TB
screen significant p <.0001.

Reports as
“useful insights
for new employee
TB screening
programs”

Internal Validity- Not a controlled
study so there are other variables
that could be the cause of the result.
Some investigator bias- expected
the decrease in clearance and
increase in compliance. No attrition
External Validity- The conclusion
can apply to similar sized healthcare
settings with similar age group of
employees but perhaps not to other
employers or healthcare settings in
other countries. The author did not
overly generalize.
Construct validity- Good. Measured
clearance time as stated.
Reliability- It was admitted that
clearance time was affected by
vacation of the provider that signs
off on clearance, and a chart was
misplaced. Failure to return rate was
estimated and could be higher or
lower than expected and affect cost
estimates.

Statistically significant compliance
rates – 77% to 97% -2011/2013 p
<.0001 and 2012/2013 p <.001.
Meaning statistically increased
compliance rate with IGRA vs TST.
Compliance= completions of preplacement process within 14 days or
less.
Cost savings found 78.53 vs 47.02 per
person. No statistical analysis with
several assumptions regarding failure
to return rate, staffing costs.
38-40% reduction in cost for TB
screening

Mentions- intrasubject variability
with IGRA
results confusing
management.
Lack of “true
gold standard for
latent TB”.
IGRAs attractive
diagnostic aid
IGRA potentially
expedites and
improves new
hire tuberculosis
screening process

- T-SPOT®.TB used for
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IGRA

Precision- statistically significant
result p<.0001 for clearance time.
95% confidence interval

Reference, Type, Quality

Methods

Threats

Findings

Conclusions

Article 2

Group of experts
reviewed 96 out of 152
reports to develop
recommendations for
IGRA’s. Studies
included
sensitivity/specific of
GFT-GIT/ T-SPOT®.TB
, agreement of tests
with each other or with
TST, association with
risk for TB. Meeting
convened to review
study results,
descriptive studies,
explanations,
commentaries from test
manufacturers. Multiple
appropriate experts
used- AAP, Am
Thoracic Society,
Advisory Council
elimination of TB,
Assoc Public Health
lab, CDC, FDA,
Infectious Disease
Society, Army, Air
Force, VA, clinicians,
labs, experts, etc.

Internal Validity- Threat
includes the use of package
inserts and test company
information that is subject to
bias. There is some discussion
about confounds in some of the
examined studies in some of
the discussion. This Article
size would be too large to
discuss all of them. Study
included some nonexperimental studies/articles
which limits the validity.

Recommendations given for General use of
IGRAs- may be used for surveillance,
qualitative & quantitative interpretation
should be used, evaluate feasibility, do not
use low risk in general;

IGRA may be used
for surveillance,
multiple
recommendations.

External Validity- the volume
of studies reviewed and
number of experts reviewing
should limit threats to external
validity.
Reliability- Reviews large
number of articles and
compares results in multiple
tables enhancing reliability of
recommendations.

Testing with IGRA & TST may be
considered- when risk or progression
increased, when initial test positive and
second test encourages compliance, low
risk for infection and progression, repeat
when result indeterminate, borderline or
invalid;

Mazurek, G.H., Jereb, J.,
Vernon, A., LoBue,
P. Goldberg, S., & Castro,
K. (2010). Updated
guidelines for using
interferon gamma release
assays to detect
mycobacterium tuberculosi
s infection- United
States. MMWR
Recommendations and
Reports, 59(RR-5), 124. Retrieved
from http://www.cdc.gov/
mmwr/preview/mmwrhtml/
rr5905a1.htm
(Mazurek et al., 2010)
Evidence Level IV Clinical
Practice
Quality A High
(Dearholt & Dang, 2012)

Test Selection, Situations which IGRA
preferred- groups w low return rates, BCG
vaccine; TST preferred- children <5;
Either TST or IGRA may be used without
preference- recent contacts with TB,
periodic occupational exposure to TB;

Medical Management after testingDiagnosis of TB should not be based on
IGRA or TST alone, +TST or IGRA should
be evaluated for likelihood TB infection,
LTBI- exclude active dx with symptoms
exam & Chest x-ray, discordant test resultsindividualized judgement
Specificity QFT®-GIT- 99%

Further study to
focus on value and
limits of IGRA

Systematic reproducible
literature search
described.

Sensitivity QFT®-GIT-81%
Recent exposure strongly associated with
positive IGRA
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Reference, Type, Quality,

Methods

Threats

Findings

Conclusions

Article 3

Setting: 18,000
employees of John
Hopkins.
Purpose- measure
cost & adherence
annual and new hire
screening.
-Measured material
& labor costsaverage labor cost.
-2nd- time motion to
measure time with
all steps using TST
or IGRA-393
randomly selected
patients,
-3rd- 743 cohort
new hire and annual
tested in parallel
(random invitation,
voluntary
participation) with
TST and IGRA to
gather data on
positivity rates.
Also questionnaire
on views of TST or
IGRA. Decisions
trees.
Retrospective

Potential Bias- Oxford Immune provided
tests free of charge and education grant to
John Hopkins of $49,300- manufacturer of T-

Cost of TST $54.09 per
annual and $81.38 two
step new hire- most due to
staff time, and patient
time off work. Adding in
follow up of positives and
symptom screens= $73.20
per person and new hire
90.80pp – nonreturn rate
considered.

TST program costs
are high due to staff
burden- $73.20 per
person
IGRA results in
better adherence and
saves if the test is
$54.83 or less per test

Wrighton-Smith, P., Sneed, L.,
Humphrey, F., Tao, X., &
Bernacki, E. (2012, July).
Screening health care workers
with interferon-y release assay
versus tuberculin skin test:
impact on costs and adherence to
testing (the Switch study).
Journal of Occupational and
Environmental Medicine, 54(7).
doi:
10.1097/JOM.0b013e318254620f
(Wrighton-Smith et al., 2012)
John Hopkins Dearholt & Dang
(2012) evidence level II: QuasiExperimental-includes
intervention, standard of care as a
control, and some randomization.
Quality: B- Good, sufficient
sample size, some control,
reasonable recommendation,
some references to scientific
evidence
Dearholt, S. L., & Dang,
D. (2012). Johns Hopkins
Nursing Evidence-Based

SPOT®.TB

Internal validity- Participation voluntary.
Possible validity threat- Employee Labor
costs estimated
External Validity- salary had to be estimated
which could slightly skew results. I’m not
sure I would include employee time away
from work in measurement of the cost but it
is an interesting approach to consider.
Precision -Multiple hypothesis measured
could account for significant p value by
chance
Precision-This study did an excellent job
testing 38 other variables to see if they
impacted test cost and they did not!
I did not see statistical analysis of
significance
Reliability- there will be different salary
structures in different organizations.

TST overall cost per
person $73.20
TST Adherence 99.1%,
97.53%-total 98.54%
IGRA Annual $78.05,
new hire- $64.47 (did not
add in cost of missing
work)
IGRA overall cost
$73.20
IGRA Adherence 99.98
(annual) and 100% (new)
Overall costs of screening
with IGRA is the same as

Positivity tests
showed high rate of
those with prior
known TST positives
are false-positivesmore than 50%
Questionnaire
showed employee
preference of IGRA
vs TST
Costly- those who do
not follow up for
reading- adherence
70.8- 98.5% would
save $366,793 per
year
-IGRA positive rate
lower than TST
-parallel- 62.5%

Practice: Models and guidelines
(2nd Edition). Indianapolis, IN,
USA: Sigma Theta Tau
International.
Retrieved
from http://www.ebrary.com

epidemiological
statists of TB
screens over 1 year
to estimate cost and
adherence rates

Limitations Mentioned by author- did not
consider accuracy of TST vs IGRA. IGRA
conversion rate assumed equal to TST
because serial testing not conducted.
Enrollment bias in positivity portionimpractical to test all employees with both
TST and IGRA
New baseline IGRAs needed for serial
testing

TST”
IGRA- test cost at which
it becomes cost savings$54.83.

preferred IGRA,
6.5% TST
-18.5% blood draw
undesirable
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Reference, Type, Quality

Methods

Threats

Findings

Conclusions

Article 4

Systematic review- of 82
studies, 29 suitable, 7
excluded non-English. 2 re
T-SPOT®.TB, 20 QFT®.
Pubmed

Used a valid search strategypub med and listed search
terms. However, searched
studies from 1990-2008older studies may not be as
reliable since IGRA’s only
began use in 2001 with the
most recent in 2008. Authors
do separate T-SPOT®.TB
articles from QFT® but I
cannot tell that they
separated the older QFT®,
QFT® gold vs QFT®-GIT.
This can affect validity and
reliability.
Also, included studies from
different countries which can
affect generalizability.

Poor agreement between
IGRA and TST in low
incidence countries-but
related to BCG vaccination.
Higher correlation in 2
higher TB incidence
countries.

Role of IGRA for
chemoprophylaxis unclear
but may be alternative to
TST for detecting
conversions.
T-SPOT®.TB not
adequately studied at the
time of this article.

Swindells, J. E., Aliyu, S. H.,
Enoch, D. A., & Abubakar, I.
(2009). Role of interferongamma release assays in
healthcare workers. J Hosp
Infect, 73(2), 101-108.
doi:10.1016/j.jhin.2009.05.005
(Swindells et al., 2009)
Level III –Systematic review
of mixed types of
articles
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Quality B Good- results
reasonably
consistent, references
to scientific literature.
Conclusions were a
little confusing

Examined agreement
between IGRA & TST;
Agreement IGRA & TST in
BCG naïve; IGRA on long
term exposure; IGRA in
contact investigation; IGRA
& sequential testing;
correlation between IGRA &
C-X-ray
They do not specify
difference in articles that
examine older QFT® vs
newer QFT®-GIT.

Only 2 reviewers- there
could be some bias.

(Dearholt & Dang, 2012)
The authors do not discuss
the limitations of the articles
reviewed.

IGRA’s did show better
correlation with markers of
TB exposure during contact
investigation than TST.
States T-SPOT®.TB has not
been adequately assessed.
This is probably due to date
of this study of 2009 and the
development of TSPOT®.TB was 2008. The
few studies did show
increased specificity of TSPOT®.TB.

Positive QFT® associated
greater exposure to TB.
Discordance between TST
and QFT® probably related
to false positive TST due to
BCG- only cites 2 studies to
back up this conclusion.
Studies on boosting of TST
show conflicting results.
States role of IGRA in
healthcare workers appears
favorable but more studies
are needed. Predictive values
are conflicting. But then
states specificity for IGRA is
improved compared to TST
and will help prevent
inappropriate prophylaxis.
These statements are a bit
contradictory.

Results, Type, Quality

Methods

Threats

Findings

Conclusions

Article 5

Purpose- to
determine
performance of
QFT®-GIT in
employees of
children’s hospital w
low incidence of TB
and to determine
need for repeat
testing for employees
with positive result.
Cohort studyretrospective
convenience sample
approved by IRB.
Reviewed
occupational health
records for TB risk
factors.
Collected repeat
QFT®-GIT in 34
employees who had
positive QFT®-GIT

Conclusions regarding repeat testing of + QFT® is
related to the results of the study leading to good
conclusion validity. The results were statistically
significant P= .01

Interferon gamma
IFNy mean lower
for those with
repeat negative
results compared
to repeat positive.
P= .01

False-positives can
occur for healthcare
providers with QFT®GIT borderline 1
IU/ml or less. Repeat
testing recommended.
However, there was
overlap and cutoff for
positive should not be
changed.
Hypothesized that
other clinical
conditions or minor
infections could have
activated T-cells. Did
cite studies that
supported this finding.

Weddle, G., Hamilton, M.,
Potthoff, D., Rivera, D., &
Jackson, M. (2014).
QuantiFERON-TB gold intube testing for tuberculosis
in healthcare professionals.
Lab Medicine, 45(3), 207210. doi:
10.1309/LMLSJ4BVXS66W
JHS
(Weddle et al., 2014)
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This study combined to
areas of assessment with one
part being non-experimental
cohort and the second part
quasi-experimental- mixed
method. I will use the nonresearch appraisal tool.
Level per John Hopkins
appraisal tool:
Level V Quality
Improvement
Quality B Good- purpose is
clear, findings clear and
relevant, recommendations
clear and linked to findings.
Description of methods a
little unclear.
(Dearholt & Dang, 2012)

However, no recommendation was really given as to
what to do with the result of no association with risk
factors and QFT® result.
Internal Validity- It is unclear as to whether the repeat
QFT®-GIT was looked at retrospectively or done at
the time of this study. 34 of the 47 positive testers
followed up. There is no discussion as to why the
other 13 did not follow up- some attrition bias.
External Validity-good conclusion, however would
only generalize to low incidence areas which is not
clearly spelled out in abstract findings.
Construct validity- It is clear that the researchers are
measuring what they intend to measure.
Reliability- For the repeat QFT® the sample is
relatively small- 34- reliability would be enhanced
with larger sample and improve statistical significance
Precision- appropriate application of p values however
which statistical test was used is not listed. Confidence
interval not discussed.
There is a larger sample size for the retrospective
portion which examines risk factors- 707 employee
records assessed which improves reliability and
precision and generalizability.

No statistical
difference for risk
factors between +
or – QFT®-GIT
result. P=.86

Risk factors for TB
such as birth country,
contact with high-risk
persons and hx of 1 +
TB test was not
significantly
associated with
prediction of QFT®GIT test results. The
study did not mention
association or
assessment of those
with BCG vaccination
which would have
been important to look
at in this study.

Reference, Quality,
Type
Article 6
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Cummings, K., Smith,
T., Shogren, E.,
Khakoo, R.,
Sharmilarani, N.,
Bunner, L., …
Weissman, D. (2009,
November).
Prospective comparison
of tuberculin skin test
and QuantiFERON-TB
gold in-tube assay for
detection of latent
tuberculosis infection
among healthcare
workers in a lowincidence setting

Methods

Threats

Findings

Conclusions

Convenience sample: June
2007 to Feb 2008, WVU new
hire health care workers

Threat to external validityLacks randomization.
Selection bias- convenience
sample

-agreement between TST and
QFT®-GIT for those without
risk factors on negative results=
99%

-Agreement between QFT®GIT good

Threat to precision &
Validity
Used Tubersol & Aplisol
brands for TST which can
have variation. Aplisol has
shown higher rates of falsepositives.

-Agreement of positive results =
0%

182 sample size which was
68% of 266 invited.
Procedure:
1. Informed Consent written.
2. Blood draw first QFT®GIT.
3. Up to 3 weeks later step 1
TST. 4. Second QFT®-GIT 1
week later. Also second TST if
needed.
Research Approvals:
-IRB approval obtained
-National Institute
Occupational Safety & Health
approval obtained

(Cummings et al.,
2009)
Evidence level II
Quasi- Experimental
B Good Qualityconsistent results,
reasonable sample size
for this study,
reasonable conclusions.
(Dearholt & Dang,
2012)

-Any ELISA QFT®-GIT that
was positive or indeterminate
was repeated. If tests agreed,
results were confirmed. If tests
disagreed, 3rd test was
completed and confirmed result
from mean of all values.
Analyses:
-Calculated % agreement TST
and first QFT®-GIT.
-specificity determined by no
reported risk factors.

Internal validity threat
Did the reader interpret the
TST result accurately?
4 reports as positive.
3 QFT®-GIT positivesstudy calculated %
agreement as low but there
were not many positives to
measure
-only 85 (47%) showed for
second QFT®-GIT- attrition
bias
Precision threat
It is unclear if the TST is
what caused the result of 2
2nd QFT®-GIT to be positive
- Enhances reliability- 96%
born in US, 93% did not
have BCG vaccine, 62% no
report of risk factors.

-2 with negative 1st QFT®-GIT
had positive QFT®-GIT
-4 had positive QFT®-GIT but
negative TST
-3 +TST but – QFT®-GIt
-1 +TST and +QFT®-GIT
-69% of indeterminate QFT®GIT were confirmed by second
ELISA (11 0f 16, the other 5
negative)
-HCW w DM or Immuno
therapy had greater odds of
confirmed indeterminate (6.8
odds ratio, CI 95%)
-Days between TST and 2nd
QFT®-GIT- no statistical
significant difference.
-there was higher IFN-y
concentration on second QFT®GIT after 1 TST (56 HCW)

-Tests did not agree on +
results
-most disagreement was
+TST with negative QFT®GIT
-reanalysis of 5 QFT®-GIT
that had + results, only
confirmed 2- conclusion that
reanalysis may identify initial
+ test results as negative.
-immunosuppression
consistent with low response
to mitogen
-effect of difference in
QFT®-GIT after TST is
questionable clinical
significance
-Fewer visits for QFT®-GIT
valuable
Author listed limitations:
-short follow up time
-limited sample size
-variation in timing of tests
and brands of PPD
-Some HCW agreed to test
but did not follow up

Likelihood ratio X2
-compared results 1st and 2nd
QFT®-GIT by mixed-model
repeated measures of analysis
of Variance (ANOVA)
- covariate-duration of time
between 1st TST and second
QFT®-GIT
-compared effect of 1
intervening TST with 2
intervening TST

Reliability Threats:
- large age range 28-62 years
-8 had diabetes or recent
immunosuppressive therapy
which can affect results of
TST or QFT®-GIT (falsenegatives)
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References, Type, Quality

Methods

Threats

Findings

Conclusions

Article 7

Estimates based on RN salaries at VHA
in 2007

-TST costlier & less
effective for all
models

Perio, M. A., Tsevat, J., Roselle,
G., Kralovic, S., Eckman, M.
(2009, January 26). Costeffectiveness of interferon
gamma release assays vs
tuberculin skin tests in health
care workers. Journal of
American Medical Association:
Internal Medicine, 169(2), 179187. Doi:
10.1001/archinternmed.2008/524

Markov state-transition model w
societal perspective & lifetime horizon
1yr
- No LTBI, no INH,
-No LTBI, INH partial,
-No LTBI, INH complete,
-LTBI, no INH,
-LTBI, INH partial,
-LTBI, INH complete

- Used hypothetical
scenario
-age 35 but did run
analysis for ages 25-55
with same results
Construct validityattempted to
generalize to entire
HCW population
based on hypothetical
results
-study is in 2009 so
figures for salary and
cost of IGRA are not
equivalent to today
-good-performed
probalistic sensitivity
analysis by Monte
Carlo simulation
-used only RN pay for
calculations- does not
consider other pay
scales

-QFT®-G & QFT®-GIT are
more effective & less costly
compared to TST for
detecting LTBI in HCW

-effectiveness measured in qualityadjusted life years (QALYs)

(dePerio et al., 2009)
-hypothetical 35 yr old HCW, pay
based on RN
Level V Financial Evaluation
(cohort)
A High Quality- clear objective,
consistent results, good lit
review, thorough methods
(Dearholt & Dang,2012)

-compared TST, QFT®-G, QFT®-GIT
-analysis vaccinated BCG vs not
-accounted for indeterminate QFT® or
failure to return for TST reading
-used statistics from VHA for
probabilities of return for TST
read/placements
-direct & indirect costs considered
including missed work
-software- Decision Maker 4.0; beta
version

Author listed
-did not assess
transmission of TB &
costs/benefits
-did not examine
subsequent annual
TST or QFT®

-if QFT®-GIT
sensitivity is better
than QFT®-G then
QFT®-GIT becomes
more cost effective
-less cost if QFT®-G
kit is $32, QFT®-GIT
$36 or less
-QFT®-G & QFT®GIT cost savings
compared to TST in
00% of 10000 Monte
Carlo simulations
-non-BCG- cost
savings 30% of time
QFT®-G, QFT®-GIT3%
BCG vaccinatedQFT®-G 21%, QFT®GIT-18%

-time costs saved with less
missed work time and
QALYs.
-IGRAs less costly if run in
batches of 12 for non bCG
and 4 for BCG-vax
-QFT®-GIT least costly and
most effective

Reference, Type, Quality

Methods

Threats

Findings

Conclusions

Article 8

-Preferred Reporting Items
for Systematic Reviews and
Meta-Analysis.
-PubMed
Search terms-workers and
tuberculosis or TB infection
or TB disease or TB and
tuberculin skin test or
tuberculin skin testing and
Quantiferon®- 2004-2013

-Validity/precision- lumped
QFT®-G with QFT®-GIT
-study assumed that TST is
an accurate test for LTBI.
-review went back a little far
2004

-One third of TST & QFT®
results discordant. K value
random effect 0.28 (CI 95%)

-overall agreement TST &
QFT® low
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Lamberti, M., Uccello, R.,
Monaco, M. G. L., Muoio,
M., Feola, D., Sannolo, N.,
Nienhaus, A., & Chiodini, P.
(2015). Tuberculin skin test
and QuantiFERON® test
agreement and influencing
factors in tuberculosis
screening of healthcare
workers: a systematic review
and meta-analysis. Journal of
Occupational Medicine and
Toxicology, 10(2),1-13. doi:
10.1186/s12995-015-0044-y
(Lamberti et al., 2015)
Level III Systematic review
with meta analysis of combo
RCT and Quasiexperimental, nonexperimental
Quality- A High- used
statistics to generate a new
effect size, listed inclusion
and exclusion criteria,
complete flow diagram of
studies, large sample size,
comprehensive review
(Dearholt & Dang, 2012)

-inclusion-screening LTBI in
HCW w TST & QFT®,
comparison between TST &
QFT®, sample vaccine rates,
English
-Excluded- duplicates, case
reports, editorials, close
contacts, immunologic or
lab, NTM, HIB, chronic
rheumatologic, infl bowel.

Author- should include
longitudinal studies in future
study

-K 0.25 (95% CI)TST &
QFT® agreement in low
incidence group, 0.19
intermediate, 0.38 in high
group
-best agreement in high
incidence group
-worst agreement
intermediate (highest vaccine
rate)

-QFT® reproducibility
unclear
-lower rate of QFT® positive
attribute to higher specificity
than TST- higher specificity
to mycobacterium tb
-BCG vaccination reduced
agreement- TST + increasing
risk of false positives
-discordant QFT® + vs TST
negative increased with age
over 40 and 50
-increasing working year and
positivity of both tests

-10 mm cutoff +PPD only

-TST should continue for
low prevalence of
vaccination or high incidence
of TB infection

-Cohen’s K applied to each
study

-QFT® is helpful for areas w
higher BCG vaccination

-29 included out of 1,430

-physicians should consider
TB incidence, vaccination
status, age and working
seniority when choosing
tests.

References, Type, Quality

Methods

Threats

Findings

Conclusions

Article 9

-update of 1994
guidelines
-based on epidemiology
reports, evidence-based
science and content
experts- experts in TB,
infection control,
environmental control,
respiratory protection and
occupational health

Very lengthy document
and lengthy list of
references that would be
difficult for one person
to review.

-lengthy document listing practice guidelines
for preventing Tb including screening of
healthcare workers and infection control for
patients. I will focus on applicable sections
for screening in my setting due to length of
this article.

Guidelines require 2
step PPD or 1
BAMT for new
hires regardless of
risk.
IGRA’s- QFT® or
T-SPOT®.TB are
acceptable per 2010
addendum

Jensen, P. A., Lambert, L. A.,
Iademarco, M. F., Ridzon,
R., & Cdc. (2005).
Guidelines for preventing the
transmission of
Mycobacterium tuberculosis
in health-care settings, 2005.
MMWR Recomm Rep,
54(RR-17), 1-141. Retrieved
from
http://www.ncbi.nlm.nih.gov/
pubmed/16382216
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(Jensen et al., 2006)

Evidence Level IV Clinical
Practice Guidelines
Quality: A High even though
not developed in the past 5
years. There is an addendum
that is 2010. Sponsored by
CDC this is nationally
recognized guidelines based
on scientific evidence
(Dearholt & Dang, 2012)

-not updated in the past 5
years except for an
addendum
-did not list search
strategy
-expertise is evident

-Low risk facilitiesNew hires- 2 step PPD or 1 BAMT
If hx positive- symptom review
No annual screening required
-outlines how to complete 2 step and when to
read
-2 step minimizes boosting leading to
unwarranted suspicion of TB with
subsequent testing
-baseline tests should be within 10 days of
HCW starting employment
-medium riskSame for new hires
Annual PPD or BAMT for all HCW
-states BAMT is more specific than skin
testing
-BAMT recommended for BCG vaccinated
-Outlines follow up for exposures
-HCW with + should have Chest X-ray and
be assessed for LTBI treatment
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Article 10

-organizational needs assessment
based on: CDC requirement,
resources, needs of employees,
logistics

-reliability threat- results
can really only be
generalized to this
practice setting but
method of determining
which method TST or
QFT® to use can be
applied.

This organization chose:
-TST for annual testing of all
without BCG vaccine.
-annual for those with BCGsigns & symptoms

-I don’t know that I agree
with this organizations
choices. The evidence does
not point to doing QFT®’s
just because someone is
pregnant. CDC
recommendations are not to
just do a symptom
assessment on BCG
vaccinated. The article did
not say it was for BCG
vaccinated with +TST. I do
realize this organization has
lab limitations that our
organization does not have.

Gonzalez, M., & Conlon, H.
A. (2013). Updating a
tuberculosis surveillance
program: considering all of
the variables. Workplace
Health & Safety, 61(6), 271278. doi:
10.3928/2165079920130516-05
(Gonzalez & Conlon, 2013)
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Level V Quality
Improvement. Quality- B
Good- clearly stated aims,
single setting only, good
references
(Dearholt & Dang, 2012)

Steps:
1.

Identify specific
organization elements
and processes
2. Match organizational
elements to testing
methods
3. 13 item chart was
created to compare each
methods attributes
Evaluate employee population
and decide which test meets
surveillance needs considering
resources of organization

-Validity threat- some
author bias- attempts to
make results easier for
the setting

Pre-employment
-no BCG-TST
-BCG- QFT®
-visiting physician-QFT®
-employee exposure to TBQFT®
-Pregnant employee- QFT®
-ImmunocompromisedQFT®

-my take away for this article
is the process to assess the
organization specific needs.

Reference, Type,
Quality
Article 11
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Diel, R., Loddenkemper,
R., Meywald-Walter,
Gottschalk, R., &
Nienhaus, A. (2009).
Comparative performance
of tuberculin skin test,
QuantiFERON®-TB-gold
in tube assay, and TSPOT®.TB . TB test in
contact investigations for
tuberculosis. Chest,
135(4), 1011-1018. doi:
10.1378/chest.08-2048
(Diel et al., 2009)
Evidence level II Quasiexperimental
Quality B goodreasonable conclusions,
large sample size,
reproducible
(Dearholt & Dang, 2012)

Methods

Threats

Findings

Conclusions

-started with 2004 close
contacts of culture confirmed
TB.
-eliminated 6 w hx prior +TST
and 2 with prior tx for active
tb.
-842+ TST > 5mm had blood
drawn for QFT® and TSPOT®.TB
-22 of those T-SPOT®.TB
result could not be determinenot enough lymphocytes, 7
indeterminate T-SPOT®.TB
-1 indeterminate QFT®

Reliability- may not be
able to reproduce due to
high rate of BCG
vaccination in this
group
-increased age and
foreign born was
associated with higher
rate IGRA positive
despite trying to exclude
those with prior TB
exposure- could be
confounding variable

-Agreement between QFT® and TSPOT®.TB high 93.9% k value 0.852
w CI 0.78 to 0.92

-IGRA reduce LTBI
screening to those truly
infected and is better for
contact investigation

-this study was focused
on community more
than HCW so less
applicability to my
setting

-contacts of AFB-positive more likely
IGRA + than AFB negative p < 0.0001

Validity threats-not a random sample
-small attrition bias-attempted to control
confound variable of
being household or
intimate contact but was
not significant variable.

- Higher cutoff of TST >15 mm was
more likely associated for IGRA
positive suggesting high specificity.

-none had
immunosuppression, HIV,
hemodialysis

-convenience sample
-215 recalled case coughing
-more than half BCG
vaccinated
-321 household/intimate
contacts
-291 coworkers
-87 pupils/teachers
-51 healthcare workers
-44 nonintimate friends
-11 copatients
-5 sports club members
-multiple regression analysis

-BCG vaccination was associated with
negative IGRA p<0.0001
-contacts who report coughing of
source more likely + IGRA- QFT®
49.8%, T-SPOT®.TB 23.1%p, 0.0001
-no significant + IGRA and cumulative
exposure time of contacts p < 0.0001

-contact with AFB-positive >40 hrs
were 6x higher rate of +IGRA

- Significant association between +
IGRA and increase age, foreign origin,
AFB positive source, source case cough
and exposure time
-Discordant results between QFT® and
T-SPOT®.TB improved with
increasing cutoffs to 9 spots for TSPOT®.TB , QFT® IU/mL 0.6 but
only slight gain of 4.8%

-Using QFT® or TSPOT®.TB would reduce
LTBI suspects to be
investigated by 70%
-IGRA more accurate
indicator of LTBI than
TST
-QF®T and TSPOT®.TB show
excellent agreement

Reference, type, quality
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Article 12

-Retrospective Chart Review
June 2005 to Aug 2006
-QFT® use for- past positive
but not documented by health
dept, questionable report past
+, hx BCG, UHS TST +
-Setting University of
Tennessee Health Science
Center- 2,200students, 6,000
employees

-did not control
extraneous variables
-External
validity/conclusion
threat- small sample size
-lacks randomization
-Did not run any
statistical analysis

-94 nonreactive, 10 reactive (8 students
& 2 employees), 5 indeterminate
-7 reactive students had BCG, 1
undocumented past + TST
-1 employee reactive with documented
+TST and 1 employee undocumented
past + TST

-Successful
implementation of QFT®TB gold for students and
employees for listed
situations.
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Veeser, P. I., Smith, P. K.,
Handy, B., & Martin, S.
R. (2007). Tuberculosis
screening on a health
science campus: use of
QuantiFERON®-TB gold
test for students and
employees. Journal of
American College Health,
56(2), 175-180. Retrieved
from
http://eds.b.ebscohost.co
m.pallas2.tcl.sc.edu/ehost/
pdfviewer/pdfviewer?sid=
3265610b-2bae-4881bdc18fa0f87a2448%40session
mgr113&vid=5&hid=120
(Veeser et al., 2007)
Evidence Level 5
Program Evaluations
Quality- B Good
Clear objectives, some
scientific evidence
(Dearholt & Dang, 2012)

-109 subjects- 55 employees,
54 students

-85% of tested nonreactive,
9% reactive, 5% indeterminate

-3 with past +TST but
nonreactive QFT®-G may
have had improper
readings or reaction to
thimerosal.
-benefits in completion
rates of TB screening,
result reporting and
surveillance capacity

Reference, Type,
Quality
Article 13
Zwerling, A., van den
Hof, S., Scholten, J.,
Cobelens, F., Menzies,
D., & Pai, M. (2012).
Interferon-gamma
release assays for
tuberculosis screening
of healthcare workers:
a systematic review.
Thorax, 67, 62-70. doi:
10.1136/thx.2010.143
180

Methods

Threats

Findings

Conclusions

-Systematic Review of studies:
1-compare IGRA performance in HCW
2- IGRA correlation to occupational exposure to
TB compared to TST
3- Rate of IGRA conversions & Reversions in
relation to IGRA and occupational exposure
compared to TST
4- summarize cost-effectiveness studies

Authors note publication
bias is always a concern.
-note lack of evidence at
highest hierarchy

-high incidence- TST
and IGRA positivity
rates high, IGRA
slightly lower
Low & Moderate- 25
studies- lower
prevalence of + QFT®
or T-SPOT®.TB than
TST with statistically
significant difference
in 17.

-IGRAs well correlated
with TB infection risk
factors in low &
intermediate incidence
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-Databases-PubMed, Embase, Biosis, Web of
Science up to Oct 2010.
-reviewed bibliographies of reviews & guidelines
on IGRA
-conference proceedings
-Experts contact
-detailed search string

(Zwerling et al., 2012)
Evidence level III
Systematic review
combination of quasiexperimental and nonexperimental
Quality- A High
Clear objectives,
multiple databases
used, details of studies
presented, conclusions
logical
(Dearholt & Dang,
2012)

-Created hierarchy of reference standards- no
studies found at 2 highest. From low to high:
Concordance with TST, Sensitivity & Specificity
in active TB, Correlation w exposure, Predictive
value of IGRA for active TB, Efficacy of
preventive therapy based on IGRA results figure
1.
-calculated Fishers exact 95% CI or prevalence
estimates
-separated studies by high, intermediate, low
incidence settings
-50 total studies:
42 IGRA studies in IGRA w main outcomes of
interest
3 cost-effectiveness

Threats-Lumped all
QFT®’s together when
the QFT®-GIT is more
specific.
-contact test
manufacturers for
citations- bias threat
-included different
countries which could
affect reproducibility

Concordance weak
between TST &
IGRA. Agreement is
improved with higher
TST cutoff of 15 mm
TST-/IGRApredominant
discordance
-low incidence-14
studies show positive
association between
IGRA + and risk
factors- high risk ward
work, Work in TB
clinic or geriatric care,
increased length of
healthcare
employment.
-conversion rates vary

-One-time screening may
result in lower prevalence
of + tests and less LTBI
tx.
-prevalence of +IGRA
lower than TST
-IGRA higher rate
reversions and
conversions if using
simple cutoffs of
positive/negative. Caution
when interpreting.
Consider absolute
increase over baseline.
Few studies examine this

3 feasibility & test implementation
2 new studies after 10/2010
-further details online supplement
-79% of studies QFT® only (35), 7% (3) TSPOT®.TB only, 14% both IGRAs
-14% only IGRA testing
11% (5) high incidence
-study size 12 to 1313 HCW for total 11,963
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Article 14

Search strategy- Medline,
Embase
Search termscost+interferon +tuberculosis
German & English
Identified 76 references,
narrowed to 13
Inclusion: study design cost
analysis or costeffectiveness. Populationhigh risk groups- HCW,
immigrants, close contacts
Outcome-cost, ratios
Screening strategies- TST
and/or IGRA

-construct validity-reviewed
other groups besides HCW
which can be a threat to
generalizability for purposes
of my study.

-in all studies the TST only
strategy was most expensive’
-all 13 studies showed
decrease in costs with use of
IGRAs
-in 4 out of 7 dual step
studies- IGRA after +TSTwas least expensive and in 2
studies IGRA only was least
expensive

-Studies show strong
evidence in support of costeffectiveness of using IGRA
for screening high risk
groups- HCW, immigrants
from high-incidence
countries, close contacts

Nienhaus, A., Schablon, A.,
Costa, J.T., & Diel, R.
(2011). Systematic review of
cost and cost-effectiveness of
different TB-screening
strategies. BMC Health
Services Research, 11(247).
doi: 10.1186/1472-6963-11247
(Nienhaus et al., 2011)
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Evidence level III
Systematic review
Quality- B Good- used
comprehensive database and
search strategy, inclusions
criteria listed, articles up to
10 years old
(Dearholt & Dang, 2012)

-precision-had to calculate
cost ratios for different
countries to compare

Author listed-assumptions regarding TST
specificity varied widely
between the studies making
comparison difficult
-different cost ratio
assumptions and test
parameters between TST and
IGRA varied and therefore
cannot be directly compared

Reference, Type, Quality
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Article 15

-Search PubMed thru 2008
-added 20 new studies to a
previous analysis and
eliminated those with less than
10 participants and those with
known immunocompromised

-most studies small
-no gold standard for dx of
TB
-variable TST methods
and cutoff
-data on T-SPOT®.TB
limited

Sensitivity:
78% QFT®-TB G (95%CI)

Pai, M., Zwerling, A., &
Menzies, D. (2008, August
5). Systematic review: Tcell-based assays for the
diagnosis of latent
tuberculosis infection: an
update. Annals of Internal
Medicine, 149(30), 177-184.
doi:10.7326/0003-4819-1493-200808050-00241
(Pai et al., 2008)
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Evidence level III
Systematic review mixed
with meta analysis
Quality- B GoodThorough literature searches
of reputable databases, used
statistics
(Dearholt & Dang, 2012)

-Fixed effects meta-analysis
with correction for over
dispersion
-Sensitivity- microbiologically
confirmed active TB, not
including immunocompromised
-specificity- healthy low-risk
participants without known
exposure to tb
-2 independent reviewers
performed searches and
selected articles
-95% Cis
-summarized results in forest
plots
-to pool estimated- fixed effects
meta-analysis with correction of
variability using MetaDiSc
-evaluated heterogeneity with
chi-square andI2 tests
Used 38 articles
-15 QFT®-G, QFT®-GIT
9 T-SPOT®.TB

70% QFT®-GIT (CI 6378%)
90% T-SPOT®.TB (CI 8693%)
Specificity:
99% for non-BCG for both
QFT®s (CI 98-100%)
96% BCG vaccinated (CI 9498%)
T-SPOT®.TB 93% (CI 86100%)
TST97% (CI 95-99%)

Conclusions
-IGRAs have excellent
specificity unaffected by
BCG
TST specificity high in nonBCG vax but low in BCGVax
Sensitivity of IGRA & TST
not consistent but TSPOT®.TB is more sensitive
T-SPOT®.TB than QFT®
and TST
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Article 16

-Retrospective review of
QFT® results of HCW with
2 or more QFT® tests June
2008-July 2010 at SUMC.
-SUMC-611 bed hospital, 14
cases TB per year
-9,153 HCW annual QFT®
results
-new positives had repeated
QFT® in within 6 weeks
-2008 QFT®-GIT upgrade

-attrition bias-11.1% n=40
did not follow up for repeat
testing- staff turnover,
refusal or preference
-there is no clear standard for
when to repeat QFT®s
-construct-generalizability
threat- lack of gold standard
to dx LTBI
-Lack of risk factor data in
cohort- other variables could
contribute such as exposures
during the year.
-precision- intervals between
tests non-standardized
-no randomization
-changing lab practices over
25 months could cause
variability.

-repeat QFT® conversion
rate was 4.4% and short term
reversion rate 64.8% (short
term is testing < 60 days
between tests)

-short term retesting new
QFT® conversions is
feasible to reduce falsepositives
-Short term retesting of
+conversions revealed 67%
reversion to negative.

Slater, M., Welland, G., Pai,
M., Parsonnet, J., & Banaei,
N. (2013, October 15).
Challenges with quantiferonTB gold assay for largescale, routine screening of
U.S. healthcare workers.
American Journal of
Respiratory Critical Care
Medicine, 188(8), 10051010. doi:
10.1164/rccm.2013050831OC
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(Slater et al., 2013)
Evidence level V
Organizational ExperienceProgram evaluation
Quality level B Goodproject aim clearly stated,
methods and results
adequately described, clear
interpretation.
(Dearholt & Dang, 2012)

-independent group t tests to
compare variables
-z statistic for proportions
-linear regression compare
independent variables
-kappa to assess agreement
between QFT® assays

-of 1,223 (13.4%) initially
+QFT®, 67.5% stayed
positive (828)
-of 8,227 – QFT®, 4.4%
(361) converted. High
proportion fell between 0.35
to 1.0 IU/ml cutoff
-positives were retested and
64% reverted short term.
Long term tested 63%
reverted
-11.1% did not return for
repeat testing
-changing QFT® cutoff
would help conversion rates

-QFT® standardization is
needed
-cutoff variability needs
examined.
-Variability sources may
include incubation time,
ELISA between run,
Manufacture related,
immunologic factors
-manufacturer definition of
QFT® conversion is inflated
and incompatible with low
risk setting.
-higher QFT® cutoff is
needed
-cutoff of 5.3 yields similar
cutoff of institutions
historical TST

Reference, Type,
Quality
Article 17
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Dorman, S. E., Belknap,
R., Graviss, E. A., Reves,
R., Schluger, N.,
Weinfurter, P., . . . Daley,
C. (2014, January 1).
Interferon-y release
assays and tuberculin skin
testing for diagnosis of
latent tuberculosis
infection in healthcare
workers in the United
States. American Journal
of Respiratory Critical
Care Medicine, (189)1,
77-87. doi
10.1164/rccm.2013020365OC
(Dorman et al., 2014)
Level II Quasiexperimental
Quality A highgeneralizable, consistent
results, large sample size,
conclusions derived from
the results (Dearholt &
Dang, 2012)

Methods
-

-

-

-

Longitudinal, cross- sectional
2,563 HCW
4 healthcare systems in USDenver, Houston, Baltimore, New
York City
Case rate low- 4-9 per 100,000
QFT®-GIT, T-SPOT®.TB, and
TST (tubersol) baseline, 6
months, 18 months 2/2008 to
3/2011
QFT®-GIT, T-SPOT®.TB
collected and TST immediately
after phlebotomy (2 step if
needed)
Interviewed at each visit
+TST were asked to repeat TST
but counseled of risks

Exclusion- Current or prior TB
- Prior anaphylaxis to TST
- TST past 6 months
Substudies- 2 sets of IGRA 2 weeks apart
without TST in between
- Concordant negative or
concordant positive baseline
included
- Repeat ELISA testing for all
positives started midway through
the study
Boosting Sub study- Repeat IGRA in 7-21 days after

Threats

Findings

Conclusions

-To prevent bias and
improve reliability-the lab
staff did not access
clinical information or
prior IGRA results and
staff performing one type
IGRA did not access
result of other IGRA

-baseline +TST
with – IGRA
associated with
BCG odds 25.1
(95%CI)

-majority of new positive TST
and IGRAs were false-positive
-reversions for all 3 tests were
observed in 50% participants
-none had conversions to all 3
tests at once
-conversions were not
associated with TB exposure
risk
-Sub study- half of new
conversions by QFT®-GIT
were not confirmed by ELISA
-IGRA specificity in US HCW
at low risk is less than
previously reported by prior
studies
-borderline cutoff would not
help clinically because only a
small proportion 15-18% of
converters were close to cut
points
-IGRAs play a role for HCW
with BC vaccine as positive
TST but negative IGRA was
strongly associated.
-false-positive conversions
occur 6-9 times more w IGRA
than TST – balance use with
logistical advantages
-repeat testing of new
converters should be
considered
-repeat ELISA from stimulated
plasma for QFT®-GIT + may
be useful

-Author did an excellent
job of listing
limitations/threats-Absence of gold-standard
-attrition- good-low rate
of loss to follow up
-reliability threat- cannot
generalize study to
immunosuppressed or
areas with higher rates of
TB
-cannot generalize to
Europe or areas with
lower rate of + IGRA
compared to TST- these
areas may use different
tuberculin and higher
rates of BCG
-not all +TST patients
accepted repeat TST
-Results could vary with
different kinds of PPD
-Varied lab practices
could affect
validity/reliability

-Test conversions
6.1% QFT®-GIT,
8.3% TSPOT®.TB , 0.9%
TST
-of test converters76.4% QFT®-GIT
reverted, 77.1% TSPOT®.TB revert
to negative at 6
months
-sub study if IGRA
retesting without
TST
-negative/positive
discordance 8.8%
QFT®-GIT, 12.6%
T-SPOT®.TB at 2
weeks lab redraw
-baseline + QFT®GIT 3.8%, TSPOT®.TB 5%,
TST 1.8%

baseline IGRA and TST
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Statistics- K coefficient- agreement
measures
- Two-proportions z test
- McNemar’s test- dependent
proportions
- Holm-Bonferroni- multiple
comparisons
- T test-compare mean changes
IGRA
- Reproducibility & repeatability
sub studies used assess variability
- Linear mixed-effects models
- Within subject standard deviation
and intraclass correlation
coefficient
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Article- 18Loddenkember, R., Diel, R.,
& Nienhaus, A. (2012, July).
To repeat or not to repeatthat is the question! Chest,
142(1), 11. doi:
10.1378/chest.12-0045

Methods not discussed in this
short article. Good research
is referenced however.
Discussed research that is in
the same periodical. This is
an editorial.

-small number of articles
reviewed
-no discussion of limitations
of the research reviewed

-High income, low TB
incidence countriesevidence points toward
positive predictive values for
IGRAs higher than TST.

-simple positive- negative
interpretation of IGRA serial
testing of HCW
overestimates conversion and
reversion rates

-gray zone 0.35 to 1.0 would
reduce conversion to <1%
-using gray zone
approximately every second
HCW will revert to negative

-recommend preventive
chemotherapy only for IGRA
> 1.0

(Loddenkemper et al., 2012)
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Level- V- Literature
Review/Expert opinioneditorial
Quality B- fairly definitive
conclusions. Short article
with only one true article
review
Article recommended by
region 4 DHEC TB control
MD

-IGRAs should be repeated
in routine TB screening in +
testers
-Chest X-rays not needed in
asymptomatic HCW with
reversion in IGRA regardless
of first positive IGRA
concentration
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Article 19
Schablon, A., Nienhaus, A.,
Ringshausen, F. C., Preisser,
A. M., & Peters, C. (2014,
December). Occupational
screening for tuberculosis and
the use of a borderline zone
for interpretation of the IGRA
in German healthcare
workers. PLoS One, 9(12).
doi:
10.1371/journal.pone.0115322

Convenience sample, cohort
of screenings in HCWhospital, nursing home, and
outpatient- conducted in
occupational health clinic
3,823 had one QFT®
817 had second QFT®whether patients had second
QFT® was not standardizedoccupational health
physician determined need
based on exposure or
working on high risk ward
-questionnaire to assess risk
-low incidence country

-convenience sample –
selection bias
- second QFT® not
standardized
- German study- could be
higher risk than is US but it
is listed as low incidence.
-This included serial testing,
not just baseline.
-Some author bias is
apparent as they specifically
examined articles regarding
variability in results and
cutoffs. I think there was an
expectation of the cutoff
being too high.
-no inclusion or exclusion
criteria

-Positive QFT® risk factors=
age >55, foreign birth, hx
TB, internal medicine work,
infection ward work,
geriatric care work.

Borderline zone 0.2 to < 0.7
may avoid X-rays and meds
that are not needed.

(Schablon et al., 2014)
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Evidence level II Quasiexperimental
Quality B Good
(Dearholt & Dang, 2012)
Article recommended by
region 4 DHEC TB control
MD

SPSS statistical software
Chi square
Odds ratios
Confidence intervals

-Conversion rate 2.8%
-Reversion 37.3%
-changing conversion
definition to <0.2 to >0.7
decreases conversion rate to
1.2%

No case of active Tb foundscreening should be
restricted to HCW w
unprotected contact
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Article 20

-PubMed, EMbase, Biosis,
Web of Science
-studies up to 6/30/11 IGRA
predictive value
-2 independent reviewers

-did not limit articles to 5
years
-most studies did not “fully
answer” whether IGRA
could predict active tb
-Authors note- most studies
have bias because they do
not assess other risk factors
for tb
-could not do formal
assessment of publication
bias- assumed some bias
-most IGRA studies have
some “industry involvement”
which may lead to bias
-most studies did not
examine high income
settings

-moderate association
between + result and TB
-IGRA + and TST + were
about the same for risk of tb
-proportion of IGRA + was
lower than for TST

-neither IGRA or TST have
high accuracy prediction
active TB

Rangaka, M. X., Wilkinson,
K. A., Glynn, J. R., Ling, D.,
Menzies, D., MwansaKambafwile, J., . . . & Pai,
M. (2012, January).
Predictive value of
interferon-y release assays
for incident active
tuberculosis: a systematic
review and meta-analysis.
Lancet Infectious Disease,
12, 45-55. doi:
10.1016/514733099(11)70210-9
(Rangaka et al., 2012)
Evidence level III –
systematic review with meta
analysis, combo type of
studies
Quality- A High- thorough
literature search, conducted
quality assessment, new
statistics, definitive
conclusions
(Dearholt & Dang, 2012)
Article recommended by
region 4 DHEC MD

-Quality assessmentNewcastle-Ottawa scalestudy group selection,
comparability of groups,
exposure or outcome of
interest
-15 studies
-26,680 participants
-StatisticsMain interest- person-years
incidence rates of disease
-calculated incidence rate
rations for disease
progression in IGRA + vs –
and also for TST
-DerSimonian & Laired
random effects relative risk
w 95% CI
-heterogeneity-I2 statistic
-country level stratificationhigh income, low, middle

This article made efforts to
improve validity through
quality assessment of articles
and statistics applied,
discussed limitations and
listed no conflicts of interest

-use of IGRA might reduce
number of people who take
preventive meds
-Which test you use should
be based on population,
logistics, cost, patient
preference rather than just
predictive ability

Reference, Type,
Quality
Article 21
Banaei, N.,Gaur, R. L., &
Pai, M. (2016).
Interferon-y release
assays for latent
tuberculosis: what are the
sources of variability?
Journal of clinical
Microbiology.
doi:10.1128/JCM.0280315
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(Banaei et al., 2016)
Evidence level V Expert
Opinion/Literature
Review
Quality A High- clear
expertise, definitive
conclusions
(Dearholt & Dang, 2012)
Article recommended by
region 4 DHEC TB MD

Methods
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Findings

Conclusions

-reviewed
literature to
summarize
sources of
variability
-method of lit
review
nonspecific.
Purpose of
paper is more
for expert
opinion.

-did not discuss
methods for
conclusions but
appears to be
updating a previous
review.
-did not list method
for search of
articles
-did not discuss
limitations of
studies reviewed

Higher rate of false- positives with IGRA

-neither IGRA or TST
have high accuracy
prediction active TB

Sources of Variability-Preanalytical
- evening blood draw related to higher response value with
QFT®-GIT
-Inadequate disinfection- can contaminate tubes
-correct order of tubes may matter- nil, antigen, mitogentube contamination- antigen contaminated with mitogen =
false +, contamination of nil tube with mitogen = false
negative
-volume of blood can alter result- inverse TB response
- vigorous shaking may increase IFN-y response- false + or
false –
- processing day 1-4 hr. before antigen stimulation can
lower t cells
-incubation delay- declines TB response
-indeterminate results increase in autumn and wintertransport in lower temp may affect result-particularly with TSPOT®.TB
- longer incubation = does not increase TB response
Analytical
-biologic fluid uncontrolled factors
-pipetting imprecision
-centrifugation error
-error in washing steps
-operator error in measurement of signal
-between run variability=+ 0.6 for all, + .24 for those with
initial borderline response
-conversion 9%, reversion 7%
Post-analytical
-clerical error data entry

-use of IGRA might
reduce number of
people who take
preventive meds
-Which test you use
should be based on
population, logistics,
cost, patient
preference rather than
just predictive ability

Manufacturing
- Some reports of false + in faulty antigen tubes
- Potential bacterial contamination
Immunologic
- Boosting by TST= increase
Immunomodulation microbes- skin microorganisms such as
staff
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Reference, Type, Quality

Methods

Threats

Findings

-Discussion of TB, TST,
IGRA pros and cons with
literature review following
-11 studies reviewed with
main findings summarized in
table.

-did not discuss inclusion or
exclusion criteria

-HCW 2-5x increase risk if
TB
- study supports use of
QFT® vs TST in neonates
exposed to HCW w TB
-greater specific of QFT®
over TST
-a single positive IGRA, may
not be infection
-QFT®-G and QFT®-GIT,
more effective & less costly
than TST whether vaccinated
with BCG or not
-IGRA appropriate for serial
screening HCW in low
incidence country w high
vaccination rates
-IGRAs cost effective for
screening high risk
individuals in low incidence
setting
- specificity IGRA higher
than TST, correlated w
exposure better
-IGRA reduces falsepositives from BCG
-good correlation betw
occupational risk factors and
IGRA +

Article 22
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Nienhaus, A. (2013). Clinical
review of literature
pertaining to the use of
interferon gamma release
assays for tuberculosis
screening in healthcare
workers: Evidence base and
clinical experience with
Quantiferon-TB Gold
(QFT®). HCW Clinical
Review. Retrieved from
http://usa.quantiferon.com/ir
m/content/pdfs/ClinRev_QF
T_HCW_EN_1013_QA_LR
%20(1).pdf
(Nienhaus, 2013)

Level V Literature
Review/Expert Opinion
Quality Good B
Expertise credible, logical
opinions for conclusions
(Dearholt & Dang, 2014)

Conclusions
-IGRA is appropriate for
HCW tuberculosis screening
-Advantages of IGRA:
-single visit
-use of positive & -controls
-unaffected by BCG vaccine
-objective interpretation
-Superior specificity over
TST in countries with low
TB burden
-Saves 25-85% of chest xrays
-IGRA correlated with TB
risk factors
--improves cost-effectiveness

Reference type, quality

Methods

Threats

Findings

Conclusions

Article 23

Case study on how lean
principles can improve new
hire onboarding and TB
screening process.

-published by Qiagen

-Use of QFT® can result in
7-9 days sooner clearance to
work for new hires

-QFT® less expensive,
faster, less false positives,
reduces waste, reduces hiring
delays and potentially lost
candidates.
-QFT® is in line with lean
principles and is more
efficient and less expensive

Graban, M., & Filby, D.
(2015). “Lean” the new hire
onboarding process for
healthcare workers:
evaluating the Quantiferon
™-TB Gold test. Qiagen.
Retrieved from
www.qiagen.com
(Graban & Filby, 2015)
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Level V Case Report
Quality B Good
Clear objectives for the
article, consistent
recommendations (Dearholt
& Dang, 2014)

-compares process to Toyota
lean principles to address:
Defects, Overproduction,
Transportation, Waiting,
Inventory, Motion, Overprocessing, Talent

-did not directly report
results of the hospital using
the QFT®

-Cost of unfilled positions,
staff overtime can be
significant in comparison to
QFT®
-labor costs savings for test
administration
-process is respectful of
candidate’s time

APPENDIX B
EVIDENCE LEVEL AND QUALITY GUIDE

Table B.1 Evidence and quality guide
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Level I
Experimental study, randomized
controlled trial (RCT). Systematic review of RCTs,
with or without meta-analysis
Level II Quasi-experimental study.
Systematic review of combination of RCTs and
quasi-experimental, or quasi-experimental studies
only, with or without meta-analysis
Level III Non-experimental study.
Systematic review of a combination of RCTs,
quasi-experimental and non-experimental studies,
or non-experimental studies only, with or without
meta-analysis. Qualitative study or systematic
review with or without a meta-synthesis

A High Quality: consistent, generalizable results; sufficient
sample size for the study design; adequate control; definitive
conclusions; consistent recommendations based on comprehensive
literature review that includes thorough references to scientific evidence
B Good quality: Reasonably consistent results, sufficient
sample size for the study design, some control, fairly definitive
conclusions, reasonably consistent recommendations based on fairly
comprehensive literature reviews that includes some reference to
scientific evidence
C Low quality or major flaws: Little evidence with
inconsistent results: insufficient sample size for the study design;
conclusions cannot be drawn

Level IV Opinion of respected authorities
and/or nationally recognized expert
committees/consensus panels based on scientific
evidence. Includes: clinical practice guidelines,
consensus panels

A High quality: Material officially sponsored by a professional,
public, private organization, or government agency; documentation of a
systematic literature search strategy; consistent results with sufficient
numbers of well-designed studies; criteria based evaluation of overall
scientific strength and quality of included studies and definitive conclusions;
national expertise is clearly evident; developed or revised within the last 5
years.
B Good quality: Material officially sponsored by a professional,
public private organization, or government agency: reasonably thorough and
appropriate systematic literature search strategic; reasonably consistent
results, sufficient numbers of well-designed studies; evaluation of strengths
and limitations of included studies with fairly definitive conclusions; national
expertise is clearly evident; developed or revised within the last 5 years
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Level V Based on experiential and nonresearch evidence. Includes: Literature reviews; quality
improvement, program or financial evaluation; Case
reports; Opinion of nationally recognized experts based
on experiential evidence

C Low quality or major flaws: Material not sponsored by and
official organization or agency; undefined, poorly defined, or limited
literature search strategy; no evaluation of strengths and limitations of
included studies, insufficient evidence with inconsistent results, conclusions
cannot be drawn; not revised within the last 5 years
Organizational Experience:
A High Quality: Clear aims and objectives, consistent results across
multiple settings; formal quality improvement, financial or program
evaluation methods used; definitive conclusions, consistent recommendations
with thorough reference to scientific evidence.
B Good quality: Clear aims and objectives; consistent results in a
single setting; formal quality improvement of financial or program evaluation
methods used; reasonably consistent recommendations with some reference to
scientific evidence
C Low quality or major flaws: Unclear or missing aims and
objectives; inconsistent results; poorly defined quality improvement, financial
or program evaluation methods; recommendations cannot be made.

Literature Review, Expert Opinion, Case Report, Community
Standard, Clinician Experience, Consumer Preference:
A High Quality: Expertise is clearly evident: draws definitive
conclusions; provides scientific rationale: thought leader in the field
B Good quality: Expertise appears to be credible; draws fairly
definitive conclusions: provides logical argument for opinions

©The John Hopkins Hospital/The Johns Hopkins
University
(Dearholt & Dang, 2014)

C Low quality or major flaws: Expertise is not discernable or is
dubious: conclusions cannot be drawn
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APPENDIX C
CONCEPTUAL FRAMEWORK


Used/Reprinted with permission from the University of Iowa Hospitals and
Clinics. Copyright 1998. For permission to use or reproduce the model, please
contact the University of Iowa Hospitals and Clinics at (319)384-90
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Organization
priority

Sufficient
base
Change
appropriate

Change
implemented

Disseminated results
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APPENDIX D
INSTITUTIONAL REVIEW BOARD APPROVALS
OFFICE OF RESEARCH COMPLIANCE

INSTITUTIONAL REVIEW BOARD FOR HUMAN RESEARCH
DECLARATION of NOT RESEARCH

This is to certify that research proposal: Pro00063801
Entitled: Tuberculosis Screening in New Healthcare Employees: A Comparision
of QuantiFERON-TB Gold In-Tube Test and Tuberculin Skin Test
Submitted by:
Principal Investigator: Mary Giovannetti
College of Nursing
1601 Greene Steet
Columbia, SC 29208
was reviewed on 1/27/2017 by the Office of Research Compliance, an
administrative office that supports the University of South Carolina Institutional Review
Board (USC IRB), and has determined that the referenced research study is not subject to
the Protection of Human Subject Regulations in accordance with 45 CFR 46 et. seq.
No further oversight by the USC IRB is required; however, the investigator
should inform the Office of Research Compliance prior to making any substantive
changes in the research methods, as this may alter the status of the project.
If you have questions, contact Arlene McWhorter at arlenem@sc.edu or (803)
777-7095.

Sincerely,

Lisa M. Johnson
IRB Manager
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Email approval from Healthcare system IRB 2/1/17:
Mary, I spoke with Frank Stewart and he said to proceed with your study. Please upload
this email as a private comment (this option is available on the left side of your eIRB
screen when you click into your study) for confirmation.

Thanks,
David

David L. Suárez, MLIS
IRB Coordinator | Office of Research Compliance

101 East Wood Street | Spartanburg, SC 29303
o: 864-560-6892 | f: 864-560-1950
e: dsuarez@srhs.com | w: SpartanburgRegional.com
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APPENDIX E
NURSING RESEARCH COUNCIL PROPOSAL AND APPROVALS
Evidence-Based Quality Improvement DNP Clinical Dissertation Project
Tuberculosis Screening in New Healthcare Employees: A Comparison of
QuantiFERON®-TB Gold In-Tube Test and Tuberculin Skin Test
Principle Investigator: Mary Giovannetti, NP
Co-Investigator: Stephanie Barnhill, NP
Faculty/Committee: Dr. Stephanie Burgess, Dr. Karen McDonnell, Dr. Abbas Tavakoli
To be conducted at: Spartanburg Regional Healthcare System
PICOT: As a foreground question, among all adult newly hired healthcare employees at
a healthcare system, how does baseline testing with QuantiFERON®-TB Gold In-Tube
test (QFT®-GIT) compare with two step PPD TB skin test in regards to time for
completion of tuberculosis screening and compliance with screening within 10 days of
orientation over a 2-month time frame?
Purpose
The purpose of this quality improvement DNP project is to compare baseline
testing with QuantiFERON®-TB Gold In-Tube test (QFT®-GIT) to the two step PPD TB
skin test in regards to tuberculosis screening time, costs, overall onboarding clearance
time, and compliance for new employees.
Spartanburg Regional Healthcare System (SRHS) currently employees
approximately 6,800 employees and experienced a 15% employee turnover rate in 2015
and 2016 which led to staffing issues and utilization of expensive locum tenems
temporary contract employees. There was an increase in hiring due to this turnover and
an increased demand for Employee Health to expedite new hire clearance. Employee
Health was asked to onboard new hires quicker and increase appointment availability.
After careful review, it was found that the long process of tuberculosis screening
contributed to the longer onboarding time for new hire employees.
The Department of Health and Human Services Centers for Disease Control and
Prevention (CDC) recommends that all healthcare workers receive initial screening for
TB upon hire by a 2-step tuberculin skin test (TST) (Jensen et al., 2006). There are three
main categories of problems with utilization of the two step tuberculin skin test: extended
screening time, noncompliance, and potential inaccuracy in placement and results.
Employee Health completes tuberculosis screening with the two step PPD skin test. This
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process takes 2-4 visits and can take 10 days to 3 weeks or more to complete. If the new
employee fails to return for a placement or reading, orientation may be delayed.
Tuberculin skin test was the only available test for TB screening until 2001 when
Interferon gamma release assays (IGRA) were developed. IGRA’s can potentially
overcome issues with TST tuberculosis clearance screening time and compliance, as well
as problems with inaccurate results. In contrast to TST, IGRA’s do not react to
nontuberculous mycobacteria or BCG vaccination. IGRA’s can also be completed in one
visit and eliminate the need for multiple visits. Furthermore, IGRAs have been found to
have a higher correlation to TB exposure than TSTs improving accuracy. IGRA’s are
more expensive than TST’s, but utilization is expect to reduce costs associated with
staffing requirements, inadequate testing results, poor employee compliance follow up,
and potential DHEC citations for organization noncompliance (Mazurek et al., 2010). In
February of 2016, Employee Health implemented QFT®-TB Gold In-Tube Test for all
new hires in place of the 2 step PPD. Preliminary assessment revealed that
implementation of QFT® for new hires along with other factors has led to increase in
available appointments, decrease in screening and onboarding time. This project will
further analyze the data for publication in dissertation and in journal publication.
Literature Review and Synthesis
Twenty-three studies were included in the review of the literature. The articles
were classified into levels I through IV according to John Hopkins Research and NonResearch evidence appraisal tools (Dearholt & Dang, 2012). Level I includes
experimental studies, II quasi-experimental, III Non-experimental, IV clinical practice
guidelines, consensus or position statements, and level V literature review, expert
opinion, community standard, clinician experience, and consumer preference (see
Appendices B for level and quality guide). Of the 23 articles analyzed there were four
level II articles, seven level III, two level IV, and 10 level V. Quality of the articles were
also analyzed as shown in table 5 according to John Hopkins appraisal tools with ratings
of A- high quality, B- Good quality, and C- Low Quality (Dearholt & Dang, 2014).
Analysis of the literature revealed pros and cons to choosing the QFT®-GIT for
TB skin testing for new healthcare workers. There are a number of positive logistical
factors that would provide value for employee health offices while improving costeffectiveness. Since QFT®-GITs are completed in one test, new hire onboarding and
tuberculosis clearance time should be reduced. This will also reduce the burden on
employee health staff time spent on tuberculosis clearance activities, and enhance
convenience to the new hire (Foster-Chang et al., 2014; Graban & Filby, 2015; Veeser et
al., 2007). Cost analysis revealed that IGRAs are cost effective (dePerio et al., 2009;
Foster-Chang et al., 2014; Graban & Filby, 2015; Nienhaus, 2013; Nienhaus et al., 2011).
The QFT®-GIT has high specificity but there are some concerns about sensitivity
(Banaei et al., 2016; Cummings et al., 2009; Dorman et al., 2014; Loddenkemper et al.,
2012; Schablon et al., 2014; Slater et al., 2013; Weddle et al., 2014; Zwerling et al.,
2012). However, sensitivity of the QFT®-GIT improves with consideration of patients
with active tuberculosis (Mazurek et al., 2010). Some studies have shown that there can
be issues with conversions and reversion and a borderline cutoff with retesting may be
appropriate (Dorman et al., 2014; Loddenkemper et al., 2012; Mazurek et al., 2010;
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Schablon et al., 2014; Slater et al., 2013; Weddle et al., 2014; Zwerling et al., 2012).
When interpreting results, the immunologic status of the patient should also be
considered with indeterminate results (Cummings et al., 2009). Standardization of lab
procedures can help overcome some of the variability in results (Banaei et al., 2016).
Overall, there is good evidence to implement QFT®-GITs in new hire healthcare workers
while considering all the interpretation factors.
Study Design
Employee Health was faced with a dilemma of increasing volume of new hires
coming for appointments and increasing frustrations by management regarding delays in
orientation. Employee Health management formed a new hire committee in Fall of 2015
to investigate the factors involved with delays in orientation. One factor identified in
orientation delays was the amount of time it takes for new employees to complete the
two-step TST. The literature was reviewed and multiple steps were taken to investigate
the ability for Employee Health to offer an IGRA for all new hires in order to reduce the
amount of time it takes to be cleared for orientation. In February of 2016, Employee
Health implemented a quality improvement project to reduce onboarding time for new
hires by implementing the QFT®-GIT in place of the two-step TST.
This quality improvement evidence-based project will be utilized to satisfy
requirements for DNP clinical dissertation. The design will be descriptive comparative
non-experimental which will compare the two methods of tuberculosis screening in
regards to tuberculosis clearance time, compliance, costs, and overall onboarding time.

Conceptual Framework and Feasibility
The Iowa Model of Evidence-Based Practice to Promote Quality Care (Iowa
Model) will be utilized to guide implementation of the project. Stakeholder support,
sample access and size, financial, legal and ethical resources are substantial. An adequate
sample size should be easily obtained through the retrospective chart review. This project
should not incur any costs other than time for the investigator.
Procedure and Data Collection
The sample will include a convenience sample of all new hire potential employees
that are scheduled for pre-placement assessment at the healthcare system Employee
Health beginning March, April, and May 2016 utilizing the QFT®-GIT, and all new hires
from March, April and May 2015 through November 2015 utilizing the two-step PPD
screening.
Data will be collected retrospectively by electronic medical record chart review
by the primary investigator employed by the Employee Health Department. Data will be
compiled in a password protected excel spreadsheet with all identifiers removed. Data
collected on each subject will include: dates for each pre-placement visit and preplacement follow up visits, dates for TST placement and readings, dates for QFT®-GIT
collection and dates results were received, dates for orientation, and dates for final
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orientation clearance. Data regarding dates for completion of requirements that could
delay orientation will also be collected including dates fit for duties, dates documentation
was received for provider work notes, pre-work screen dates, and drug screen collection
result dates. Notations will be made regarding any positive TST or QFT®-GIT results,
required chest x-ray dates and results, symptom review dates, and DHEC referrals.

Data Analysis
Once the survey data is entered into the encrypted file, the investigator in
collaboration with a statistician will review the data and, create data in the form that
would be useable in SAS for analyses. Data analysis will include both descriptive and
inferential statistics using SAS 9.4. Frequency distribution will be included for
categorical variables. The continuous variable statistics will include measures of central
tendency (mean and median) and measures of spread (standard deviation and range).
Inferential statistics will include T-test, Pearson correlation, and simple linear model.
Findings with p-values less than or equal to .05 will be considered significant.
Evaluation Plan
Questions/Outcomes/Evidence-based measures
Q1. Will implementation of QFT reduce the number of days to complete
tuberculosis screening for new hires?


Retrospective data will be collected from electronic and paper Employee
Health records. This data will be stored on a password protected
spreadsheet without patient identifiers.
 The number of days it takes to complete TST screening will include the
time from placement of step 1 to reading of the 2nd step. If the new hire
brought documentation of step 1, then only completion of step 2 will be
recorded. If the new hire fails to complete a step and has to be replaced,
then that time will also be included in the number of days for clearance.
 Total tuberculosis screening clearance time for those completing the
QFT®-GIT will include date of blood draw to date the result was
reviewed. If the QFT®-GIT needs to be repeated for borderline positive
result, this time will be included in overall screening time.
 Those with a previous positive TST will be included with days to
clearance being 1 day.
 Data will be analyzed by simple t test. Regression model will be
completed to control for demographic variables.
Q2. Will implementation of QFT for new hires reduce the overall number of days
to complete onboarding?


Time for onboarding will include days from first appointment to
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completion of all requirements including tuberculosis screening,
assessments, fit for duties, lab results, and review of any requested
records. Completion of immunizations and Hepatitis B waivers will not be
included because those are not completed until after orientation.
 Data will be analyzed by t test
Q3. Will implementation improve compliance with completion of tuberculosis
screening within 10 days of orientation?


Compliance will be defined as completing both steps of the 2 step skin test
within 10 days of orientation or completion of any required repeat QFT®GITs, symptom reviews, or chest x-rays.
 The proportion test will be used to compare two proportions.
Q4. Will implementation of QFT be cost-effective?


A simple review of associated costs with QFT versus PPD including staff time
will be reviewed. Actual average salary of Employees in Employee Health in
relation to time it takes to completion of testing and assessment requirements,
phone calls to contact non-compliant employees, and call employees with results
of lab testing will be considered. Cost of supplies will include the cost for the
PPD derivative, the syringe/needle, and cost of lab charges for QFT®-GIT. Labor
costs from missed work for the new hire will not be considered since the new hire
is not yet working for the organization and current salary cannot be determined.

Timeline
Upon approval of the Nursing Research Council, SRHS IRB, and USC IRB, data
collection will begin. Data collection and analysis will be completed by the end of March
2017 with DNP defense March 31, 2017. Manuscript with summary of findings will be
submitted to Association of Occupational Health or related journal for consideration of
publication.

Human Subjects
An application for exempt status will be submitted to two IRBs: the healthcare
system and University of South Carolina. The University of South Carolina typically
grants exempt status for quality improvement projects which are focused on improving
outcomes/processes in the setting and are not research to generate new knowledge. After
approval, the investigator will begin to collect data. The primary investigator is in charge
of routinely collecting data regarding onboarding times and has access to the electronic
medical records. The investigator will only retrieve data essential for project. The excel
spreadsheet will be saved in the investigator’s access limited S-drive folder, with a
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password protected spreadsheet. All computers are password protected and all data on the
healthcare system’s computers are encrypted. All identifiers will be removed from the
spreadsheets. The investigator has completed Collaborative IRB Training Initiative
(CITI) courses. Data will be disseminated in the aggregate.
Nursing Research Council
Final Approval Form with Two Scientific Reviews
(This completed form will be placed in the Principle Investigator’s (eIRB) Smart Form)
Principle Investigator (PI): Mary Giovannetti, Nurse Practitioner

Date: 1/24/17

Study Name: Tuberculosis Screening in New Healthcare Employees: A Comparison of
QuantiFERON®-TB Gold In-Tube Test and Tuberculin Skin Test
(Required 2 Independent Peer Reviewers: See Scientific Review Tools for Comments)
Reviewer’s Name & Credentials
Mary Alice Hodge, PhD, RN, CNL
Jo Vaughn, MSN, RN

Title
Professor, USC
Upstate School of Nursing
Corp Educ –Hospital
Educ

Review
Date
1/20/17
1/20/17

The scientific review was completed by a minimum of two independent reviewers
who are members of the Nursing Research Council. Members of the research team, PI, or data
collectors cannot participate in the review. The Scientific Reviewer Tool for Nursing Research
Proposals was used as a guide in the review process by the review team.
We attest that the above information is correct and that, to the best of our
knowledge, scientific review and approval of this PI’s research proposal has been performed by
a group of independent peer reviewers.
Tim Fagan, MA, MSN, CPHQ
Nursing Research Council – Co-chairperson’s Signature
Betty Warlick, MN, RN
Nursing Research Council – Co-chairperson’s Signature

1/24/17
Date
1/24/17
Date

Instructions for the Nursing Research Council:
1. The Nursing Research Council’s Co-chairpersons will complete this form & email it to the
Principle Investigator (PI).
Instructions for the Principle Investigator (PI):
1. The PI will work with the IRB Manager to upload into the eIRB their Nursing Research
Proposal. This form, the scanned Preliminary Approval for Research Form plus other
forms will also be uploaded into the eIRB Smart Form on the last page “General
comments.”
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2. The PI will email the NRC’s Co-chairpersons that they have uploaded these forms &
completed the eIRB process.
2017
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APPENDIX F
POSTER ABSTRACT
QuantiFERON®-TB Gold In-Tube Test for Baseline Tuberculosis Screening
in New Healthcare Employees: A Review of the Literature
Author:

Contact:

Mary Giovannetti, MSN, APRN, BC-FNP,
Manager, Spartanburg Regional Healthcare System Employee Health
Nurse Practitioner, Medical Group of the Carolinas Occupational Health
DNP Student, College of Nursing, University of South Carolina
mgiovannetti@srhs.com, 864-497-4087 (cell phone)

Additional Authors: Stephanie Burgess, PhD, APRN, BC, FAANP,
Clinical Professor, Associate Dean for Practice, Director
DNP/MSN,
College of Nursing, University of South Carolina
Karen McDonnell, PhD, RN, OCN
Assistant Professor
College of Nursing, University of South Carolina
Abstract
Introduction: The two step tuberculin skin test is recommended by Centers for Disease
Control and Prevention for all new healthcare workers. The two step TST has limitations
including compliance with both steps, subjective reader interpretation, and false-positive
results. This can be problematic for Employee Health departments and cause delays in
orientation. A systematic review of the literature was conducted to determine the
evidence regarding implementation of Interferon Gamma Release Assays (IGRA) in
Employee Health for new hire employees. This literature review is preliminary work for
an evidence-based project to determine if baseline testing with QuantiFERON®-TB Gold
In-Tube test (QFT®-GIT) will reduce tuberculosis screening time and improve
compliance in new employees at Spartanburg Regional Healthcare System.

Methods: CINAHL, PubMed, and Science Direct were searched with keywords IGRA,
Interferon Gamma, tuberculosis screening, quantiferon, employee, healthcare worker, and
tuberculosis. Studies published in English, conducted in low or medium TB incidence
settings which included information regarding IGRA testing in healthcare workers
including QFT®, QFT®-TB Gold, QFT®-GIT, or T-spot from 2005 to present met the
inclusion criteria.
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Results/Limitations/Conclusions: Twenty-three studies were included in the literature
review. The John Hopkins nursing evidence-based practice model and guidelines was
utilized to rate the evidence and quality of the studies. There were five level II studies, six
level III, two level IV and ten level V. Eight studies were high quality, and fifteen studies
were rated good. Low quality studies were excluded. The analysis of the literature was
grouped into topics of the tuberculosis screening process, cost, accuracy, and
conversions/reversions. Synthesis of the literature revealed a number of positive logistical
factors that would provide value for employee health offices including reduced number of
visits for the new hire and reduced burden on employee health office staff time spent on
tuberculosis clearance. The cost analysis revealed that utilization of IGRAs has been
found to be cost effective and in some cases saves money. The literature showed that the
QFT®-GIT has high specificity but there are conflicting reports on sensitivity. There
may be reductions in false-positives due to elimination of subjective reader interpretation
and IGRAs do not react to other non-mycobacterium tuberculosis. The review also
showed that positive results in a borderline interpretation zone can have conversions and
reversions with some studies recommending retesting. One limitation of this review is
that there was no level I study found. In conclusion, the literature review showed that
utilization of the QFT®-GIT has potential to improve tuberculosis screening processes,
reduce costs, reduce false-positive results with improved specificity, and has the potential
to contribute to reduced tuberculosis screening time and improve compliance.

Implications for practice: Employee Health and occupational health departments that
are required to conduct tuberculosis screening for new hire employees should conduct a
needs assessment in their organization and review the evidence to determine if IGRAs
would improve processes, be cost effective, and align with organization priorities.
Organizations implementing IGRAs for new hires should develop policies and
procedures with consideration of the evidence with regards to sensitivity, specificity,
conversions, and reversions with consideration for retesting guidelines.

Applying for Poster Presentation
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APPENDIX G
CONFERENCE PRESENTATION APPLICATION

CALL FOR SPEAKERS
AOHP 2017 NATIONAL CONFERENCE
September 6-9, 2017

Sheraton Denver Downtown Hotel, Denver, CO
Thank you for considering speaking at the AOHP 2017 National Conference. The speaker
submission will be in two phases.
The first submission will help the committee decide if your presentation meets the needs of the
conference. Please provide as much detail as possible in your submission, including a description of
any relevant methods, techniques, tools, results, lessons learned, etc.
 Deadline to submit: January 31, 2017
 Successful applicants will be notified by April 24, 2017.
All presentation submissions will be reviewed and selected by a committee of volunteer professionals
according to the following evaluation criteria. Preference will be given to abstracts that include
appropriate detail.





Originality of presentation
Overall quality of content
Relevance/timeliness to current issues
Well-defined focus

Please complete the form below with following:
 Presentation Title
 Presenter’s Bio
 Topic Overview - Describe the basic content of the proposed presentation – a minimum of
50 words and maximum of 300 words is needed.
 Purpose – Describe as an outcome statement.
 Description of current state
 Description of desired achievable state
 Identify at least three objectives for the proposed presentation
 Provide an outline of the content for each objective
 Type of presentation, level and time frame.
Submission abstracts should be submitted to AOHP National Headquarters via email at
info@aohp.org by January 31, 2017.
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We appreciate your interest and welcome your submission. AOHP reserves the right to
review and accept only those proposals deemed suitable for the program. The conference committee
will review all valid submissions. The choice of a session will be based on the presentation of the
session, its value to professionals, the location of the speaker to promote local experts, and
comprehensiveness of the required information submitted. Speakers will be contacted individually
about their submission, accepted or not.
Session speakers are asked to participate on a “gratis” basis. Speakers receive FREE
registration for the day of their presentation and one complimentary night hotel stay. To
discuss alternative speaker compensation, please contact AOHP Headquarters at
info@aohp.org
We appreciate your time and look forward to working with you for the 2017 Conference.
Sincerely,
Dana Jennings Tucker, RN, BSN, CCM
AOHP 2017 National Conference Chair
Deadline to submit: January 31, 2017

Successful applicants will be notified by April 24,
2017.

AOHP Headquarters: 125 Warrendale Bayne Road, Suite 375, Warrendale, PA 15086
www.aohp.org Email: info@aohp.org
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SPEAKER SUBMISSION FORM
AOHP 2017 National Conference  September 6 – 9, 2017
Sheraton Denver Downtown Hotel  Denver, CO

PRESENTER
Mary Giovannetti, APRN, DNP, C-FNP (I graduate May 6, if you
publish before then use APRN, MSN, C-FNP)
ADDRESS

913 Palmdale Court

CITY, STATE &
ZIP
PHONE

Boiling Springs, SC 29316

864-497-4087

CURRENT POSITION &
EMPLOYER
COPRESENTER

mgiovannetti@srhs.com

Manager/NP Spartanburg Regional Healthcare System
Employee Health

Stephanie Barnhill, APRN, MSN, C-FNP

ADDRESS

236 Orchard Grove Road

CITY, STATE &
ZIP
PHONE

EMAIL

Campobello, SC 29322

864-497-5089

CURRENT POSITION &
EMPLOYER

EMAIL

sbarnhill@srhs.com

NP Spartanburg Regional Healthcare System
Employee Health

COPRESENTER
ADDRESS
CITY, STATE &
ZIP
PHONE

EMAIL

CURRENT POSITION &
EMPLOYER
COPRESENTER

(Please provide your full name with credentials that you prefer to show on our
publications.)

ADDRESS
CITY, STATE &
ZIP
PHONE

EMAIL

CURRENT POSITION &
EMPLOYER
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Presentation Title

Presenter’s Bio
(Please provide a
brief bio, not CV,
for each
presenter.)
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Abstract/Presentation Overview - Describe the basic content of the proposed presentation – a
minimum of 50 words and maximum of 300 words is needed.
Authors: Mary Giovannetti, DNP, APRN, BC-FNP; Stephanie Burgess, PhD, APRN, BC,
FAANP; Karen McDonnell, PhD, RN, OCN; Abbas Tavakoli, DrPH, MPH, ME; Stephanie Barnhill,
MSN, APRN, BC-FNP
Background: Streamlining onboarding processes for new hires to maximize efficiency
and reduce costs while meeting regulatory requirements is a constant challenge for
healthcare systems’ Employee Health staff. Health screening is a required step and includes
obtaining a detailed health history, tuberculosis screening, drug screens, immunizations, fit
for duty examinations, obtaining medical records, clarification of disability accommodations,
pre-work screens, and other tests which are time consuming and result in delays in hire dates.
Faced with a high volume of potential new employee hires a major southeast healthcare
system was concerned about delays in new hire start dates. The two-step tuberculin skin test
administration and follow-up process was identified as a potential area for improved
onboarding efficiency.
Method: A quality improvement study was designed and implemented to compare
baseline testing for new employees with an Interferon-Gamma Release Assay (IGRA) known
as QuantiFERON®-TB Gold In-Tube Test (QFT®-GIT) to the two step PPD Tuberculin Skin Test
(TST) for tuberculosis screening time, overall onboarding time, compliance with screening
within 10 days of hire date, and associated costs. A retrospective electronic record review
included a sample of 484 new hire employees.
Results: Results showed that the QFT®-GIT for tuberculosis screening in comparison
to the TST testing significantly reduced tuberculosis screening time for new hire employees
(TST = 8.03 days, QFT®-GIT = 4.11 days; p<.0001) and overall onboarding time (TST = 7.92
days, QFT®-GIT = 5.07 days; p<.0001) while improving compliance with tuberculosis screening
within 10 days of hire date (TST = 92.92%, QFT®-GIT =100%; p<.0001).
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Conclusions: The utilization of QFT®-GIT for tuberculosis screening of new employees
significantly reduced screening and onboarding time while improving compliance with
screening within 10 days of the hire date.
Implications: Healthcare systems should consider implementation of an IGRA in
order to streamline processes for onboarding new employees. New processes require
negotiations between healthcare systems and lab vendors, changes in policies and
procedures, and employee health and laboratory staff development.

Learning Outcome:
Learners will be able to describe how implementation of an Interferon Gamma Release Assay
(IGRA) can be utilized for tuberculosis screening of new healthcare workers.
Description of current state:

Delays in orientation and health clearance due to
long process of tuberculosis screening

Description of desired
achievable state:

Reduce number of days needed to complete
tuberculosis screening

Identify at least three
objectives for the proposed
presentation.

Provide an outline of the content for each objective. It
must be more than a restatement of the objective.

1.

Discuss problems with
tuberculosis screening
for healthcare workers

2.

Describe pros and cons
of Interferon Gamma
Release Assays
Identify steps for
implementation of
IGRAs for new
healthcare employees
Describe results of IGRA
implementation for
tuberculosis screening
and compliance

3.

4.

Review author’s department experience with TST’s and
onboarding and have learners interactively discuss their
experience with TST’s or IGRA’s for tuberculosis
screening.
Summarize the Review literature results of 23 articles
including: TB screening process, cost, accuracy,
conversions/reversions
Discuss how the healthcare system implemented the
IGRA including successes and problem resolution.
Review results of data analysis for sample of 485 subjects.

5.
What level do you consider your presentation?
Basic
Intermediate
What time frame is needed? Check all that apply.
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Advanced

Workshop (2 to 8
hours
hours):
x
General Session (60 minute included
x
Breakout Session (60 minute included
Q&A)
Q&A)
Type of presentation, check all that apply.
x
Case study
Topic discussion
Forum Discussion
4

Roundtable discussion

Other

Submission abstracts should be submitted to AOHP National
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Email info@aohp.org by January 31, 2017.
Maximum of four speakers for workshops and two speakers for sessions.

Session handouts will be made available to attendees for download and in notebook and CD
format. AOHP reserves the right to request or make last minute changes to any program. Speakers
who do not comply with given deadlines may be removed from the program.

Disclaimer: AOHP 2017 National Conference sessions and workshops must be educational in

nature. The conference objective is to provide participants with practical knowledge and tools that
can be easily implemented in their own organizations. We believe that an objective presentation, one
that meets the educational expectations of the audience, will enhance the credibility of the speaker,
the speaker’s employer and the event. No product or service promotion will be permitted. All
presentations must avoid commercialism, promotion and advertising. Presentations that are a simple
description of company products will NOT be allowed. Statements in the presentation are the sole
responsibility of the author. No presenter statements should be viewed as, or considered
representative of, any formal stance or position taken on any product, subject or issue by AOHP.
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APPENDIX H
JOURNAL MANUSCRIPT
Tuberculosis Screening of New Healthcare Workers utilizing an Interferon
Gamma Release Assay (IGRA): Quality Improvement in Screening time,
Onboarding time, and Compliance1

1
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FAANP; Karen McDonnell, PhD, RN, OCN; Abbas Tavakoli, DrPH, MPH, ME;
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Abstract
Background: Streamlining onboarding processes for new hires to maximize
efficiency and reduce costs while meeting regulatory requirements is a constant challenge
for healthcare systems’ Employee Health staff. Health screening is a required step and
includes obtaining a detailed health history, tuberculosis screening, drug screens,
immunizations, fit for duty examinations, obtaining medical records, clarification of
disability accommodations, pre-work screens, and other tests which are time consuming
and result in delays in hire dates. Faced with a high volume of potential new employee
hires a major southeast healthcare system was concerned about delays in new hire start
dates. The two-step tuberculin skin test administration and follow-up process was
identified as a potential area for improved onboarding efficiency.
Method: A quality improvement study was designed and implemented to
compare baseline testing for new employees with an Interferon-Gamma Release Assay
(IGRA) known as QuantiFERON®-TB Gold In-Tube Test (QFT®-GIT) to the two step
PPD Tuberculin Skin Test (TST) for tuberculosis screening time, overall onboarding
time, compliance with screening within 10 days of hire date, and associated costs. A
retrospective electronic record review included a sample of 484 new hire employees.
Results: Results showed that the QFT®-GIT for tuberculosis screening in
comparison to the TST testing significantly reduced tuberculosis screening time for new
hire employees (TST = 8.03 days, QFT®-GIT = 4.11 days; p<.0001) and overall
onboarding time (TST = 7.92 days, QFT®-GIT = 5.07 days; p<.0001) while improving
compliance with tuberculosis screening within 10 days of hire date (TST = 92.92%,
QFT®-GIT =100%; p<.0001).
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Conclusions: The utilization of QFT®-GIT for tuberculosis screening of new
employees significantly reduced screening and onboarding time while improving
compliance with screening within 10 days of the hire date. Anecdotal feedback from
hiring managers and senior management indicated improved satisfaction with the
Employee Health hiring process.
Implications: Healthcare systems should consider implementation of an IGRA
to streamline processes for onboarding new employees. New processes require
negotiations between healthcare systems and lab vendors, changes in policies and
procedures, and employee health and laboratory staff development. Future research
should focus on cost analyses, as well as, IGRA use for annual screenings.

Introduction

Employee health offices are challenged with streamlining onboarding processes
for new hires to maximize corporate efficiency and reduce costs meeting regulatory
requirements. Health screening is a key step and includes multifaceted components such
as obtaining a detailed health history, tuberculosis screening, drug screens,
immunizations, fit for duty examinations, obtaining medical records, clarification of
disability accommodations, and other pre-work screens which are often time consuming
resulting in delays in hire dates. A large healthcare system experienced a high volume
new hires and concern regarding delays in new hire start dates. The Healthcare System
Corporate Administration engaged the Employee Health Manager to assess and develop
solutions for increased onboarding efficiency. A potential area identified as a concern
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was the two-step tuberculin skin test administration and follow-up process. The purpose
of this quality improvement study was to compare baseline testing for new healthcare
employees with QuantiFERON®-TB Gold In-Tube Test (QFT®-GIT) to the two step
PPD Tuberculin skin test (TST) for tuberculosis screening time, overall onboarding time,
compliance with screening within 10 days of hire date, and associated costs.

Tuberculosis Screening
Historically, the tuberculin skin test was the only available test for TB screening
until 2001, when Interferon gamma release assays (IGRA) were developed. Interferon
gamma release assays are blood tests which specifically measure the interferon-gamma
released by T cells in response to white blood cells exposed to TB, thus releasing
interferon-gamma (TFN-ƴ )(Swindells, Aliyu, Enoch, & Abubakar, 2009) Two currently
available IGRAs include the QuantiFERON®-Gold In-Tube Test (QFT®-GIT) and the
T-SPOT®.TB. The T-SPOT®.TB measures the number of interferon gamma producing
cells by counting spots and is collected in one blood tube (Foster-Chang, Manning, &
Chandler, 2014). In contrast, the QFT®-GIT measures the TFN-ƴ protein response
quantitatively utilizing whole blood enzyme linked immunosorbent assay (ELISA). The
procedure for testing includes drawing one milliliter of blood collected in 3 tubes
including the nil (negative control), TB antigen (ESAT-6, CFP-10, and TB7.7), and
mitogen (positive control). All tubes are gently shaken 10 times and must be transferred
to a 37ºC+ 1 incubator within 16 hours. Results are measured by TB antigen minus nil
and positive is > 0.35 IU/ml. Results are measured by TB antigen minus nil and positive
is > 0.35 IU/ml (Nienhaus, 2013).
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IGRA’s can potentially overcome barriers with TST extended tuberculosis
clearance screening time, noncompliance, and inaccuracies in results. In contrast to TST,
IGRA’s do not react to nontuberculous mycobacteria or BCG vaccination. IGRA’s can
also be completed in one visit and eliminate the need for multiple visits. Furthermore,
IGRAs were found to have a higher correlation to TB exposure than TSTs, thus,
improving accuracy. IGRA’s are more expensive than TST’s, but utilization can reduce
costs associated with onboarding, staff time for TST implementation and follow-up
processes, and reducing potential regulatory citations for organizational noncompliance
(Mazurek et al., 2010).

Literature Review
A review of literature was conducted for levels of evidence, quality, and summary
to compare TST testing and a blood assay for mycobacterium tuberculosis screening of
new hires for a healthcare system. Database searches included CINAHL, PubMed and
Science Direct. Search terms included a combination of IGRA, Interferon gamma,
tuberculosis screening, quantiferon, employee, healthcare worker, and tuberculosis.
Search inclusion criteria included studies published in English conducted in low or
medium TB incidence settings from 2005 to present with relevant information to IGRA
testing in healthcare workers including QFT®, QFT®-TB Gold, QFT®-GIT, or TSPOT®.TB. Studies were excluded that were conducted primarily in high TB incidence
settings, did not include healthcare workers, were published in other languages, and those
that involved only children or immune compromised patients. Articles were limited to the
past 10 years. However, the Centers for Disease Control (CDC) study published in 2005
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was included since it provides the guidance for landmark regulatory compliance for
occupational health onboarding. Twenty-three studies were included in the final literature
review. The John Hopkins nursing evidence-based practice model and guidelines were
utilized to appraise the evidence. The search yielded There five level II studies, six level
III, two level IV and ten level V. Eight studies were high quality, and fifteen studies were
rated good. Low quality studies were excluded.

The literature analysis was organized into topics of the tuberculosis screening
process, cost, accuracy, and conversions/reversions. Synthesis of the literature revealed a
number of positive logistical factors that provided value for employee health offices
including reduced number of visits for the new hire and reduced burden on employee
health office staff time spent on tuberculosis clearance and follow-up while improving
compliance (Cummings et al., 2009; Foster-Chang et al., 2014; Gonzalez & Conlon,
2013; Graban & Filby, 2015; Mazurek et al., 2010; Rangaka et al., 2012; Veeser, Smith,
Handy, & Martin, 2007; Wrighton-Smith, Sneed, Humphreys, Tao, & Bernacki, 2012).
Since QFT®-GITs are completed at one visit , new hire onboarding and tuberculosis
clearance time was reduced (Cummings et al., 2009; Foster-Chang et al., 2014; Graban &
Filby, 2015; Mazurek et al., 2010). Studies also found an enhanced convenience to the
new hire using QFT®-GITs testing (Foster-Chang et al., 2014; Graban & Filby, 2015; Veeser
et al., 2007). Cost analysis revealed that IGRAs are cost effective by reducing staff testing

and follow-up time, reducing missed work time, and reducing treatment for falsepositive results (dePerio, Tsevat, Roselle, Kralovic, & Eckman, 2009; Foster-Chang et
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al., 2014; Graban & Filby, 2015; Nienhaus, 2013; Nienhaus, Schablon, Costa, & Diel,
2011).

The literature also demonstrated that the QFT®-GIT has high specificity but there
are conflicting reports on sensitivity (Banaei, Gaur, & Pai, 2016; Cummings et al., 2009;
Dorman et al., 2014; Loddenkemper, Diel, & Nienhaus, 2012; Schablon, Nienhaus,
Ringshausen, Preisser, & Peters, 2014; Slater, Welland, Pai, Parsonnet, & Banaei, 2013;
Weddle, Hamilton, Potthoff, Rivera, & Jackson, 2014; Zwerling et al., 2012).).
Explanations offered were reductions in false-positives due to elimination of subjective
reader interpretation and the lack of reaction of IGRAs to other non-mycobacterium
tuberculosis (Dorman et al., 2014; Lamberti et al., 2015; Rangaka et al., 2012; Swindells
et al., 2009) . However, sensitivity of the QFT®-GIT improves with consideration of
patients with active tuberculosis (Mazurek et al., 2010). Some studies have shown that
there can be issues with conversions and reversion and a borderline cutoff with retesting
may be appropriate (Dorman et al., 2014; Loddenkemper et al., 2012; Mazurek et al.,
2010; Schablon et al., 2014; Slater et al., 2013; Weddle et al., 2014; Zwerling et al.,
2012). When interpreting results, the immunologic status of the patient should also be
considered with indeterminate results (Cummings et al., 2009). Standardization of lab
procedures can help overcome some of the variability in results (Banaei et al., 2016).

One limitation of the review was the lack of Level I studies. In conclusion, the
literature review showed that utilization of the QFT®-GIT has potential to improve
tuberculosis screening processes, reduce costs, reduce false-positive results with
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improved specificity, and has the potential to contribute to reduced tuberculosis screening
time and improve compliance (Banaei et al., 2016; Cummings et al., 2009; Dorman et al.,
2014; Foster-Chang et al., 2014; Graban & Filby, 2015; Loddenkemper et al., 2012;
Nienhaus, 2013; Nienhaus et al., 2011; Schablon et al., 2014; Slater et al., 2013; Veeser
et al., 2007, 2007; Weddle et al., 2014; Wrighton-Smith et al., 2012; Zwerling et al.,
2012).

Purpose
Historically, the healthcare system completed two-step tuberculosis skin testing
for new hire employees. With the increase volume of new hires, hiring managers and
Corporate Administration requested that Employee Health expedite onboarding time for
new hires. Hiring managers expressed frustration with delays in onboarding times for
new hires, especially for TST screening processes. Thus, Corporate Administration
directed Employee Health to investigate new processes for onboarding new hires and
develop recommendations. In the Fall of 2015, the Employee Health Manager convened
a new hire committee to review all onboarding processes and to recommend changes to
streamline processes. Information regarding the benefits of implementation of QFT®GITs for new hire tuberculosis screening was presented to the new hire committee, the
Vice-President of Human Resources, and Employee Health staff. Support was obtained,
and Employee Health staff initiated a new procedure, specifically QFT®-GIT testing for
new hires. Employee Health staff received training for policies and procedures for
implementing the QFT®-GIT. The internal lab and an outside vendor lab was advised of
the changes and capacity for incubation was determined. The state regulatory agency was
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contacted to ensure that the blood test would be accepted and further guidance was
sought for retesting borderline positive results of less than 1 was obtained. In February of
2016, the healthcare system began QFT®-GITs for tuberculosis screening of all new hire
employees. At the time of formation of the new hire committee, the Employee Health
office completed 100-125 pre-placement visits per month. By July of 2016, the Employee
Health office completed 187 pre-placement visits in one month.

Methods
Setting
The setting for the quality improvement project was a major southeast healthcare
system comprising of 6,800 employees and consisting of 2 acute care hospitals, a postacute facility, hospice facility, home health agency, multiple outpatient offices, and other
specialty healthcare services. The healthcare system is identified as a TB low risk facility
per CDC guidelines. The healthcare system contracts with a local lab vendor to complete
QFT®-GIT at a negotiated price of $53 per QFT®-GIT. Since CDC recommendations
do not have a preference of QFT versus T-spot®, the QFT®-GIT was selected for the
project (Mazureck et al., 2010).

Data Collection
Data was collected by the primary author retrospectively through electronic
medical record review, new hire spreadsheets, and the human resources database. All
data was stored in a password protected excel spreadsheet with all personal identifiers
removed that could be traced back to the new hire. Data points collected included
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tuberculosis screening time (TB clear days), either total number of days to complete two
step TST placement and readings or number of days for results of the QFT®-GIT. If any
testing by TST or QFT®-GIT was positive, then time for completion of symptom review
and chest x-ray was included in tuberculosis screening time. Overall onboarding time
(clear days) included placement and reading of at least one TST, QFT®-GIT result and/or
symptom assessment, drug screen results, lab results, and if required chest x-ray, fit for
duty examination, pre-work screens, or personal provider work notes.

Sample
The initial sample included 537 subjects who had pre-placement assessments at
the healthcare system’s Employee Health department in April and May of 2015 and 2016.
Subjects were excluded from the study included volunteers (n=40), new hire subjects
with positive drug screens (n=6), subjects who failed to report for employment (n=4) or
failed fit for duty examination (n=1), subjects who failed pre-work screen (n=1) or did
not show for pre-work screen (n=1). The final sample size included 484 new hire
employees comprising 81.4% female subjects (see Table 1). The three most frequently
hired age groups included ages 21, 25, and 27 years. The mean age for the sample was
35.08 (n=484) (see Table 1). There were 323 Caucasian subjects (66.73), 112 African
American (Black) (23.14), 13 Hispanic (2.69), 12 Asian (2.48), and 24 other (4.96). The
most frequent job title for the sample was registered nurses (n=111), followed by nursing
support (n =62). Of the sample, 227 had TST testing and 257 had QFT Testing.
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Results
The mean number of days for completing all onboarding requirements to begin
orientation was 6.40 days. The mean number of days to complete tuberculosis screening
by TST was 8.06, ranging from 0-36 days. One hundred twenty-four subjects supplied
documentation of at least one previous TST, thereby reducing the number of days
required for subsequent testing. Seven subjects required repeated TST’s due to failure to
follow up for TST reading. TB clear days included the amount of time required for
tuberculosis screening and was 5.92 mean days for the TST and the QFT groups.
However, Quantiferon® testing yielded an average 4.11 days to complete testing with a
range of 1 to 10 days. There were four positive QFT® results with 3 of those being
borderline less than 1.0. The mean number of days for drug screen results was 2.71 days
with a maximum of 19 days resulting from subjects who had 2 dilute drug screens,
necessitating a hair drug screen. Thirty-six employees were required to have pre-work
screen tests, averaging 5.68 days to complete. Six subjects were required to bring
documentation from their personal health care provider regarding work status (see Table
2).

Question 1. Will implementation of QFT®-GIT reduce the number of days to
complete tuberculosis screening for new hires?
There was a statistically significant difference in number of mean days to
complete tuberculosis screening for the QFT® group in comparison to the TST group
(p<.0001) (see Table 3). The average mean number of days to clear tuberculosis
screening was 8.03 for TST and 4.11 for the QFT®. When comparing mean age between
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the two groups for testing completion days, there was no statistically significant
difference (p=0.0849) (see Table 3).

Question 2. Will implementation of QFT®-GIT for new hires reduce the
overall number of days to complete onboarding?
Findings indicated a statistically significant difference in the overall number of
mean days to complete Employee Health screening for the QFT®-GIT in comparison to
the TST group (p<.0001) even when adding in other new hire screening requirements. A
reduction in number of days was demonstrated for onboarding days when using the QFT
method from 7.92 (TST group) to 5.07 (QFT® group) (p<.0001). There was no
statistically significant difference between the TST and the QFT® groups in the number
of mean days to complete drug screens (p=0.8009), fit for duties (p=0.8009), or pre-work
screens (p=0.1265) (see Table 4).
Data was further analyzed to determine if there was a correlation between
onboarding clearance time and age, TST clear days, QFT®-GIT clear days, drug screen
days, fit for duty days, pre-work screen days, or PCP note days. A weak but positive
correlation was demonstrated between overall onboarding time and age (r=0.10094,
p=0.0268) (see Table 5). However, findings showed a statistically significant stronger
positive relationship between overall onboarding time and number of days to complete
TST screening (r=0.71838, p<.0001) and number of days for clearance by QFT®
(r=0.62275, p<.0001). A positive relationship was also found between onboarding
clearance time with number of days to complete drug screens (r=0.30298, p<.0001).
There was also a positive relationship between the number of days and fit for duties
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(r=0.76433, p<.0001), however, only 36 subjects were required to complete the
examination. For onboarding time with the number of days to complete pre-work screens,
a positive correlation was found among six subjects (r=0.68600, p<.0001) but none was
found between onboarding clearance time and the number of days to bring documentation
clearance from the PCP (r=0.40584, p=0.4247) (see Table 5).

Question 3. Will implementation of QFT®-GIT for new employees improve
compliance with completion of tuberculosis screening within 10 days of
orientation?
Analyses showed a statistically significant improvement in compliance with the
QFT® group in comparison to the TST group (p<.0001) (see Table 6). Overall, the
compliance rate for completing the tuberculosis screening was 99.29% in the TST group
and 100% the QFT group. There was no statistical difference for tuberculosis screening
compliance between races. However, there was a statistically significant difference in
compliance between genders with an increase in compliance among female employees
(97.96%; p=.0010) (see Table 6). Three employees failed to complete two step TSTs. Ten
employees failed to have at least one TST with a final reading prior to orientation.
Sixteen employees in the TST group failed to complete tuberculosis screening within 10
days of orientation. No QFT group subjects failed to complete screening within 10 days
of hire date.

Q4. Will implementation of QFT®-GIT be cost-effective?
The average cost for a two-step TST in Employee Health was estimated at $87.87
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per person and for QFT® $101.66 (cost of lab test, supplies, staff time for review of
results). At initial glance, the QFT®-GITs appears to cost more per person ($13.79).
However, further consideration is warranted when factoring other variables. Seven
subjects failed to have at least one TST read and had to be replaced which required a
second TST at an additional cost of $30.01- $37.76 per person (total costs of $210.07).
Sixteen subjects failed to complete screening within 10 days of orientation which resulted
in an increase in Corporate cost to allocate Employee Health staff time recalling these
new hired employees ($25 per hour x 8 hours per week used for recalls = $200.00 per
week). Corporate could have been forced to contract with a staffing agency for 16 locum
tenens nurses while onboarding new hire employees to replace those who failed to
comply with initial testing resulting in an additional cost of $76,800 per month ($30/hr
for each locum tenens for full time x 160 hours in month = $4,800 x 16 employees =
$76,800). Four subjects in the TST group did not complete both steps of the two-step
tuberculin skin test within the specified time frame, which potentially placed the system
at risk for DHEC penalties ranging from $12,675 to $126,749 each for violations
(S.C.Department of Health and Environmental Control, 2015). Occupational Health
Safety Administration (OSHA, 2017). Fortunately, Employee Health staff were vigilant
in their efforts to complete the testing later but again allocating staff time was costly to
Corporate.
Conclusions
The utilization of the QFT®-GIT for tuberculosis screening of new hire
healthcare employees in comparison to the TST testing significantly reduced tuberculosis
screening and onboarding time while improving compliance with tuberculosis screening
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within 10 days of hire date (p<.0001; TST = 8.03 days, 4.11 days = QFT group).
Anecdotal feedback back from hiring managers and senior management indicated an
improvement in satisfaction with the Employee Health new hire process. They fully
appreciated the decrease in onboarding time, quicker start dates for new hires, less delays
in orientation, and an increase in volume of new hire visits. Employee Health manager
admits to receiving less complaints regarding appointment availability for screening
processes and orientation start dates for new hires. Streamlining processes has also
facilitated regulatory site visits with the QFT®-GIT because data is more easily
retrievable and accurate. Clearly, the cost of QFT®-GIT can be more as a single test but
agencies should account for other variables in the cost analyses including, staffing costs,
lab testing, and locum tenens use. Streamlining processes and improved efficiency are
critical to Corporate overhead costs and compliance.

Implications for Practice and Future Research
Organizations should consider implementation of an IGRA to streamline
processes for onboarding new hires. Of course, new processes require negotiations
between hospital departments and lab vendors, changes in policy and procedures, and
Employee Health staff development for IGRA testing procedures to facilitate new hires
onboarding.
Future research should include discrete cost analyses comparing screening with
TST versus QFT®-GITs for both new hires and annual testing. A pilot study could
provide foundation for future research to compare annual screening with QFT®-GIT and
TST. Analyses could include measurements of process improvement, screening time, and
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employee satisfaction surveys for onboarding.
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Manuscript Tables
Table H.1
Frequency distribution for demographic variables
Sample demographic variables

N

%

Gender
Male
Female

90
394

18.60
81.40

Age: Most frequently hired
25 yrs.
27 yrs.
21 yrs.
Other

24
24
23
413

4.96
4.96
4.75
85.33

Race
White
Black
Hispanic
Asian
Other

323
112
13
12
24

66.73
23.14
2.69
2.48
4.96

Job
RN
Nursing Support
EMS/Transport
Resident physicians
Epic/IS
Other

111
62
32
15
14
245

185

23.03
12.86
6.4
3.11
6.64
47.96

Table H.2
N, means, standard deviation, minimum, maximum for select variables
Variable

Label

N

age
cldy
tstcldy
tbclrd
qftdy
dsdy
ffddy
pwsdy
pcpndy

Age
Clear days
TST clear days
TB clear days
# days result QFT
d/s days
FFD days
PWS days
PCP note days

Mean

484 35.08
481 6.40
223 8.06
481 5.92
255 4.11
481 2.71
36 7.94
31 5.68
6 7.17

Std
Dev Minimum Maximum
11.54
5.08
7.16
5.35
1.26
2.27
4.26
4.77
8.57

18.00
1.00
0.00
0.00
1.00
1.00
2.00
0.00
1.00

Table H.3
N, mean, standard deviation for select variables by group
Variable

TST group

QFT group

Age

N Mean Std.
227 34.11 11.78

N Mean Std.
257 35.93 11.27

TB screen clear days b

224

QFT complete days

0

TST complete days

223

a

8.03

7.16

257

4.08

1.29

.

.

255

4.11

1.26

8.06

7.16

a. t-test p=0.0849
b. t-test p<.0001

186

0

67.00
30.00
36.00
36.00
10.00
19.00
18.00
21.00
24.00

Table H.4
N, mean, standard deviation for select onboarding variables by group
Variable

Clear days

TST group
a

N Mean
223 7.92

QFT group

Std.
6.54

N Mean
256 5.07

Std.
2.68

Drug screen daysb

225

2.74

2.84

256

2.68

1.61

Fit for duty daysc

11

10.18

5.10

25

6.96

3.52

Pre-work screen daysd

20

6.6

5.0

11

4.00

4.00

6

7.17

8.57

0

.

PCP note days

.

a. t-test p<.0001
b. t-test p=0.8009
c. t-test p=0.0768
d. t-test p=0.1265

Table H.5
Spearman Correlation of selected variables for onboarding clearance days
Variable

Onboarding Clear Days
N

Correlation

Agea

481

0.10094

TST clear daysb

223

0.71838

QFT days b

255

0.62275

Drug screen days b

479

0.30298

Fit for duty days b

36

0.76433

Pre-work screen days b

31

0.68600

PCP note days c

6

0.40584

a. p=0.0268
b. p<.0001
c. p=0.4247
187

Table H.6
Frequency distribution for clear within 10 days

Variables

Yes

No

N

%

N

%

Gendera
Female
Male

385
82

97.96
91.11

8
8

2.04
8.89

Raceb
White
Black
Other

309
109
49

95.96
97.32
100

13
3
0

4.04
2.68
0

92.92
100

16
0

7.08
0

Groupc
TST
210
QFT
257
d. Fisher exact test p value = .0010
e. Fisher exact test p value = .3092
f. Fisher exact test p value <.0001

Permission to Publish Manuscript in Dissertation for ProQuest
Email 3/9/17 from the AOHP Journal Editor
We will definitely grant that permission…just site that the article was “originally published in
AOHP Journal..and the issue”
Kim Stanchfield, RN COHN-S

188

